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Abstract 
Antiphospholipid antibodies (aPL) are associated with an increased thromboembolic 
risk but the mechanism is unclear. Warfarin anticoagulation has traditionally been 
employed in thrombotic antiphospholipid syndrome (APS), but direct oral 
anticoagulants such as rivaroxaban have recently become available.  
 
The aims of this thesis were to: 
1. Investigate the frequency, mechanism and clinical associations of activated protein 
C resistance (APCr) in thrombotic APS 
2. Assess the effects of rivaroxaban on lupus anticoagulant tests  
3. Investigate the efficacy of rivaroxaban in terms of thrombin generation (TG) and 
haemostasis activation markers in thrombotic patients with or without APS  
 
Thrombotic APS patients had greater APCr than disease controls.  Nearly 50% of 
APS patients had anti-protein C (anti-PC) antibodies; those with high avidity 
antibodies had significantly greater APCr using either exogenous activated PC or 
activation of endogenous PC with Protac®.  High avidity anti-PC antibodies were 
strongly associated with a severe thrombotic phenotype in APS. There was a wide 
variation in the sensitivity of thromboplastin reagents to rivaroxaban. Of the six 
commonly used thromboplastin reagents studied, Neoplastin®R was the most 
sensitive while Innovin® and Thromborel®S were the least sensitive. False positive 
dilute Russell’s viper venom time occurred in patients with therapeutic levels of 
rivaroxaban. Taipan /Ecarin venom clotting time ratio and Textarin time were not 
affected irrespective of the rivaroxaban level, enabling accurate detection of LA.  In 
vitro studies showed that aPL did not influence the anticoagulant activity of 
rivaroxaban as measured by TG and anti-Xa assays. Both rivaroxaban and warfarin 
achieved effective anticoagulation, as assessed by inhibition of TG and in-vivo 
coagulation activation markers in patients with and without APS. 
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 Introduction Chapter 1
1.1 Normal haemostasis 
The fine balance between procoagulant and anticoagulant factors, fibrinolytic plasma 
proteins, platelets, leucocytes and the vascular endothelium maintain the blood 
fluidity in the circulation without thrombosis or bleeding in normal circumstances. 
Disturbance of this fine balance of the normal haemostatic mechanism results in 
either bleeding or thrombosis. When the activated haemostatic system overwhelms 
the normal regulatory mechanisms that localise the thrombus formation to areas of 
injury, pathological thrombus occurs. In a cell based model of haemostasis, 
formation of fibrin clot occurs on different cell surfaces by three overlapping steps of 
initiation, amplification and propagation (Hoffman & Monroe, III, 2001). 
1.1.1 Initiation 
When injury occurs to a blood vessel leading to expression of collagen and tissue 
factor (TF), the zymogens of the procoagulant proteins are converted sequentially to 
enzymes  that initiate thrombus formation (Furie & Furie, 2007). Formation of the 
TF-factor VIIa (FVIIIa) complex activates additional FVII to FVIIa allowing to 
generate more TF-FVIIa complex activity. The TF-FVIIIa complex activates a small 
amount of factor IX (FIX) and factor X (FX)(Hoffman & Monroe, III, 2001).  Tissue 
factor pathway inhibitor (TFPI) and antithrombin rapidly inactivate activated FX 
(FXa) that escapes into the cell surface environment, whereas FXa that moves onto 
the surface of nearby cell surfaces (platelets or other cells) is not inhibited by TFPI.  
FXa activates prothrombin (factor II) to form small amount of thrombin (FIIa) which 
is an essential step for the activation of platelets, FVIII, FV and the formation of 
large amount of thrombin by a positive feedback mechanism. 
1.1.2 Amplification 
A small amount of thrombin generated at the initiation phase of coagulation, diffuses 
away from the TF-bearing cells to activate the platelets that leak from the blood 
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vessels at the site of injury (Monroe et al, 1996). Binding of thrombin to the platelet 
surface receptors causes conformational changes, expose procoagulants on the 
platelet membrane surface and release platelet granular contents that are required for 
the clotting reactions. Platelet granules contain a large number of proteins and  
agonists to induce further platelet activation (Smith, 2009). Furthermore, thrombin 
generated in the initiation phase of the coagulation process, converts Factor XI (FXI) 
to FXIa and factor V (FV) to FVa on the platelet surface.  
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Figure 1-1 Cell based model of the coagulation cascade 
 
Adapted from: (URL: www.discoverymedicine.com/Ingo-Ahrens/2012/06/23/development-and-
clinical-applications-of-novel-oral-anticoagulants-part-i-clinically-approved-drugs, accessed 23rd 
February 2015).  
In addition, thrombin cleaves von Willebrand factor (vWF) and the factor VIII 
complex, releasing vWF to mediate platelet adhesion and aggregation. Thrombin 
activates FVIII to FVIIIa (Hoffman, 2003). 
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Figure 1-2 The central role of thrombin in haemostasis 
 
Thrombin is generated in small quantities during the initiation phase which occurs on the TF-bearing 
cell, then in larger quantities on the platelet surface in the propagation phase. Thrombin becomes 
anticoagulant via thrombomodulin-mediated activation of the protein C system. Thrombin also 
impacts on clot structure through activation of cross-linked FXIII, and thrombin activatable 
fibrinolysis inhibitor [adapted from (Smith, 2009)]. 
1.1.3 Propagation 
Release of granular contents from the small number of platelets activated in the 
amplification phase results in recruitment of more platelets to the site of injury, and 
the propagation phase occurs on the surface of these platelets. FVIIIa combines with 
FIXa (generated by TF-FVIIa complexes in the initiation phase) to form intrinsic 
‘tenase’ complexes on the activated platelet surfaces. The FVIIa/FIXa complex is a 
potent and major activator of FX. FXa in amalgamation with its co-factor FVa and 
calcium ions forms prothrombinase complexes, which is 300,000 fold more active 
than FXa alone in activating prothrombin to thrombin, thus generating large amount 
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of thrombin locally (thrombin burst)(Hoffman & Monroe, III, 2001;Mann et al, 
2003).  
1.2 Role of phospholipids in haemostasis 
 The central role of phospholipids in the coagulation cascade has been well 
established for many years (Mann et al, 1990). The negative charges on the 
phospholipids are recognised as necessary for the binding of the vitamin K-
dependent enzymes and substrate through their N-terminal Gla domains. During 
post-translational processing, vitamin K-dependent proteins undergo carboxylation 
of the glutamic (Glu) acid residues at their N-terminus, by a vitamin K-dependent 
carboxylase. This process is required for biologically active proteins and results in 
the unique and characteristic presence of nine to thirteen γ-carboxyglutamic (Gla) 
residues consisting of the Gla domain (Freedman et al, 1995).  
The Gla domain is essential for establishing a strong association with Ca2+, which is 
crucial for both the interaction of the Gla-containing proteins with negatively 
charged phospholipids and for their correct structural folding. Intra-chain interactions 
between Ca2+ and Gla residues induce a structural transition of the Gla domain, 
transforming it from an unfolded and non-functional unit to a tight folded and 
essentially functional domain. Folding of the Gla domain also exposes a hydrophobic 
patch of three residues within the Gla domain, termed as the ‘ω loop’, which enables 
interaction with cell membranes. Positively charged Ca2+-bound Gla residues form 
ion bridges with the negatively charged phosphate head groups of phospholipids, 
facilitating localisation of the vitamin K-dependent proteins on the surface of cell 
membranes where assembly of procoagulant and anticoagulant complexes takes 
place (Huang et al, 2003). Although the Gla domains of all vitamin K-dependent 
proteins are highly conserved, their affinities and binding rates for membranes vary 
considerably between the different members of the family. For instance, protein S 
has one of the highest affinities for negatively charged phospholipids (dissociation 
constant (KD) ~10 nM), whereas protein C exhibits a ~100-fold weaker affinity (KD 
~1 μM) (Nelsestuen et al, 1978;Sun et al, 2003).   
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1.3 Antiphospholipid syndrome 
Antiphospholipid syndrome (APS) is characterized by thrombosis (venous and/or 
arterial or microvascular) and/or pregnancy loss or morbidity in association with 
persistent positivity of a heterogeneous group of autoantibodies known as 
antiphospholipid antibodies (aPL) (Miyakis et al, 2006). The International consensus 
criteria (Sydney; updated Sapporo) for APS were designed for scientific clinical 
studies, however, these clinical and laboratory diagnostic criteria have been adapted 
for the diagnosis of APS in routine clinical practice. The primary targets of aPL are 
phospholipid-binding proteins, although antibodies directed against phospholipids 
and other proteins also occur. One or more of the non-criteria features of APS such 
as heart valve disease, livedo reticularis, thrombocytopenia and nephropathy may 
present in association with thrombosis and/or pregnancy morbidity or as isolated 
features. aPL are a heterogeneous group of autoantibodies, which include lupus 
anticoagulant (LA), IgG and/or IgM anticardiolipin antibodies (aCL) and anti-β2-
glycoprotein-I (aβ2-GPI) antibodies, of moderate or high positivity (>40 GPL or 
MPL units, or exceeding the 99
th
 centile). The International consensus classification 
criteria now define persistently positive aPL as those being present on two or more  
consecutive occasions at least 12 weeks apart (Miyakis et al, 2006).  
The prevalence of aPL in the form of LA or aCL is 1–5% of healthy individuals. The 
prevalence increases in the elderly and in those with chronic disease (Keeling et al, 
2012).  Conditions that are associated with production of aPL are listed in Table 1-1. 
APS has been described as secondary if there is an associated autoimmune disorder, 
however, the international consensus classification advises against using the term 
‘secondary’ on the basis of that the relationship between APS and systemic lupus 
erythematosus (SLE) is undefined  (Miyakis et al, 2006). Several studies have shown 
that the prevalence of aPL in SLE patients is variable (15–86%). The frequency of 
antibody positivity is likely to be around 30%, with the wide variation found in the 
literature explained by study variations, ethnicity, and extent of autoimmune disease 
activity. Up to an estimated 40% of patients with SLE and aPL will eventually 
develop clinical features consistent with APS, whereas under 5% of patients with 
APS will develop SLE.  
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Table 1-1 Associations of antiphospholipid antibodies 
Conditions associated with production of antiphospholipid antibodies 
Systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Behçet's 
disease, temporal arteritis, Sjögren's syndrome 
Infections – HIV, varicella, hepatitis C, syphilis, malaria, leprosy 
Drugs – phenothiazines, procainamide, phenytoin, quinidine, hydralazine 
Lymphoproliferative disease (lymphoma, paraproteinaemia) 
1.3.1 Pathogenesis 
Despite clear associations between aPL and thrombosis as well as with pregnancy 
morbidity, the pathophysiology of these complications is not well understood, with 
their heterogeneity suggesting that more than one pathogenic aetiological process is 
involved. Proposed mechanisms of aPL-mediated thrombosis and pregnancy 
complications are listed in Table 1-2 and Table 1-3. The clinical significance of any 
one or more of these hypotheses remains unclear and reflects the likely multifactorial 
complex nature of this condition, as is generally the case in acute thrombosis. 
Despite the persistent presence of aPL in the systemic circulation, thrombotic events 
occur only occasionally, suggesting that the presence of aPL alone may not be 
sufficient to cause thrombosis and/or pregnancy morbidity. The development of aPL 
is probably only one step towards the development of APS, and it is likely that other 
factors play a role. Such ‘second hits’ or ‘triggers’ may tip the 
thrombotic/haemostatic balance in favour of a prothrombotic state, and include 
infection, endothelial injury, and other nonimmunological procoagulant factors 
(Pengo et al, 2011). The patient’s genetic make-up, in relation to candidate genes for 
inflammatory mediators, may also be a critical variable for the development of 
clinical APS manifestations. Data from several studies and systematic reviews 
suggest that positive LA are a stronger risk factor for the development of thrombosis 
than are aCL or aβ2-GPI (DE Groot et al, 2005;Galli et al, 2003;Boey et al, 1983). In 
addition, a first thromboembolic event is considered rare in  individuals positive  for 
aPL but the increased risk in those who are ‘triple positive’ for all of LA, aCL and 
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aβ2-GPI appears to be considerable, showing a 30% recurrence rate over a 6-year 
follow up period (Pengo et al, 2010). 
Patients with APS inherently differ from other patients with venous and arterial 
thrombosis due to the presence of aPL, which are known to interfere with a number 
of haemostatic mechanisms. There is some evidence that patients with APS may 
have antibodies which recognize protein C, protein S and thrombomodulin, which 
are naturally occurring anticoagulants, thus generating a prothrombotic state (Malia 
et al, 1990). Generation of thrombin is a pivotal component of the haemostatic 
mechanism, with increased ex vivo thrombin generation a key marker of 
thrombogenic potential with predictive value for the development of recurrent VTE 
(Eichinger et al, 2008;Hemker & Beguin, 2000). Limited data suggest an activated 
protein (APC) resistant phenotype, demonstrated in a thrombin generation-based test, 
is seen in individuals with APS exhibiting LA with a history of thrombotic events. In 
these patients, aPL are associated with a stronger resistance to the anticoagulant 
effects of APC (Liestol et al, 2007b).  
Whilst studies in animals, employing administration of aPL from humans, tend to 
suggest that the antibodies are directly pathogenic in pregnancy failure and 
thrombosis (Branch, 1990;Blank et al, 1991). However, no single mechanism of 
action has been convincingly demonstrated. Among those postulated, the more 
persuasive include accelerated thrombin generation through antibody-mediated 
concentration of prothrombin on anionic phospholipids (Rao et al, 1996) or increased 
cellular expression of tissue factor (Branch & Rodgers, 1993;Amengual et al, 1998) 
and  through displacement of annexin V from phospholipid (Rand et al, 1997b;Rand 
et al, 1997a;Rand et al, 1998). Annexin V is a potent anticoagulant that serves a 
thrombomodulatory function in the placental circulation (Rand et al, 2003). It may 
also play a thrombomodulatory role in the systemic circulation. Annexin V is highly 
expressed by human endothelial cells and is present on the surface of endothelial 
cells (Rand et al, 1997a). It has been demonstrated that aPL reduce the quantity of 
annexin 5 on the surface of cultured placental trophoblasts (Rand et al, 1997b;Rand 
et al, 1997a;Rand et al, 1998) and endothelial cells  (Rand et al, 1997a), where they 
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accelerate coagulation reactions. This has been proposed as mechanisms for 
pregnancy losses and thrombosis in APS (Rand et al, 2003). Understandably, early 
studies concentrated on pathogenic mechanisms involving the coagulation and 
haemostatic systems; however in a ground breaking publication, Girardi et al 
demonstrated activation of complement by aPL, through the classical pathway 
(Girardi et al, 2004). Despite these uncertainties regarding pathogenesis there is no 
doubt that, although APS is an immune-mediated condition, the principal 
manifestation is a prothrombotic state which leads frequently to arterial, venous and 
microvascular thrombosis, and even ischaemic multiorgan failure. It is unsurprising 
therefore that clinical management has centred around the use of various 
antithrombotic compounds. 
There is evidence that other pathogenic factors, such as complement activation, with 
excess C3a and C5a generation, may contribute to thrombotic manifestations in APS, 
as has been observed in several animal models. Complement is implicated in APS 
via generation of the potent inflammatory mediator C5a which contributes to 
vascular inflammation and complement inhibition may ameliorate aPL‐induced 
thrombosis (Girardi et al, 2003;Pierangeli et al, 1999). Murine models and human 
studies suggest involvement of the complement system in thrombotic APS (Misita & 
Moll, 2005;Oku et al, 2009). It has also been suggested that complement activation is 
a central mechanism in aPL‐induced pregnancy loss and intrauterine fetal growth 
restriction (Cohen et al, 2011;Salmon et al, 2003;Salmon & Girardi, 2008). Also to 
further strengthen this hypothesis, low complement levels (C3, C5) have been 
demonstrated in patients with APS (Breen et al, 2012). Widespread complement 
activation may also play a role in catastrophic APS (CAPS) as some case reports 
described patients with CAPS successfully treated with complement inhibition with 
eculizumab (Lonze et al, 2010;Shapira et al, 2012).  
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Interference with the components of the coagulation cascade 
Inhibition of protein C activity (acquired protein C resistance) 
Inhibition of protein S cofactor activity 
Inhibition of antithrombin activity 
Inhibition of protein Z pathway 
Activation of contact pathway 
Inhibition of tissue factor pathway inhibitor 
Activation of factor XI 
Induction of platelet aggregation 
Induction of microparticle formation 
β2GPI-thrombin interaction 
Impairment of fibrinolysis 
Complement activation 
Cell interactions 
       -Induction of proinflammatory phenotype on endothelial cells 
       -Induction of procoagulant activity of activity on endothelial cells and 
monocytes 
Oxidant-mediated endothelial injury 
Disruption of annexin V shield 
ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type 1 
motif, member 13) dysfunction 
Table 1-2 Proposed mechanisms for development of thrombosis in APS 
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Table 1-3 Proposed mechanisms for aPL-mediated fetal loss or complications 
 
 
 
 
 
1.3.2 Diagnosis of antiphospholipid syndrome and the identification of 
relationships between assay results and clinical manifestations 
In the years which followed the first identification of APS in the 1980s as an 
important acquired prothrombotic condition there were extensive attempts to 
improve the sensitivity and specificity of the essential diagnostic laboratory assays, 
both coagulation- based and solid phase, as well as investigations into the mechanism 
of the prothrombotic state.  Detection of aCL and aβ2-GPI are commonly done by 
radioimmunoassays, enzyme-linked immunosorbent assays (ELISAs) (Loizou et al, 
1985). In relation to assay performance, despite considerable efforts to improve 
sensitivity, specificity and reproducibility there remain limitations (Favaloro & 
Silvestrini, 2002;Pengo et al, 2007) although the implementation of guidelines, both 
laboratory and clinical, has improved the accuracy of diagnosis (Miyakis et al, 
2006;Jennings et al, 2002;Keeling et al, 2012). Whilst the identification of the most 
important antigen, β2 glycoprotein I, offered hope of improved assay specificity and 
performance, this has been achieved only partially (Santiago et al, 2001;Favaloro et 
al, 2007). It has been shown by Galli and colleagues in a systematic review,  that LA 
is a stronger risk factor for thrombosis than aCL (Galli, 2003), and, subsequently by 
Pengo and colleagues that those subjects who react positively in all three of LA, aCL 
and aβ2GPI  assay systems have a particularly high rate of thrombosis (Pengo et al, 
2012;Pengo et al, 2011) 
Intraplacental thrombosis 
Complement activation 
Inflammation 
Inhibition of syncytium-trophoblast differentiation 
Disruption of annexin V shield 
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Detection of LA requires provision of evidence that results of phospholipid–
dependent screening tests are prolonged above the 99
th
 centile of the normal healthy 
people (Pengo et al, 2009;Tripodi et al, 2011b). A large number of tests have been 
suggested for LA screening and confirmation, which have interference with different 
parts of the coagulation pathway. It is generally recommended that evidence must be 
provided that the phospholipid dependent clotting time from the screening procedure 
is not corrected upon the addition of equal volume of pooled normal plasma (PNP) to 
patient plasma. If the clotting of the 1:1 patient and PNP is higher than 99
th 
centile of 
the normal healthy people, a confirmatory assay should be performed. Confirmatory 
tests involve repeating the abnormal screening test with an increased phospholipid 
concentration. The presence of LA is confirmed when the percentage of correction 
(screening versus confirmatory test) of the clotting time is above the local cut-off 
\value (Pengo et al, 2009). A large number of tests have been suggested for LA 
screening and confirmation, which cause interference with different parts of 
coagulation pathway. The British Committee for Standards in Haematology (BCSH) 
recommended that two test systems employing different principles should be used to 
ensure that weak LA are detected and to improve specificity (Keeling et al, 2012). 
Clinical evidence based on associations with thrombosis suggest that the DRVVT 
(diluted Russell’s viper venom test) has good value and should be one of the tests 
(Keeling et al, 2012). The other tests are usually an activated partial thromboplastin 
time (APTT) with a reagent with proven LA sensitivity, a modified APTT or a dilute 
prothrombin time. 
The Kaolin clotting time (KCT) is another test used for detection of LA (Exner et al, 
1978), however this test has poor sensitivity and specificity  and is more liable to 
variation due to poor sample quality  (Jennings et al, 1997). For snake venom assay, 
screening tests involve Taipan venom time (TVT) or Textarin time and confirmatory 
test, Ecarin clotting time (ECT) (Moore et al, 2003;Moore, 2007). The utility of these 
tests to detect LA in the presence of non-vitamin K antagonist oral anticoagulants 
(NOAC), mainly the direct factor Xa inhibitor rivaroxaban, will be discussed further 
in relevant chapters.  
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1.3.3 Clinical manifestations of APS 
 APS is a multisystem disorder affecting almost all the organs in the body. Clinical 
manifestations in patients with aPL are listed in Table 1-4 . 
Table 1-4 Clinical manifestations in patients with aPL 
Thrombotic- venous/arterial thromboembolic disease and microvascular 
thrombosis 
Obstetric – recurrent miscarriage, intrauterine foetal death (IUFD), stillbirth, early 
severe pre-eclampsia, HELLP* syndrome, placental insufficiency, prematurity, 
intrauterine growth restriction (IUGR) 
Cardiovascular- valvular heart disease, sterile endocarditis with embolism 
Neurological – cerebral ischaemic events, chorea, dementia, psychiatric disorders, 
transverse myelopathy, seizures, Guillain–Barré syndrome, Sneddon's syndrome 
Haematological – autoimmune thrombocytopenia, autoimmune haemolytic anaemia 
Dermatological – livedo reticularis 
 
1.3.3.1 Thrombosis 
The association between aPL and thrombotic events is well established. Venous 
thromboembolism (VTE) is a common disorder, occurring in 1 per 1000 people per 
year (White, 2003) with APS accounting for approximately 10% of these acute VTE 
cases. Thrombosis of the deep veins of the lower limbs (deep venous thrombosis; 
DVT) is the most common site of venous thrombosis in APS and nearly half of 
patients presenting with DVT also have pulmonary embolism (PE). The most 
frequent site of arterial occlusion is in the cerebral vasculature, which may be 
thrombotic or embolic, resulting in transient cerebral ischaemic attacks (TIAs) and/or 
stroke. Estimates vary for the true frequency of aPL in stroke. A study by the 
AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal 
Networking (APS ACTION), based on analysis of 120 full-text papers and 
calculation of the median frequency for positive aPL tests for clinical outcome, has 
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estimated the overall frequency of aPL in stroke and TIA to be 13.5% and 7%, 
respectively (Andreoli et al, 2013;Sciascia et al, 2014). Furthermore, more than 20% 
of strokes in patients younger than 45 years of age are probably associated with APS. 
However, the association between aPLs and stroke recurrence in older patients are 
conflicting. Limitations of the literature were that 60% of the papers were published 
before 2000, all 3 criteria aPL tests were performed in only 11% of the papers, 36% 
of papers used a low-titer aCL cutoff, aβ2GPI cutoff was quite heterogeneous, aPL 
confirmation was performed in only one-fifth of papers, and the study design was 
retrospective in nearly half of the papers. Therefore, authors stated that appropriately 
designed population studies are required to determine the true prevalence.The British 
Committee for Standards in Haematology (BCSH) guidelines recommend that young 
adults (<50 years) with ischaemic stroke should be screened for aPL (level 2C) 
(Keeling et al, 2012).  
1.3.3.2 Neurological manifestations 
Ischemic stroke due to arterial thrombosis is the most common neurological 
manifestation (>50% of central nervous system complications) in APS. Recurrent 
stroke can lead to multi-infarct dementia. aPL have also been linked to Sneddon's 
syndrome (recurrent stroke and livedo reticularis). The revised international 
consensus (Sydney) classification criteria do not include other neurological 
manifestations which may be associated with aPL such as cognitive dysfunction, 
headache or migraine, multiple sclerosis-like disease, transverse myelitis, epilepsy, 
psychiatric disorders, ocular symptoms or chorea (Miyakis et al, 2006). Headache is 
one of the most often described neurologic manifestations in patients with APS 
presenting with either chronic headache or episodes of migraine, although there are 
conflicting data on a possible relationship between migraine and aPL (Nunez-
Alvarez & Cabiedes, 2011). 
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1.3.3.3 Pregnancy morbidity 
The association between aPL and pregnancy loss was probably first noted in the 
1970s (Nilsson et al, 1975). There is considerable evidence linking aPL to recurrent 
pregnancy loss (RPL) (Laskin et al, 1997;Rai et al, 1995), however the evidence is 
not robust for late pregnancy complications (Branch et al, 2001;Out et al, 1992). 
Furthermore, evidence suggests that fetal death is most specific for APS and 
recurrent early miscarriage may be the most sensitive manifestation of obstetric APS. 
However, the specificity of recurrent early miscarriage is probably low due to 
difficulty in fully excluding other potential causes (Miyakis et al, 2006) and the 
commonest cause of early miscarriage is a chromosomal abnormality (Porter & 
Scott, 2005;Stephenson, 1996). 
LA is the most frequent aPL in thrombotic APS and in a systematic review, LA 
appears to be the strongest risk factor for thrombosis (Galli et al, 2003). Furthermore, 
a meta-analysis of the association between aPL and recurrent fetal loss in women 
without autoimmune disease, demonstrated that LA was associated with late RPL 
(OR 7.79, 95% CI 2.30-26.45), by which time the placenta is well formed. However, 
data were insufficient to analyse the association of LA with early miscarriages (<13 
weeks) (Opatrny et al, 2006). IgG aCL, when combining both low and moderate to 
high antibody levels, were associated with both early (OR 3.56, 95% CI 1.48-8.59) 
and late RPL (OR 3.57, 95% CI 2.26-5.65). Restricting analysis to include only 
women with moderate to high aPL levels (>99th centile) increased the strength of the 
association (OR 4.68, 95% CI 2.96-7.40). IgM aCL was also associated with late 
RFL (OR 5.61, 95% CI 1.26-25.03). However, there was no association found 
between early RPL and aβ2GPI (OR 2.12, 95% CI 0.69-6.53) (Opatrny et al, 2006). 
Gardiner et al, (Gardiner et al, 2013) demonstrated that over 50% of women with 
clinical features of obstetric APS, but no thrombosis, had weak aCL and/or aβ2GPI in 
the absence of LA. Detection of positive or negative LA might depend on how LA 
testing is performed (i.e. the combination of tests used), for example the APTT and 
KCT or Kaolin cephalin clotting time would  detect anti-FXII, which appears to be 
more frequent in obstetric APS, whereas the  diluted prothrombin time and dilute 
Russell viper venom time might be more sensitive to prothrombin antibodies (Fleck 
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et al, 1988). In the study by Gardiner et al, showed IgG / IgM aCL levels and IgM 
aβ2GPI levels were significantly higher in patients with a history of thrombosis than 
in women with a history of purely obstetric APS (p<0.05), while the rate of LA 
positivity was significantly higher in patients with a history of thrombosis compared 
with those with obstetric APS alone (50.5% v 15%; p<0.0002).  
1.3.3.4 Catastrophic APS (CAPS) 
 Catastrophic antiphospholipid syndrome (CAPS) is a rare but potentially fatal 
variant of APS, which is characterized by sudden multiple sites extensive 
microvascular thrombosis leading to multiorgan failure (Cervera et al, 2011). 
Clinically CAPS is characterised by clinical evidence of multiorgan involvement 
developing over a very short period time period, histological evidence of multiple 
small vessel occlusions, and laboratory confirmation of aPL (Cervera, 2010). 
Widespread complement activation may play a role. Although less than 1% of 
patients with APS develop CAPS, currently the outlook for these patients is very 
poor with the mortality rate as high as 50%, even with intensive treatment (Cervera 
et al, 2002). The evidence base to guide management of CAPS is weaker due to the 
low frequency of the condition. 
1.3.3.5 Other clinical manifestations associated with APS 
Although thrombosis and pregnancy morbidities are the hallmark of APS, there are 
other clinical manifestations associated with the syndromes, which are collectively 
referred to as non-criteria manifestations of APS. Thrombocytopenia, heart valve 
disease, chorea nephropathy and livedo reticularies are all likely to associated with 
APS but none of them are specific to the syndrome (Miyakis et al, 2006) 
1.3.4 Management of thrombosis in antiphospholipid syndrome 
Typically, the initial treatment of acute thrombosis has been with heparin and 
vitamin K antagonists such as warfarin rather than immunosuppressives agents. For 
example, an review of APS by Bingley and Hoffbrand contains a report of two 
patients with recurrent arterial events treated with warfarin, one of whom had 
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initially received steroids and azathioprine with no reduction in anticardiolipin levels 
(Bingley & Hoffbrand, 1987). Warfarin continued to be the mainstay of treatment 
and in the 1990’s the perception that the re-thrombosis rate was particularly high 
compared with other prothrombotic states led to the promotion of high intensity oral 
anticoagulation for the prevention of thrombosis in APS (target INR higher than the 
usual 2.5). However this was based upon observational data from case series at 
tertiary referral centres (Khamashta et al, 1995;Rosove & Brewer, 1992), and 
subsequently two important randomised controlled trials demonstrated that high-
intensity warfarin is not superior to moderate-intensity warfarin (INR 2.0-3.0) for the 
prevention of recurrent thrombosis (Crowther et al, 2003;Finazzi et al, 2005). When 
the results of the 2 studies were combined in a meta-analysis, a significant excess of 
minor bleeding was evident in patients allocated to high-intensity warfarin (Finazzi 
et al, 2005). Use of moderate intensity anticoagulation with warfarin reduces the risk 
of recurrent VTE by 80% to 90% as compared to no treatment (Lim et al, 2006).  
Despite the above, the optimal intensity of anticoagulation following arterial, as 
opposed to venous, thrombosis in patients with antiphospholipid syndrome remains 
controversial. Patients with arterial thrombosis and patients with recurrent 
thrombosis whist on therapeutic anticoagulation were poorly represented in these 
trials of Crowther and Finazzi. Patients with arterial thrombosis represented only, 
24% and 32% respectively in the two trials. Of note, of 6 patients who develop 
recurrence of thrombosis in the high intensity arm in the study by Crowther et al, 3 
had subtherapeutic INRs and one had been off warfarin for a considerable period; the 
Finazzi study did not report on this issue. However, patients with arterial thrombosis 
and patients with recurrent thrombosis whist on therapeutic anticoagulation were 
poorly represented in these trials. An earlier prospective cohort study, the 
Antiphospholipid Antibodies and Stroke Study (APASS), had found no benefit of 
warfarin anticoagulation (target INR 1.4-2.8) over aspirin (325mg/day) in stroke 
prevention (Levine et al, 2004). However, the study had important limitations, not 
least antiphospholipid antibody testing being performed only on entry to the study 
raising the possibility that some recruits may have had transient antibody positivity,  
especially in this elderly cohort (average age 60 years). More recently, Ruiz-Irastorza 
37 
 
and colleagues recommended, following a systematic review of cohort studies, that 
APS with arterial thrombosis and/or recurrent venous events should be treated with 
warfarin at an INR >3.0 (Ruiz-Irastorza et al, 2007). The task force at the 13th 
International Congress on Antiphospholipid Antibodies also recommended that 
patients with definite APS and arterial thrombosis should be treated with warfarin at 
an INR >3.0 or combined platelet inhibitor-anticoagulant (INR 2.0–3.0) therapy. 
(Ruiz-Irastorza et al, 2011). However this was a non-graded recommendation due to 
lack of consensus. In current practice many clinicians opt for a target INR of 2.5, 
with escalation to a higher target INR should thrombosis recur despite this.  
There are limited therapeutic options for patients who have recurrent thrombotic 
events despite high intensity warfarin. These include addition of an anti-platelet 
agent or low molecular weight heparin (LMWH). However, the risk of bleeding 
associated with high intensity anticoagulation with warfarin and with combined 
anticoagulant and an anti-platelet treatment may be a concern (Keeling et al, 2012) .  
1.3.5 Warfarin 
Warfarin has been the mainstay of long term anticoagulation therapy for several 
decades. Warfarin inhibits vitamin K epoxide reductase (VKOR) to disrupt the 
vitamin K cycle, resulting in under-carboxylation of the vitamin K-dependent 
proteins and lowering of the functional levels of the vitamin K-dependent 
coagulation protein factor II, VII, IX and X and also naturally occurring 
anticoagulants; protein C and S levels (Furie et al, 1999;Stanley et al, 1999;Stenflo et 
al, 1974;Stenflo, 1974). Warfarin is readily absorbed from the gastro-intestinal tract. 
Its plasma half-life is about 40 hours. It is metabolised in the liver, and is excreted in 
the urine mainly as metabolites (SPC warfarin, 2014). Therapeutic doses of warfarin 
reduce the production of functional vitamin K–dependent clotting factors by 
approximately 30 to 50 percent (Horton & Bushwick, 1999). The use of warfarin is 
complicated by its complex pharmacokinetics and pharmacodynamics requiring 
frequent monitoring and dose adjustments. Warfarin has a narrow therapeutic range 
and care is required with all concomitant therapy. The individual product information 
for any new concomitant therapy should be consulted for specific guidance on 
38 
 
warfarin dose adjustment and therapeutic monitoring. Increased monitoring should 
be considered when commencing any new therapy if there is any doubt as to the 
extent of interactions (SPC warfarin, 2014). 
Use of warfarin in patients with APS can be further complicated by the variable 
responsiveness of the thromboplastin reagents to LA, leading to discrepancy of INR 
results. Furthermore it may cause instability of INR necessitating more frequent 
monitoring of the INR and means the result may not accurately reflect the true level 
of anticoagulation. Furthermore, LA detection in patients on warfarin may be 
problematic because of a prolonged basal clotting time, which limits the test’s 
diagnostic utility and ability to monitor LA status in patients with established APS 
(Della et al, 1996).  However, a multicentre study of laboratory INR testing in 
patients with APS concluded that LA interference on the PT-INR results, measured 
with the majority of commercial thromboplastins is not enough to cause concern if 
insensitive thromboplastins, properly calibrated to assign them an instrument-specific 
International Sensitivity Index (ISI) are used. It was suggested that new 
thromboplastins, especially those made of relipidated tissue factor, should be 
checked for their responsiveness to LA, before they are used to monitor oral 
anticoagulant treatment in patients with APS (Tripodi et al, 2001). 
1.3.6 Low molecular weight heparin 
LMWHs are parenteral anticoagulants; derived from unfractionated heparin (UFH) 
by chemical or enzymatic depolymerization to yield fragments that are 
approximately one third the size of heparin. Like UFH, they are heterogeneous with 
respect to molecular size and anticoagulant activity. LMWHs have a mean molecular 
weight of 4000 to 5000, with a molecular weight distribution of 1000 to 10 000 
(Weitz, 1997). LMWHs are cleared principally by the renal route, and their 
biological half-life is increased in patients with renal failure (Caranobe et al, 1985). 
The main mechanism of action of LMWH is the potentiation of the ability of 
antithrombin to inhibit coagulation factor proteases, with the main target being factor 
Xa. Depending on the chain length of LMWH, they have a variable factor IIa (FIIa) 
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activity; than its anti-Xa activity with a ratio ranging from 2:1 to 4:1(Bendetowicz et 
al, 1994).  
Routine monitoring of LMWH activity is usually not required. However, when 
monitoring is required in certain clinical situations or patient groups, such as with 
clinically significant bleeding, renal dysfunctions, extreme body weight, pregnant 
women, using high intensity LMWH, infants and neonates;  measurement of  anti-
Xa, using specific calibrators is recommended (Kitchen et al, 2014). Heparin induced 
thrombocytopenia (HIT) is an immune prothrombotic disorder characterised by 
thrombocytopenia with or without thrombosis. IgG antibodies formed against the 
platelet factor 4 (PF4)/heparin complex bind to these complexes on the platelet 
surface and thereby cause intravascular platelet activation by cross-linking Fcϒ 
receptor IIA; this leads to a platelet count decrease and/or thrombosis. The incidence 
of HIT is dependent on the degree of sulphation and the chain length of heparin, 
therefore incidence is higher in patients treated with UFH compared to LMWH 
(Martel et al, 2005). 
1.3.7 Non-vitamin K antagonist oral anticoagulants  
The non-vitamin K antagonist oral anticoagulants (NOAC) or oral direct acting 
anticoagulants include dabigatran etexilate (Pradaxa®) a direct thrombin inhibitor, 
and rivaroxaban (Xarelto®), apixaban (Eliquis) and edoxaban, (Lixiana®) which are 
direct anti-Xa inhibitors. These agents represent a major clinical advance as, unlike 
warfarin, they do not interact with dietary constituents and alcohol intake, and have 
few reported drug interactions which affect anticoagulant intensity (SPC Pradaxa 
hard capsules, 2014;SPC Xarelto film-coated tablets, 2014).  
The efficacy of these anticoagulants has been demonstrated in a number of large 
phase III randomised clinical trials (RCT). NOAC are fixed-dose orally administered 
agents which exert their anticoagulant effects within hours rather than days and, due 
to their predictable pharmacokinetics, do not require routine laboratory monitoring 
with coagulation tests. Following phase III international multicentre trials in a total 
of about 21,500 patients, dabigatran and rivaroxaban were licensed in the UK and 
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Europe for the prevention of VTE in adults undergoing elective total hip replacement 
or knee replacement in 2009 (Eriksson et al, 2007;Kakkar et al, 2008;Lassen et al, 
2008;Turpie et al, 2009). 
A number of phase III clinical trials have been undertaken in conditions other than 
major lower limb orthopaedic surgery. Following two phase III RCT of warfarin 
versus single dose rivaroxaban (ROCKET-AF) (Patel et al, 2011)  and two fixed 
doses of dabigatran (RE-LY) (Connolly et al, 2009) involving a total of 32284 
patients with non valvular atrial fibrillation (AF) for the prevention of stroke or 
systemic embolization, rivaroxoban and dabigatran were licensed for stroke 
prevention in 2011. They were approved by National Institute for Health and care 
Excellence (NICE) and US Food and Drug Administration (FDA) for the same 
indication in 2012 (NICE technology appraisal guidance 249., 2012;NICE 
technology appraisal guidance 256., 2012;Approval of drugs by FDA available from 
http: & www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs, 2014). 
Rivaroxaban has been licenced for treatment and prevention of recurrent DVT and 
PE after an acute DVT and PE in adults following the results of EINSTEIN-DVT 
(Bauersachs et al, 2010) and EINSTEIN-PE (Buller et al, 2012)  international 
multicentre randomised trials. Rivaroxaban has been approved by the US Food and 
Drug Administration (FDA) and NICE for the above indications in patients with non-
APS. However none is currently licensed specifically for use in patients with venous 
thromboembolism in antiphospholipid syndrome. The use of rivaroxaban in this 
context is currently being evaluated in a phase II/III trial (http://www.controlled-
trials.com/ISRCTN68222801). Owing to their structure, direct acting oral 
anticoagulants such as rivaroxaban and dabigatran do not interact with PF4; this has 
been demonstrated in in vitro studies, therefore HIT is unlikely (Krauel et al, 2012). 
Rivaroxaban for the treatment of HIT is currently being assessed in a phase III Open 
Label study (ClinicalTrials.gov Identifier: NCT01598168). 
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Table 1-5 Comparison of the pharmacological characteristics of NOAC 
Drug Rivaroxaban 
(Xarelto®) 
Apixaban  
(Eliquis®) 
Edoxaban 
(Lixiana®) 
Dabaigatran 
(Pradaxa®) 
Target  Factor Xa  Factor Xa Factor Xa Thrombin 
Pro drug No No No Yes-
Dabigatran    
etexilate 
Bioavailabiliy >80% >50% 50% 6% 
Plasma protein 
binding 
92–95% 87% 40–59% 34–35% 
Time to reach 
peak drug level 
3 hours 3 hours 1-2 hours 2 hours 
Half-life with 
normal 
creatinine 
clearance 
9 hours 9-14 hours 9–11 hours 
 
14-17 hours 
Dosing Fixed dose 
once daily 
Fixed dose 
twice daily 
Fixed dose 
once daily 
Fixed dose 
twice daily 
Drug monitoring No No No No 
Drug interaction CYP3A4 
inhibitors, P-
gp inhibitors, 
azole 
antifungals  
HIV protease 
inhibitors 
CYP3A4 
inhibitors, 
P-gp 
inhibitors 
Potent 
inhibitors of 
both 
CYP3A4 and 
P-
gpinhibitors 
Proton pump 
inhibitors 
Elimination 66% renal 
33% fecal 
25 renal 
55% fecal 
35% renal 
62% fecal 
Renal (80% 
unchanged 
Adapted from (Arachchillage & Cohen, 2013). 
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To date clinical trials with NOACs have been undertaken in excess of 150,000 
patients. Table 1-2 summarises the clinical trial and licence status of the NOACs and 
as well as the situation as regards endorsement by NICE. The safety and efficacy of 
NOAC in children up to 18 years have not been established and no published data are 
yet available. Therefore, NOACs are not recommended for use in children/teenagers 
below 18 years of age (SPC Eliquis film-coated tablets, 2014;SPC Pradaxa hard 
capsules, 2014;SPC Xarelto film-coated tablets, 2014).  
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Table 1-6 Development status of rivaroxaban, apixaban, edoxaban and dabigatran 
Indication Rivaroxaban Apixaban Edoxaban Dabigatran 
Venous 
thromboembolism 
(VTE) prevention 
orthopaedic 
surgery 
Phase III 
completed 
(Licensed for 
use) 
Approved by 
NICE and 
FDA 
Phase III 
completed 
(Licensed for 
use) 
Approved by 
NICE 
Phase III 
completed 
 
Phase III 
completed 
(Licensed for 
use) 
Approved by 
NICE 
Stroke prevention 
in  nonvalvular 
atrial fibrillation 
(AF) 
Approved by 
NICE and 
FDA 
Approved by 
NICE and 
FDA 
 Use only in 
Japan  date) 
 
Approved by 
NICE and 
FDA 
Acute coronary 
syndrome (ACS) 
Phase III 
completed 
 
Phase II 
completed 
No study in 
progress 
Phase II 
completed 
VTE prevention in 
medical inpatients 
Phase III 
completed 
 
Phase III 
completed 
 
No study in 
progress 
No study in 
progress 
VTE treatment Phase III 
completed 
(Licensed for 
use) 
Approved by 
NICE and 
FDA 
Phase III  
completed 
(Licensed for 
use) 
 
Phase III 
completed 
(Use only in 
Japan  date) 
 
Phase III 
completed 
(Licensed for 
use) 
 
Adapted from (Arachchillage & Cohen, 2013).  
1.3.8 Management of CAPS 
Anticoagulation, intravenous immunoglobulin, plasma exchange, 
immunosuppressive therapy, prostacyclin, fibrinolytics and defibrotide have all been 
used. Eculizamab is a humanised monoclonal antibody terminal complement 
inhibitor which is approved for the treatment of paroxysmal nocturnal 
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haemoglobinuria and atypical haemolytic uraemic syndrome. Individual case reports 
suggest possible efficacy in CAPS unresponsive to other treatments (Lonze et al, 
2010; Shapira et al, 2012). Eculizamab is under evaluation in a phase II clinical trial 
for its ability to prevent CAPS after kidney transplantation in patients with a prior 
history of CAPS (http://clinicaltrials.gov/show/NCT01029587). Rituximab is a 
chimeric monoclonal antibody against CD20, which is primarily located on B cells. 
It is an effective treatment for B cell non-Hodgkin’s lymphoma (Molina, 2008) and 
has been used in several autoimmune diseases including SLE and thrombotic 
thrombocytopenic purpura (Terrier et al, 2010;Scully et al, 2012). There are reported 
cases of use of rituximab in patients with CAPS. Espinosa et al reviewed 9 patients. 
Two patients died, but notably in three of the surviving patients tests for 
antiphospholipid antibodies became negative after rituximab treatment (Espinosa et 
al, 2011). 
1.3.9 Management of asymptomatic carriers of aPL 
Another unanswered question is whether primary thromboprophylaxis is indicated in 
asymptomatic subjects with antiphospholipid antibodies and how the risk of a first 
thrombosis can be stratified in order to personalise treatment. Based on limited data, 
unselected asymptomatic antibody positive patients have an annual thrombosis risk 
of around 3% (Finazzi, 2012). In a prospective multicentre Italian registry with 360 
unselected individuals with antiphospholipid antibodies (>90% of them positive for 
lupus anticoagulant), 34 patients developed a thrombotic complication, which 
accounted for a total incidence of 2.5% per year, the median follow up period being 
3.9 years (range 0.5-5.0) (Finazzi & Barbui, 1996). The Antiphospholipid Syndrome 
Study Group of the Italian Society of Rheumatology prospectively evaluated the 
incidence of, and risk factors for, a first vascular event in 258 asymptomatic 
individuals with antiphospholipid antibodies. The annual incidence rate of first 
thrombosis was 1.86% with a median follow up of 35 months (range 1-48). 
Multivariate regression analysis identified hypertension and the presence of lupus 
anticoagulant as independent risk factors for development of thrombosis (Ruffatti et 
al, 2011). In an important study 104 subjects positive for all three of LA, aCL and 
anti-β2GPI were followed up for a mean of 4.5 years. There were 25 first thrombotic 
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events (5.3% per year) with a cumulative incidence of 37.1% (95% confidence 
interval [CI]: 19.9%-54.3%) after 10 years suggesting that subjects with so-called 
triple positivity may represent a high risk group for thrombosis. Aspirin did not 
significantly affect the incidence of thromboembolic events (Pengo et al, 2011). The 
Antiphospholipid Antibody Acetylsalicyclic Acid (APLASA) study is the first 
clinical trial of individuals with asymptomatic, persistently positive antiphospholipid 
antibodies randomised to receive a daily dose of 81mg of aspirin or placebo (Erkan 
et al, 2007). There was no significant difference in outcome between the two arms. 
The overall estimated rate of thrombosis was 2.75 per 100 patient-years for 
individuals treated with aspirin and 0 per 100 patient-years for the placebo treated 
subjects. A limitation of this study was small sample size. However, based on current 
evidence, thromboprophylaxis with aspirin and/or vitamin K antagonist is not 
recommended routinely for asymptomatic, antiphospholipid antibody positive 
individuals. Attention to additional risk factors is advisable e.g. avoidance of 
smoking, oestrogen-containing oral contraception and hormone replacement therapy. 
Whether primary prophylaxis with aspirin is useful for some subjects who may be at 
particularly high risk of thrombosis, such as those with specific patterns of 
antiphospholipid antibodies, especially triple positivity, remains to be established. 
Nevertheless the task force at the 13th International Congress on Antiphospholipid 
Antibodies suggested long-term thromboprophylaxis with low-dose aspirin in those 
with a high-risk antibody profile, especially in the presence of other thrombotic risk 
factors (Ruiz-Irastorza et al, 2011).  Furthermore, they recommended that patients 
with SLE and lupus anticoagulant or persistent anticardiolipin antibody at medium–
high titre receive primary thromboprophylaxis with hydroxychloroquine and low-
dose aspirin (LDA). It is apparent that more high quality evidence is required. 
1.3.10 Alternatives to anticoagulants in the management of the 
antiphospholipid syndrome 
Although anticoagulant therapy has been the mainstay of management in 
antiphospholipid syndrome, potential alternative or additional strategies are 
emerging. These include hydroxychloroquine, HMG-CoA reductase inhibitors, and 
rituximab and complement inhibitors. 
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Hydroxychloroquine 
Hydroxychloroquine is a well-established treatment for patients with SLE and 
rheumatoid arthritis due to its anti-inflammatory effects. It is currently recommended 
as a baseline therapy in all patients who have no contraindications (Ruiz-Irastorza et 
al, 2010). In addition to anti-inflammatory activity hydroxychloroquine may reduce 
blood coagulability, purportedly through reduced red cell sludging and blood 
viscosity and possibly through some inhibition of platelet reactivity (Madow, 1960; 
Ernst et al, 1984; Jancinova et al, 1994; Espinola et al, 2002; Petri, 2011). Because 
of its perceived antithrombotic activity, in the past it was employed in prophylaxis 
against deep vein thrombosis after hip surgery (Carter et al, 1971; Johnson & 
Charnley, 1979). More recently it has been shown to protect against thrombosis and 
increase survival in patients with SLE.  Recent consensus guidelines for management 
of antiphospholipid syndrome support the use of hydroxychloroquine as an adjuvant 
therapy to anticoagulation in patients with recurrent thrombosis despite 
anticoagulation (Ruiz-Irastorza et al, 2011). A current phase III multicentre, 
international, prospective randomised-controlled trial is exploring the  effect  of 
hydroxychloroquine as primary thrombosis prophylaxis in individuals with 
persistently positive antiphospholipid antibodies and no history of thrombosis or 
systemic autoimmune diseases as a part of APS ACTION (Erkan & Lockshin, 2012). 
https://clinicaltrials.gov//NCT01784523. 
Statins 
Statins inhibit the enzyme HMG-CoA reductase which has a central role in hepatic 
cholesterol production. Statins are widely prescribed to reduce cardiovascular risk. It 
has become increasingly apparent that the drugs have pleiotropic effects including 
anti-inflammatory and antithrombotic actions (Ferrara et al, 2003;Halcox & 
Deanfield, 2004). For example statins down-regulate inflammatory cytokines in 
vascular endothelial cells, decrease the expression of adhesion molecules in 
monocytes and influence leucocyte-endothelial cell interactions (Ferrara et al, 2003). 
In addition there is evidence of increased fibrinolysis and decreased tissue factor 
mRNA in response to statins. It is noteworthy therefore that antiphospholipid 
antibodies have been shown to increase pro-inflammatory cytokine production by 
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vascular endothelial cells and to increase transcription and expression of tissue factor 
(Ferrara et al, 2004). These observations raise the question of possible benefit from 
statin use in APS, supported by a small study which showed a reduction in some 
inflammatory markers such as vascular endothelial growth factor and tissue necrosis 
factor alpha (Jajoria et al, 2009). A phase II clinical trial assessing the safety and 
efficacy of fluvastatin in reducing the risk of cardiovascular disease and thrombosis 
in patients with aPL or APS is currently underway 
(http://clinicaltrials.gov/NCT00674297).    
Rituximab 
Rituximab appears to be an effective treatment for thrombocytopenia and haemolytic 
anaemia associated with antiphospholipid antibodies (Erre et al, 2008) and may 
improve some other occasional manifestations of antiphospholipid syndrome such as 
skin ulcers (Erkan et al, 2013) [RITAPS: A Pilot Study of Rituximab For The 
Anticoagulation-Resistant Manifestations Of Antiphospholipid Syndrome] . Like all 
of these novel approaches, the precise role of rituximab in the management of 
antiphospholipid syndrome remains to be determined. 
Complement inhibition 
The experimental evidence that complement activation may have a role in some 
manifestations of APS has led to speculation that inhibition of complement may be a 
useful therapeutic strategy.   In addition to use of eculizamab in some patients with 
CAPS, phase II multicentre clinical trial of evaluating the safety and tolerability of 
intravenous (IV) ALXN1007 (complement inhibitor) in persistently aPL -positive 
patients with at least one of the non-criteria manifestations of APS: aPL-
nephropathy, skin ulcers and/or thrombocytopenia is underway 
https://clinicaltrials.gov/NCT02128269. 
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1.3.11 Treatment of obstetric APS 
In a meta-analysis of data from five trials involving 334 patients (Mak et al, 2010), 
the overall live birth rates were 74.27 and 55.85% in patients who received a 
combination of heparin and aspirin versus that in those treated with aspirin alone. 
Patients who received combination treatment had significantly higher live birth rates 
(RR 1.301; 95% CI 1.040, 1.629) than with aspirin alone. No significant differences 
in pre-eclampsia, preterm labour and birth weight were found between both the 
groups. The American College of Chest Physicians (ACCP) guidelines (Bates et al, 
2012) recommend treating women with obstetric APS, who meet revised Sapporo 
criteria, should be treated with heparin and LDA in the antepartum period as soon as 
pregnancy is confirmed. Use of heparin has become the standard of care in many 
centres and  LMWH is generally favoured due to a lower incidence of HIT and low 
risk of osteopenia compared to UFH (Robertson & Greaves, 2006). A paradox has 
been the apparent efficacy of heparin, an antithrombotic, in preventing early 
miscarriage occurring prior to placentation. The key observations made by Girardi et 
al in 2004 that complement activation may be important in pathogenesis, and that 
heparin may be effective through inhibition of complement rather than as a 
coagulation inhibitor, provides a possible explanation for this apparent efficacy in 
prevention of early miscarriage in antiphospholipid syndrome (Girardi et al, 2004). 
 A small prevalence study in 20 women with obstetric APS (Rai et al, 1995), 
demonstrated that persistent weak aCL (<99
th
 percentile) was associated with a 
>90% fetal loss rate in untreated pregnancies of women with recurrent miscarriage, 
and with significantly improved pregnancy outcome following treatment with low-
dose aspirin or heparin and aspirin (Rai et al, 1997;Granger & Farquharson, 1997). 
Many obstetricians choose to treat other women with RPL, but no evidence of aPL, 
with LDA with or without heparin (Mekinian et al, 2012). Pregnancy outcome was 
considerably improved in women diagnosed as obstetric APS either with moderate to 
strong, or weak aPL when they were treated with heparin/LDA. In a retrospective 
observational cohort study by Cohn et el  (Cohn et al, 2010), 79% of women with 
obstetric APS diagnosed using the  aCL cut off  values  ≥ log-transformed mean plus 
two SDs of results in 50 healthy adults, received aspirin and heparin during their 
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pregnancy had a live birth, compared to 62% of women with aPL who received 
aspirin only (adjusted OR 2.7, 95% CI 1.3–5.8). Given the potential devastating 
impact of long term disability associated with late obstetric morbidity, prospective 
data suggesting a benefit of standard treatment for obstetric APS in women with non-
criteria manifestations, and the favourable risk/benefit ratio of heparin plus aspirin 
treatment during pregnancy for obstetric APS, it appears reasonable at present to 
offer this treatment during pregnancy to women with low-positive aPL associated 
obstetric morbidity as soon as the pregnancy is confirmed during the first trimester 
(Arachchillage et al, 2014b). 
1.4 Aims of my thesis  
The aims of my thesis were to: 
1.   Investigate the frequency and nature of activated protein C resistance (APCr) and 
resistance to activation of endogenous protein C activation using thrombin 
generation in patients with thrombotic antiphospholipid syndrome  
2. Assess the effects of rivaroxaban on the prothrombin time and LA detection; and 
assess the influence of aPL on the anticoagulant activity of rivaroxaban  
3. Define the impact of rivaroxaban and warfarin on thrombin generation and 
haemostasis activation in thrombotic patients with or without APS  
The purpose of my work was to explore the role of APCr in the pathogenesis of 
thrombotic APS and to inform the use of the rivaroxaban in patients with thrombotic 
APS, which is of crucial importance for effective and safe management of these 
patients 
1.4.1 Frequency and nature of activated protein C resistance (APCr) and 
resistance to activation of endogenous protein C activation  
The anticoagulant protein C pathway plays a central role in the regulation of 
coagulation and maintenance of the fluidity of blood. Activated protein C (APC) 
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exerts its anticoagulant effects by proteolytic inactivation of factor Va and factor 
VIIIa (Kalafatis et al, 1994;Nicolaes et al, 1995). aPL interference with the 
anticoagulant activity of  APC, resulting in acquired APC resistance (APCr) has been 
proposed as a key mechanism of aPL-initiated thrombosis (3), although a direct 
association between an aPL-dependent APCr phenotype and thrombotic events has 
not been established (Male et al, 2001;Nojima et al, 2005). The most common 
antigenic targets of aPL antibodies are β2 glycoprotein I (β2GPI) and prothrombin. 
However, protein C, as a phospholipid-binding protein, may also be an important 
target (Nojima et al, 2002), and aPL inhibition of the thrombomodulin mediated 
activation of protein C, as well as the anticoagulant activity of APC (Malia et al, 
1990) , have  been observed. Furthermore, β2GPI binding to protein C can modulate 
its action (Keeling et al, 1993) and its subsequent binding to phospholipid surfaces, 
thereby increasing the risk of thrombosis (Mori et al, 1996). 
Generation of thrombin is a pivotal component of haemostasis, with increased ex 
vivo thrombin generation (TG) a key marker of thrombogenic potential (Eichinger et 
al, 2008;Hemker & Beguin, 2000) . Comparison of ex vivo TG in the presence and 
absence of  recombinant human activated protein C (rhAPC) or Protac®, an enzyme  
isolated  from Agkistrodon contortrix contortrix venom which converts endogenous 
protein C into APC  was perfomed to  assess  the function of the protein C system. 
1.4.2 Interactions between rivaroxaban, aPL and haemostasis activation 
It is clinically relevant to establish interactions between rivaroxaban with aPL and 
haemostasis, for the following main reasons. First, to establish anticoagulant 
intensity and thus efficacy in patients with aPL treated with rivaroxaban. Secondly, 
to enable monitoring of anticoagulant intensity in patients with thrombotic APS 
treated with these agents. Thirdly, it is important to establish how to detect LA in 
patients taking rivaroxaban. aPL are associated with multisystem clinical 
manifestations including haematological, dermatological, neurological and valvular 
cardiac lesions, and therefore continued aPL activity monitoring as a marker to 
assess disease activity is essential. There is a paucity of information on laboratory 
interactions between NOAC and aPL. Dabigatran, as a direct thrombin inhibitor, 
51 
 
prolongs the activated partial thromboplastin time (aPTT) and rivaroxaban does so to 
a lesser extent. Therefore, it is possible that these agents could modify the 
coagulation tests used to detect LA. In an ex vivo study on 19 patients, one of whom 
was stated to have a LA, rivaroxaban was reported to increase dilute Russell’s viper 
venom time (DRVVT) ratio (Merriman et al, 2011). In addition, limited in vitro 
studies on the addition of rivaroxaban to plasma from patients with LA suggest that 
Taipan and Ecarin, snake venoms which directly activate prothrombin and which can 
be used to detect LA, are not affected by the presence of rivaroxaban (van Os et al, 
2011). A detailed and systematic approach was undertaken in the work for my thesis 
to establish how best to test for LA in APS patients treated rivaroxaban.  
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 Methods Chapter 2
2.1 Ethical Committee Approval 
The study was reviewed and given a favourable ethical opinion by the Leicester 
Research Ethics Committee as a proportionate review body and approved by the 
Research and Development office at University College London Hospitals (UCLH) 
NHS Trust (Reference number:13/EM/0150). Patients were provided with written 
information sheets and informed consent was obtained prior taking venous blood 
samples at the time of venepuncture for their routine clinic blood tests. All patients 
from Rivaroxaban in Antiphosphospholipid Syndrome (RAPS) trial 
(http://www.controlled-trials.com/ISRCTN68222801) had consented to samples 
being taken at study time point for translational research (Reference number: 
12/SC/0566).  Following written informed consent, blood samples from healthy 
volunteers (haematology staff and friends) were obtained as the controls. 
2.2 Blood sample collection 
Venous blood samples for measurement of haemostatic markers, thrombin 
generation and complement activation markers were obtained using 21 gauge 
butterfly needle with minimal stasis. Blood was drawn into 5ml citrated BD 
Vacutainers® (BD, Plymouth, UK) containing 0.5ml of 0.105M buffered tri-sodium 
citrate at a ratio of 1 part anticoagulant to 9 parts blood and into tubes containing 
EDTA. Within 1 hour of collection, citrated  platelet poor plasma (PPP) and EDTA 
plasma were prepared by double centrifugation at ambient temperature (2000g for 15 
minutes x 2) and aliquots of each type of plasma were frozen to -80°C. Immediately 
prior to analysis the samples were thawed for 10 minutes at 37°C in a water bath. 
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2.3 Prothrombin time/ International Normalised Ratio (INR) 
Reagents 
 Thromboplastin reagents (i.e  Innovin®, Recombiplastin 2G etc), which 
contain recombinant human tissue factor, Calcium Chloride (CaCl2) and 
heparin neutralising reagent (hexadimethrine bromide). 
Method 
The PT was measured on a Sysmex CS-5100 analyser (Sysmex UK Ltd, Milton 
Keynes, UK) 
The International Normalised Ratio (INR) was calculated using the following 
formula: INR= PTR
 (ISI)
; where PTR= Patient PT/geometric mean normal PT; ISI = 
International sensitivity index 
The geometric mean normal PT was established by testing a minimum of 30 normal 
samples, and can vary from lot to lot of reagent.  
2.4 Rivaroxaban anti- Xa assay (Chromogenic assay for rivaroxaban level) 
Principle 
Biophen DiXaI is a chromogenic assay for in vitro quantitative measurement of 
direct factor Xa inhibitors such as rivaroxaban, on citrated human plasma. The assay 
is based on the inhibition of exogenous Factor Xa (FXa), by the tested DiXaI, and 
hydrolysis of a Factor Xa specific chromogenic substrate, by the residual factor Xa. 
Para-nitro aniline (pNA) is released from the substrate and measured at 405nm. The 
amount of pNA released is inversely proportional to the concentration of the FXa 
inhibition in the test sample. 
Reagents: Biophen DiXaI (Hyphen BioMed, NEUVILLE-SUR-OISE, France). 
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Method 
The assay was performed on a Sysmex CS-2000i (Sysmex UK Ltd, Milton Keynes, 
UK) 
Calibration was performed using the Biophen Rivaroxaban calibrator with a   
rivaroxaban range of 0 to 500ng/mL.  
 Samples were tested in duplicate and two control samples with known 
rivaroxaban level (C1: rivaroxaban level 40-140ng/mL and C2: rivaroxaban 
level 220-380ng/mL) were tested.  
 Rivaroxaban concentration (anti-Xa) of  test samples was derived from the 
calibration curve 
 Samples with rivaroxaban levels above the range of the standard curve were 
automatically re-tested at a higher dilution. 
2.5 Dilute Prothrombin Time (dPT) in KC4A 
Principle 
Clotting is initiated by activating the tissue factor (TF) coagulation pathway with 
tissue factor in the presence of calcium ions. TF binds to factor VIIa resulting in the 
activation of FIX and X. Factor Xa converts prothrombin to thrombin which initiates 
clot formation by cleaving fibrinogen to fibrin. Activation of tissue factor pathway 
bypasses the contact (intrinsic) pathway and excludes any interference from 
deficiencies of factor XII. 
Reagents 
 ACTICLOT® dPTTM r reagents (American diagnostic GmbH, Germany) 
which consist of LA buffer, LA phospholipids and dPT activator 
 KC4A coagulometer 
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Method 
 In the screening step, the patient plasma is mixed with LA buffer and dPT 
activator. The clot time is determined in semi-automated KC4A 
coagulometer. A positive result is indicated by a prolonged clot time relative 
to normal range.  
 In the confirmatory step, the patient sample is mixed with LA phospholipids 
and dPT activator. A positive result is indicated by a significant reduction in 
the clot time relative to the screening step. 
2.6 Dilute Russell Viper Venom Time (DRVVT) (in house method) 
Principle 
Russell's viper venom [RVV] isolated from the snake Daboia russelii contains a 
potent activator of factor X. In the presence of phospholipid [PL], prothrombin and 
calcium ions resulting FXa, causes fibrin clot formation. In the LA, clotting time is 
prolonged. As the RVV directly activates factor X, the test is only affected by LA 
and deficiencies of factors II, V and X. Substitution of the diluted phospholipid 
reagent with a platelet neutralisation (washed, activated platelets), demonstrates the 
phospholipid specificity of the antibody. If LA is present, the clotting time becomes 
relatively shortened in the platelet neutralisation step. 
Reagents 
 Russell Viper Venom (Diagnostic Reagents Ltd, Thame, UK) 
2mg/ml vial of RVV was reconstituted with 2ml of isotonic saline and 30 µl of RVV  
further diluted in  2.5ml  Imidazole /BSA buffer (Imidazole buffer (0.5M) was made 
using 3.4g Imidazole and 5.8g NaCl in to 900ml of water and then adjust the pH to 
7.3 with final volume of 1L. Imidazole/BSA buffer was made by dissolving 1g of 
bovine serum albumin (A 7030, Sigma) in 100ml of Imidazole buffer) 
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 Phosphoipid reagent (‘‘Bell and Alton’’ Platelet Substitute, Diagnostic 
Reagents Ltd). One vial was reconstituted in 5ml of distilled water which was 
then diluted 1 part with 3 parts of Imidazole buffer. 
 Pooled normal Plasma (platelet poor) prepared locally. Each vial of 
lyophilised platelet poor plasma was reconstituted in 1ml of distilled water, 
left for 5 minutes and mixed gently. 
 0.025M CaCl2.  
Method 
 100µL of normal plasma and 100µL of phospholipid reagent were mixed at 
37C.  
 100µL of reconstituted RVV was added and incubated for 30 seconds.  
 100µL of 0.025M CaCl2 was added and time to clot formation was recorded. 
 Procedure was repeated with platelet neutralisation reagent instead of 
phospholipid and ratio was calculated. 
Normalised screen, confirm and screen/confirm ratio are calculated as follows:     
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑆𝑐𝑟𝑒𝑒𝑛 𝑟𝑎𝑡𝑖𝑜 =
𝑃𝑎𝑡𝑖𝑒𝑛𝑡 𝑃𝑙𝑎𝑠𝑚𝑎 𝑆𝑐𝑟𝑒𝑒𝑛 𝑡𝑖𝑚𝑒
𝑁𝑜𝑟𝑚𝑎𝑙 𝑃𝑙𝑎𝑠𝑚𝑎 𝑆𝑐𝑟𝑒𝑒𝑛 𝑡𝑖𝑚𝑒
 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐶𝑜𝑛𝑓𝑖𝑟𝑚 𝑟𝑎𝑡𝑖𝑜 =
𝑃𝑎𝑡𝑖𝑒𝑛𝑡 𝑃𝑙𝑎𝑠𝑚𝑎 𝐶𝑜𝑛𝑓𝑖𝑟𝑚 𝑡𝑖𝑚𝑒
𝑁𝑜𝑟𝑚𝑎𝑙 𝑃𝑙𝑎𝑠𝑚𝑎 𝐶𝑜𝑛𝑓𝑖𝑟𝑚 𝑡𝑖𝑚𝑒
 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑇𝑒𝑠𝑡: 𝐶𝑜𝑛𝑓𝑖𝑟𝑚 𝑟𝑎𝑡𝑖𝑜 =
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑆𝑐𝑟𝑒𝑒𝑛 𝑟𝑎𝑡𝑖𝑜
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐶𝑜𝑛𝑓𝑖𝑟𝑚 𝑟𝑎𝑡𝑖𝑜
 
If the normalised test: confirm ratio >1.2 it confirms the presence of LA  
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2.7 Dilute Russell Viper Venom Time (DRVVT) (IL ACL TOP 500 
Method  
Reagents 
 DRVVT Screen Reagent  
 DRVVT Confirm Reagent 
 LA Negative Control  
 LA Positive Control 
 Pooled normal plasma 
All reagents are from Instrumentation laboratory, Warrington, UK 
Method 
LA screen and confirm steps were done are per manufacture’s standard protocol and 
normalised screen, confirm and screen/confirm ratio were calculated as described in 
2.6 
2.8 Dilute Russell Viper Venom Time (DRVVT) (CS-5100 / CS-2000i 
analyser: Sysmex UK Ltd, Milton Keynes, UK)  
 LA1 screening reagents 
 LA2 confirmation reagents 
 LA Negative Control  
 LA Positive Control 
 Pooled normal plasma 
All reagents are from Siemens Healthcare Diagnostics Products GmbH, Marburg, 
Germany. 
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Method 
LA screen and confirm steps were done are per manufacture’s standard protocol and 
normalised screen, confirm and screen/confirm ratio were calculated as described in 
2.6. 
2.9 Taipan venom test /Ecarin clotting time (KC4A method) 
Principles 
The Taipan venom time (TVT) employs a reagent isolated from the venom of the 
Taipan snake (Oxyuranus scutellatus) that directly activates prothrombin in the 
presence of phospholipid and calcium. Therefore it is independent of the plasma 
concentration of FV, FX and VII. Taipan snake venom (TSV) may be used to detect 
lupus anticoagulant (LA). Phospholipid, TSV and calcium ions are added to plasma, 
causing the conversion of prothrombin to thrombin and fibrin clot formation. By 
contrast, Echis carinatus venom (Ecarin) is able to convert native and PIVKA 
prothrombin to meizothrombin in the absence of Ca
2+
 and phospholipid. These 
characteristics make Taipan snake venom time (TSVT) and Ecarin clotting time 
(ECT), when performed in parallel, a useful assay in the detection of LA. If LA is 
present in the sample, the phospholipid dependent TSVT will be extended, while the 
ECT will remain normal. 
Reagents 
 Imidazole Buffer (0.5M) 
 Taipan Snake Venom (Diagnostic Reagents). One vial was reconstituted in 
5ml of distilled water and diluted with 1 in 1 0.025M CaCl2 
 Phosphoipid reagent (‘‘Bell and Alton’’ Platelet Substitue, Diagnostic 
Reagents Ltd) One vial was reconstituted in 5ml of distilled water which was 
then diluted 1 part with 3 parts of Imidazole buffer. 
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 Normal Plasma (platelet poor) prepared locally. Each vial of lyophilised 
platelet poor plasma was reconstituted in 1ml of distilled water, left for 5 
minutes and mixed gently. 
 Ecarin (Echis carinatus) venom (Diagnostic Reagents Ltd). Reconstitute with 
2.0ml distilled water 
 0.025M CaCl2.  
Method 
TVT 
 100µL of normal plasma and 100µL of phospholipid reagent were mixed at 
37C.  
 100µL of TSV /CaCl2 was added and time to clot formation was recorded. 
ECT 
 100µL of Ecarin is added to 100µL of test plasma and time to clot formation 
is recorded. 
2.10 Textarin® /Ecarin ratio to detect lupus anticoagulants 
 Principle 
Textarin® is a serine proteinase, isolated from the venom of the Australian Brown 
Snake Pseudonaja textilis; is a phospholipid, factor V and calcium dependent 
prothrombin activator. It is independent of other plasma clotting factors and 
generates thrombin activity from prothrombin. As the action of Textarin® is affected 
by antiphospholipid antibodies, if the Textarin® clotting time is performed in 
parallel to the phospholipid –independent ecarin clotting time, , the ratio can be used 
to detect LA. 
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Instruments and reagents 
 Textarin® (Pentapharm Ltd) 
 0.025M CaCl2 
 Immunoglobulin solution from patients with positive LA 
 Pooled normal plasma 
 Amelung-Coagulometer (KC4A) 
Method 
 100µL of normal plasma and 100µL of phospholipid reagent were mixed at 
37 C°.  
 100µL of reconstituted Textarin was added and incubated for 30 seconds.  
 Then 100µL of 0.025M CaCl2 was added and time to clot formation was 
recorded. 
2.11 TVT and ECT in Sysmex CS-5100i /analyser (Sysmex UK Ltd) 
Reagents 
 Taipan (Oxyuranus scutellatus) venom (Diagnostic Reagents Ltd). 
 Reconstitute with 5.0ml deionised water, dilute 1:1 with Calcium Chloride/BSA and 
use immediately (tests to be completed within 1 hour). 
 Ecarin (Echis carinatus) venom (Diagnostic Reagents Ltd). 
Reconstitute with 2.0ml distilled water (Stable for 7 days at 2-8°C). Dilute 1/5 with 
Imidazole Buffer (Stable for 1 working day at 2-8°C). 
 Bell and Alton Platelet Substitute (Diagnostic Reagents Ltd).  
 Reconstitute with 5ml deionised water and dilute 1/8 with Imidazole Buffer. 
 Calcium Chloride/ bovine serum albumin (BSA) - 25 mMol/L Calcium 
Chloride solution (Siemens Healthcare, Ref: ORHO37); add 1g/100ml Bovine 
Serum Albumin (A-7030, Sigma Aldrich). 
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 Imidazole buffer (Siemens Healthcare, Ref: OQAA33) Ready to use. 
 
 LA Control Low (Siemens Healthcare, Ref: OQWE11) Reconstitute with 1.0ml 
deionised water. 
 LA Control High (Siemens Healthcare, Ref: OQWD11) Reconstitute with 1.0ml 
deionised water. 
2.11.1 TVT 
 40μL of plasma mixed with 40μL of Bell and Alton platelet substitute and 
incubate for 60seconds. 80μL of Taipan + CaCl2 was added over 130 seconds 
and measured the reaction time over 300seconds. 
2.11.2 ECT 
 100μL of ecarin is added to 50μL of plasma over 110 seconds and the 
reaction time is measured over 180seconds. 
2.12 D dimer 
Principle of method-Immunoturbidometric assay 
D dimer is generated when cross –linked fibrin is degraded by plasmin. Dilutions of 
standards and test plasma are mixed with a reaction buffer and latex particles coated 
with a monoclonal antibody to a D dimer epitope (antigen). The antigen-antibody 
complexes produced by the addition of samples containing D dimer causes increased 
turbidity.   
Reagents: Innovance D-dimer kit 
 Method 
The assay was performed in Sysmex CS 5100 analyse using manufacture’s standard 
protocol. The standard curve ranging from 1.5 to 5.0mg/L FEU was generated using 
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the reference plasma by the analyser with its auto-dilution mode. Normal D dimer 
reference level is <0.55mg/L FEU.  
2.13 Prothrombin fragments 1.2 (F1.2) 
Principle of method –ELISA assay 
Prothrombin fragment 1.2 (F1.2), is an activation peptide released from prothrombin 
during its factor Xa –catalysed conversion to thrombin 
Reagents: Enzygnost® F1.2 (monoclonal) ELISA kit (Siemens Healthcare, Marburg, 
Germany) 
Method 
Assay was performed in an ELISA using manufacture’s standard protocol.  
2.14 Thrombin-Antithrombin complexes (TAT) 
TAT complexes formed following the neutralization of thrombin by antithrombin III 
(AT) have been used as a surrogate marker for thrombin generation 
Principle of method –ELISA assay 
Reagents: Enzygnost® TAT micro kit (Siemens Healthcare, Marburg, Germany) 
Assay was performed in an ELISA using manufacture’s standard protocol.  
2.15 Thrombin generation test 
Principle of method 
TG using the calibrated automated thrombogram (CAT) method was developed by 
Hemker et al (2003). The CAT system allows continuous measurement of TG in 
clotting plasma. Thrombin generation is initiated by the addition of a combined 
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calcium/fluorogenic substrate (Z-Gly-Gly-Arg-AMC) in the presence of tissue factor 
(TF)/phospholipid trigger. The fluorescent signal generated is transmitted to and 
processed by a computed with specific software (Thrombinoscope 
TM)
) to assess 
/measure thrombin generation.  A thrombin calibrator (Thrombin α2- macroglobulin 
complex) is run in parallel with each sample to compensate the inner-filter effect and 
substrate consumption.  The fluorescent signal from the sample is compared to that 
of the calibrator by the Thrombinoscope software. A TG curve is generated, (an 
example of which is shown in Figure 2-1.  
Figure 2-1 A representative thrombin generation curve 
 
Reagents 
 HEPES Buffer: 20mM HEPES, 140mM NaCl, 0.02% Sodium Azide at pH 
7.35 
 Fluo-Buffer: 20mM HEPES buffer with 60mg/mL BSA  
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 PPP –reagent (Thrombinoscope BV, Maastricht, The Netherlands) 5 pM 
Tissue Factor and 4 µM Phospholipids reconstituted with 1ml of H2O  
 Thrombin calibrator (Thrombinoscope BV) reconstituted with 1ml of H2O  
 Fluorogenic substrate: 100 mM solution of Z-Gly-Gly-Arg-AMC (Bachem, 
Bubendorf, Switzerland). in Dimethyl sulfoxide (DMSO, Sigma-Aldrich, 
Poole, UK) 
 FluCa reagent: 2.275mL Fluo-Buffer, 0.26 mL 1M CaCl2 (incubated at 37
°
C). 
Immediately prior to use 65µL of 100 mM Fluorogenic substrate was added 
and vortex mixed. 
 CAT system 
Method 
Six wells were allocated for each sample: three for monitoring TG and three for the 
thrombin calibrator (TC) in a 96- well transparent, microtitre plate (Immulon 2HB 
clear U-bottom, Diagnostic Stago). 20 µL of PPP reagent was added to each TG 
well. 20 µL of thrombin calibrator was added to each thrombin calibrator well and 80 
µL of plasma sample was added to each well (TG and TC). The microtitre plate was 
transferred to a pre-warmed Ascent Fluorskan plate reader. 20 µL of FluCa reagent 
was dispensed automatically by the instrument and the reaction was monitored for 60 
minutes. 
Results and raw data were then transferred to a Microsoft Excel spread sheet. Peak 
TG and area under the curve; known as endogenous thrombin potential (ETP) were 
normalised relative to reference plasma, tested in each analytical run, and reported as 
a percentage of the reference plasma. The lag time and time to peak were also 
recorded. 
 
 
65 
 
2.16 Activated protein C resistance determined by thrombin generation  
Principle of method 
TG was performed in the absence and presence of activated protein (APC) C or 
Protac® which activates endogenous protein. Resistance to APC or Protac® was 
calculated as a percentage inhibition in relation to normal reference plasma. 
Reagents 
 Reagents as per TG  
 Activated protein C (Eli Lilly) stock in 5μmol 
 Coagulation reference plasma (Technoclone GmbH, Austria, Vienna) 
Method 
 20μL of PPP reagent was added to each TG measurement well. 
 20μL of thrombin generation calibrator was added to calibrator well (as the 
same reference plasma was used for TG with different concentrations of 
APC, same calibrators were used all TG reactions) 
Keeping the plasma volume constant at 65μL, 15 μL of APC (1 to 20nM) in buffer 
containing 20mM HEPES, 140mM NaCl pH 7.35 in 1% was added. Following 10 
mins incubation period, 80μL of the plasma +APC added to TG wells which in to 
give a final assay concentration of APC as shown in Table 2-1.  
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Table 2-1 Preparation of increasing concentration of rhAPC for thrombin generation 
 Final rhAPC  concentration in each 
thrombin generation test well (nM)) 
Final concentration of  rhAPC in each 
15μL of buffer (nM) 
2 16 
5 40 
7.5 60 
10 80 
12 96 
15 120 
20 160 
                                                                                                                                                                                                                                                                                                                                                                                                                      
As anticipated, there was an APC concentration dependent reduction in thrombin 
generation. APC concentration that produced about 50% reduction in thrombin 
generation (5nM)  was selected and repeated the assay to confirm the reproducibility 
and to check the inter-assay coefficient of variation (n=8).Results of the thrombin 
generation are shown below Figure 2-2. 
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Figure 2-2 Thrombin generation with increasing concentration of APC 
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The following graph (Figure 2.3) demonstrates the concentration dependent 
reduction in TG in reference plasma. 
Figure 2-3 APC concentration dependent inhibition of Thrombin generation 
 
2.16.1 The assessment of resistance to activation of endogenous protein C 
using Protac®  
Reagents 
 Reagents as per TG  
 Coagulation reference plasma (Technoclone GmbH, Austria, Vienna) 
 Protac® (Pentapharm), 5U per vial was dissolved in 500µL of distilled water 
to get Protac® concentration 10U/mL. 
To keep the volumes of plasma (65μL)  and Protac® (15µL) constant, the following 
concentrations of Protac® were prepared  as the final volume of mixture in each well 
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as 120µL; plasma, Protac®, tissue factor and Fluorogenic substrate):Table 2-2 
Preparation of increasing concentration of Protac® for thrombin generation 
Table 2-2 Preparation of increasing concentration of Protac® for thrombin generation 
Final Protac®  concentration in each 
thrombin generation test well (units) 
Final concentration of  Protac® 
(units) in  each 15μL buffer 
0.02 0.16 
0.025 0.2 
0.05 0.4 
0.075 0.6 
0.1 0.8 
0.2 1.6 
0.5 4.0 
1.0 8.0 
 
 20μL of PPP reagent was added to each TG measurement well. 
 20μL of thrombin generation calibrator was added to calibrator well (as the 
same reference plasma was used for TG with different concentrations of 
APC, same calibrators were used all TG reactions) 
 65µL of reference plasma and 15μL of increasing concentration of Protac® in 
buffer B gently mixed with the pipette. 
 Following 10 mins incubation period, 80μL of the plasma + Protac® was 
added TG wells which in to give a final assay concentration of Protac®as 
table 2.2.  
 The microtitre plate was then transferred to a pre-warmed Ascent Fluorskan 
plate reader. Incubation and priming instructions from Thrombinoscope 
70 
 
Software were followed. 20 µL of FluCa reagent was dispensed automatically 
by the instrument, which allows the reaction to take place and was monitored 
for 60 minutes.  
 As expected, there was a Protac® concentration dependent reduction in 
thrombin generation (Figure 2.4) and Protac® that produces approximately 
50% reduction in thrombin generation was selected for sample testing.  
 The reproducibility was checked, intra and the inter-assay coefficient of 
variation were determined. 
Figure 2-4 Thrombin generations with varying concentration of Protac® 
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10 minutes before use. The concentrations of rhAPC and Protac® that produced 
approximately 50% inhibition of peak TG in PNP were selected this study. All TG 
reactions for samples and calibrators were tested in triplicate and PNP was run in 
parallel on each plate.   
2.17 Chromogenic Protein C assay  
Principle of the method-chromogenic assay 
Protein C is activated using an extract from a snake venom (Akistrodon contortrix 
contortrix). The resulting activated PC (APC) cleaves an amidolytic substrate 
releasing the chromophore para-Nitroaniline (pNA). This reaction is monitored 
kinetically at 405nm. The amount of PC activity is proportional to the absorbance.     
The assay is based on the following reactions. 
Protein C sample      Protein C activator      APC  
p-Glu-Pro-Arg-MNA    APC                    p-Glu-Pro-Arg-OH +MNA 
Reagents and instrumentation: 
 All reagents were from Siemens Diagnostics Healthcare (Marburg, 
Germany), and the assay was performed on a Sysmex CS-2000i (Sysmex UK 
Ltd, Milton Keynes, UK). 
 Berichrom Protein C kit (composed of: Protein C activator; Substrate reagent 
and a Hepes buffer solution for reconstitution of the activator reagent) 
 Calibrator (Standard Human Plasma [SHP]) 
 Control plasma N (normal) 
 Control plasma P (pathological) 
 Owren’s veronal buffer (OVB) 
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Method 
 Assay was performed using manufacture’s standard protocol.  
 Samples with protein C levels above the range of the calibration curve were 
re-tested at higher higher dilution.  
2.18 Free protein S antigen assay 
Principle of the method: Immunoturbidometric assay    
A suspension of latex particles coated with monoclonal antibodies specific for free 
protein S is mixed with test plasma. The antigen–antibody reaction leads to 
agglutination of the latex particles, causing an increase in absorbance reaction 
medium. The absorbance of the medium is measured photometrically at 800nm. The 
degree of agglutination and hence the absorbance is directly proportional to the free 
protein S concentration in the test sample.  
Reagents and instrumentation: 
All reagents were from Siemens Diagnostics Healthcare (Marburg, Germany), and 
the assay was performed on a Sysmex CS-2000i (Sysmex UK Ltd, Milton Keynes, 
UK). 
 The INNOVANCE® Free PS Ag assay (composed of: Free protein S (FPS) 
buffer and FPS reagent i.e. anti-FPS coated latex particles) 
 Calibrator (Standard Human Plasma [SHP]) 
 Control plasma N (normal)  
 Control plasma P (pathological) 
 Owren’s veronal buffer (OVB) 
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Method 
 Assay was performed using manufacture’s standard protocol.  
 Samples with free protein S antigen levels above the range of the calibration 
curve were re-tested at higher dilution.  
2.19 ELISA for Protein C Antibodies 
Principle of the method  
Microplate is coated with human purified protein C (PC). Test samples, diluted in 
sample buffer are added to PC coated wells in duplicate; if antibodies to P Care 
present they bind to well. After washing step to remove unbound antibodies and non-
specific particles, PC antibodies were detected by the addition of the 
immunoconjugates followed by substrate for colour development. 
Reagents 
 Protein C concentrate 500units (42.5mg) (Baxter Healthcare Ltd, Norfolk, 
UK), reconstituted in 5ml of distilled water. Following reconstitution, each 
vial contains: 8.5mg/mL protein C, 8mg/mL human albumin, 4.4mg/mL 
disodium citrate dehydrate and 8.8mg/mL sodium chloride.  
 Detection antibody - Horseradish peroxidase- conjugated goat antihuman IgG 
(α-chain specific; cat.no. A-2290, Sigma-Aldrich company Ltd, Dorset, UK) 
 Coating Buffer - TBS/Ca - 0.05M Tris, 0.1M NaCl, 5mM CaCl2, pH 7.4 
 Blocking Buffer – TBS/Ca - 0.05M Tris, 0.1M NaCl, 5mM CaCl2, pH 7.4 
3% bovine serum albumin [BSA] (Product A-7030, Sigma-Aldrich company 
Ltd, Dorset, UK)  
 Washing Buffer – TBS/Ca - 0.05M Tris, 0.1M NaCl, 2.5mM CaCl2, pH 7.4 
 Sample Buffer  – TBS/Ca - 0.05M Tris, 0.1M NaCl, 5mM CaCl2, pH 7.4, 1% 
BSA 
 Substrate buffer – 0.1M Citrate phosphate buffer pH 5.0 
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Distilled water           950ml 
Disodium hydrogen orthophophate dodecahydrate (VWR product code: 
102484A) 23.87g 
Citric acid anhydrous (Sigma C0759) 7.3g 
Make up to 1litre with distilled water; adjust to pH 5.0 with 4M Sodium Hydroxide 
and store at 4
0
C. 
 Substrate solution:  
               Ortho phenyldiamine dihydrochloride 15mg tablet 
               Citrate phosphate buffer- 24ml 
6% hydrogen peroxide -10μl  
 Stopping agent – 2.0M Sulphuric acid 
 Method 
 An irradiated polystyrene plate (MaxiSorp; Fisher Scientific UK Ltd, 
Loughborough, UK) was coated with 100uL, 10mg/L Protein C diluted in 
coating buffer per well in the  first half of the plate and 100uL coating buffer 
alone, second half as a control area for non-specific binding.  
 The plate was covered and incubated overnight at 4°C. 
 Following 3 washes with 250µL of washing buffer; wells were blocked with 
180uL of blocking buffer for 60 min and then washed 3 times. 
 100μl of each diluted test plasma samples (diluted as 1/25 in sample dilution 
buffer) was added to each well in duplicate.  
 After 60 min incubation at room temperature, the wells were washed 3 times 
100 μL of detection antibody diluted 1:1500 in sample Buffer, was added as 
the secondary antibody. 
 After 60 min incubation period, wells were washed 3 times and colour was 
developed by means of 100 μl substrate.  
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 The enzyme reaction was stopped after suitable colour development by 
adding 50μL of 2M H2SO4 to each well. The absorbance was measured at 490 
nm. 
 Positive and negative quality control samples were run on each plate. 
2.20  Detection of protein S antibodies (anti-protein S IgG ELISA) 
Principle of the method 
Microplate is coated with human purified protein S (PS). Test samples, diluted in 
sample buffer are added to PS coated wells in duplicate; if antibodies to PS are 
present they bind to well. After washing step to remove unbound antibodies and non-
specific particles, PS antibodies were detected by the addition of the 
immunoconjugates followed by substrate for colour development. 
 Detection of anti-PS IgG was done using anti-PS IgG ELISA kit from Stago 
R&D (Gennevilliers Cedex, France), which was a kind gift from Dr. Mariette 
Adam and Dr Bary Woodhams.  
 Assay was performed essentially according to the instruction provided by the 
manufacture. 
  In brief, all samples from patients and normal controls were diluted 1:101 in 
dilution buffer provided. PS standard was tested from in serial double dilution 
from 100% to 1.56% to obtain the standard curve. 200µL of each sample, the 
standard and the control was added to each well of the PS coated plate in 
duplicate.  
 Following 60 minutes of incubation period at room temperature, plate was 
washed 5 times with washing solution and 200µL of immunoconjugates was 
added to each well. Following another 60 minutes incubation period at the 
room temperature, plate was washed ×5 and colour was developed by means 
of 200 μL of TMB substrate. After 5 minutes the enzyme reaction was 
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stopped by adding 50μL of 1M H2SO4 to each well and the absorbance was 
measured at 450 nm.  
 Samples were considered positive for anti-PS  antibodies if the absorbance 
was greater than 3SD above the mean 0.086 of normal controls (cut-off = 0.1. 
Standard, positive and negative samples were run on each plate for quality 
control purposes. 
2.21 Determination of the avidity of IgG protein C and protein S antibodies  
 The avidity of the IgG PC and PS antibodies was assessed by introducing 
chaotropic conditions to the ELISA using a method adapted from (Cucnik et 
al, 2004). 
  Briefly, the assay was performed as above for protein C antibodies, but 
samples positive for IgG  protein C antibodies  were diluted in coating buffer 
containing either: 0.1, 0.15, 0.25, 0.5, 1.0, 2.0, 4.0, or 6.0M NaCl and loaded 
onto the microplate before incubating for 90 minutes. Bound IgG was 
detected as described above for detection of anti-protein C antibodies and 
avidity was determined by calculating the percentage of maximum binding at 
0.1M NaCl. 
 Samples positive for IgG PS antibodies were also tested for avidity as 
described above for the avidity determination for anti-protein C antibodies. 
Samples from 7 APS patients and the one non-APS patient positive for 
antibodies were diluted in sample buffer  without NaCl and  with the 
increasing  concentration of NaCl (0.1M, 0.25M, 0.5M, 1M, 2M and 4M) and 
ELISA was performed  as described above for detection of anti-PS 
antibodies. Avidity was determined by calculating the percentage of 
maximum binding in the absence of NaCl. 
77 
 
2.22 Purification, Dialysis, and concentration of IgG  
Principle of method 
Affinity chromatography separates proteins on the basis of a reversible interaction 
between a protein (IgG immunoglobulin) and a specific ligand (Protein A/G 
Agarose) covalently immobilized onto a chromatographic matrix. The sample (serum 
or plasma) is applied to the matrix. Unbound material is washed away, while the 
bound target protein is recovered by changing conditions to those favouring elution. 
Elution of IgG is performed by changing the matrix to acid pH.  IgG is collected, 
dialysed and concentrated. The pH of the medium is neutralised by adding a 
neutralising buffer.  
Instruments and reagents 
 Nab protein G spin column (Pierce) Thermo Fisher Scientific UK 
 Spin column (AMICON ultra, centrifugal filter units, Millipore UK or Fisher, 
30 K cut off, code: UFC 803024)  
 Binding (Equilibrating/Washing) Buffer - 0.1M Phosphate - pH 7.2  
 Elution Buffer- 0.1M glycine pH 2.7  
 Neutralisation Buffer-1M Tris pH 9 (add HCl to adjust pH) 
 Dialysis solution - Phosphate buffered saline (PBS) (Sigma-Aldrich 
Company Ltd) 
 All Buffers need to be filter sterile and this is achieved by using either 
vacuum filtration or a syringe and Millex-GS filters 0.22 µm (code: 
SLG50335S) 
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Method 
 The column was washed with 5 ml binding buffer to pre-equilibrate, serum or 
plasma samples were diluted 1:1 with binding buffer and applied to the 
column.  
 The column was washed with 15 ml of binding buffer to elute any non-
specific binding proteins.  
 4 ml of elution buffer was added to the column and the eluent was collected 
in a single tube.   
 400 µl of neutralisation buffer was added immediately to the elution fraction   
and mixed in order to neutralise the pH (100 µl of neutralisation buffer for 
each ml of elution buffer).  
 The purified IgG was added to a spin column (AMICON ultra, centrifugal 
filter units, (30 K cut off, code: UFC 803024) Millipore UK, centrifuged and 
then dialysed with PBS. 
2.23 Quantification of IgG (IgG ELISA) 
Principle of method 
A polystyrene microtitre plate (Nunc Maxisorp) is coated with a monospecific rabbit 
antibody to human IgG. After incubation the plate is washed and the plate is 
incubated with blocking agent (3% bovine serum albumin (BSA) in PBS) and 
washed again. Dilutions of control and samples are applied and the plate is 
incubated.  Subsequent to another washing step, a second antibody is applied 
(Horseradish peroxidase-conjugated rabbit antihuman IgG) and the plate is 
incubated. Excess antibody is removed by washing the plate and quantitation is done 
in a colourimetric enzyme substrate reaction, the colour intensity produced being 
directly proportional to the concentration of IgG present in sample. 
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Instruments and reagents 
 MRX Microplate Reader DYNEX Technologies, Inc. 
 Equipment Automatic pipettes 5-50, 50-200, 200-1000, and 1000-5000μl and 
disposable tips 
 Multi-channel pipette 50-300μl and disposable tips. 
  Coating antibody: Rabbit anti-human IgG (Dako Ltd A0423) 
 Detecting antibody: Horseradish peroxidase-conjugated rabbit antihuman IgG 
(Dako  Ltd, P0214) 
 6% Hydrogen Peroxide (Pharmacy) 
 Concentrated sulphuric acid (~ 19M) (Merck 10276) 
 Reference preparation for IgG Human serum protein calibrator (Dako Ltd 
X0908). Store at 4
◦
C. 
 Plate coating buffer – phosphate buffered saline (PBS), pH 7.2. Prepare using 
buffer tablets; store at 4
◦
C. 
 Sample and HRP conjugate antibody dilution buffer -1% BSA in PBS 
 Blocking buffer: 3% BSA in PBS 
 Washing buffer- 0.1% Tween 20 in PBS (PBST) 
 Substrate buffer - 0.1M Citrate phosphate buffer pH 5.0 
Distilled water           950ml 
Disodium hydrogen orthophophate dodecahydrate (Merck 102484A) 23.87g 
     Citric acid anhydrous (Sigma C0759) 7.3g 
           Make up to 1litre with distilled water; adjust to pH 5.0 with 4M Sodium      
           Hydroxide and store at 4
0
C. 
 Substrate solution  
           Ortho phenyldiamine dihydrochloride 15mg tablet 
80 
 
             Citrate phosphate buffer- 24ml 
  6% hydrogen peroxide -10μl  
 Stopping agent -2.0M Sulphuric acid 
Method 
 100μl of coating antibody diluted 1:500 in coating buffer was added to each 
well of a microtitre plate using a multi-channel pipette.  
 The plate is covered and incubated overnight at 4◦C. 
 After washing the plate three times with 250μl of washing buffer the plate 
was blocked with 180μl of blocking buffer. The plate was covered and 
incubated for 1.5 hours.  
 The plate was washed three times and the standard was added in duplicate 
with serial double dilutions in sample buffer from 1:100,000 to 1:6400, 000 
(A1/2 to G1/2) and the blanks (sample buffer) to last 2 wells (H1/2). 
Following the placement of the test samples in duplicate (1:100,000 to 
1:200,000 in sample buffer) to other wells, the plate was covered and 
incubated for 1 hour at room temperature.  
 After 1 hour of incubation, the plate was washed three times, 100 µL of 
detecting antibody diluted  1:500 in sample buffer was added to each well and 
incubated for another 1 hour in room temperature. 
 The plate was washed three times and freshly prepared 100µL of peroxidase 
substrate was added to each well.  
 The plate was incubated in the dark at room temperature until gradation of 
colour was seen throughout the standard curve.  
 The enzyme reaction was then stopped by adding 50μL of stopping agent to 
each well. The plate was read at 490 nm on MRX Microplate Reader. 
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 Using the standard curve, and the absorbance of the samples   IgG levels were 
calculated. 
2.24 Rivaroxaban preparation for in vitro experiments 
Method is based on (Molenaar et al, 2012). 
Range of rivaroxaban concentration for experimentation is 1-1000µg/L 
Reagents 
 Rivaroxaban (Bayer Healthcare) 50mg (material no.80058013) 
 DMSO (Sigma lot 276855) 
 OVB (Siemens Haelthcare) 28.4mM Sodium Barbitone, 0.125M NaCl,pH 
7.35 
 Preparation of stock and working solutions: 
 50mg rivaroxaban was dissolved   by gradually washing the vial contents into 
a beaker using the DMSO.  Contents were transferred to a volumetric flask 
and adjusted final volume to 500mL using DMSO and stirring thoroughly. 
This solution has a concentration of 100µg/ml of rivaroxaban and stored in 
room temperature (in poisons cabinet for security reasons) 
 1 mL of 100µg/ml rivaroxaban preparation was diluted with 4ml of Owren’s 
veronal buffer (OVB) to get 20µg/mL of rvaroxaban and at the same time 
1mL of DMSO was diluted with 4mL of OVB as the control of 0µg/ml 
rivaroxaban. Both preparations were stored at room temperature. 
 250µl of 20µg/mL of rivaroxaban was diluted with 4750µL of normal plasma 
to get concentration of 1000µg/L of rivaroxaban in plasma and 250µl   of 
DMSO/OVB solution was diluted with 4750µl of normal plasma to get 0µg/L 
concentration of rivaroxaban/DMSO control in plasma. 
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Range of rivaroxaban concentrations were prepared by mixing the 1000µg/L 
rivaroxaban and 0µg/L rivaroxaban /DMSO control solutions as in Table 2-3. 
Table 2-3 Preparation rivaroxaban concentrations 
Rivaroxaban final 
concentration(µg/L) 
 Volume of 
Rivaroxaban 1000µg/L 
in plasma(µL) 
Volume of 
Rivaroxaban /DMSO 
control 0µg/L in 
plasma(µL) 
0 0 1000 
50 50 950 
100 100 900 
150 150 850 
200 200 800 
300 300 700 
400 400 600 
500 500 500 
700 700 300 
800 800 200 
1000 1000 0 
 
2.25 Effect of antiphospholipid antibodies on rivaroxaban in thrombin 
generation and anti-Xa assay 
Reagents 
 Reagents for TGT as described in section 2.3   
 IgG purified from patients and normal controls as described in section 2.7, 
quantified by IgG ELISA as described in section 2.8. 
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 Different concentration of Rivaroxaban (25ng/mL, 50ng/mL and 100ng/mL) 
in DMSO/OVB (as described in section 2.9) 
 Phosphate buffered saline (PBS) as the buffer control 
Method 
 Final IgG concentrations of 250μg/mL and 500μg/mL and rivaroxaban 
concentration of 25ng/mL to 100ng/mL were selected for the experiments.  
 Pooled normal plasma was spiked with IgG and rivaroxaban to make final 
mixture of 10% IgG, 10% Rivaroxaban and 80% plasma of the total 80mL of 
plasma and incubated for 10 minutes prior to adding 20μL of 5pmol tissue 
factor.  
  TG was performed and following parameters were recorded: Lag time, ETP, 
peak thrombin and the time to peak. Anti-Xa of the each sample was 
measured using Biophen DiXaI (Hyphen BioMed, Neuville-Sur-Oise, 
France) on a Sysmex CS-2000i (Sysmex UK Ltd, Milton Keynes, UK). 
 Rivaroxaban anti-Xa level was assessed as described in section53 2.4. 
2.26 Statistical analysis 
Data analysis was performed using Microsoft®Excel and Analyse-it software version 
2.26 (Analyse-It Software Ltd, Leeds, UK). Data showing a normal distribution were 
analysed using Student’s t-test and non-parametric data using Kruskal-Wallis 
ANOVA (for multiple groups comparisons) and the pair-wise comparisons were 
made using Mann-Whitney ‘U’ test. For multiple analyses, the p-values derived from 
Kruskal-Wallis ANOVA were adjusted by by Bonferroni correction. Fisher’s exact 
test (FET) was used to study associations. A p value of <0.05 was considered 
significant.   
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 Activated protein C resistance (APCr) and resistance to Chapter 3
activation of endogenous protein C activation 
determined using thrombin generation patients in with 
thrombotic antiphospholipid syndrome. 
3.1 Introduction 
Protein C (PC), protein S (PS) and thrombomodulin are naturally occurring 
anticoagulants designed to regulate coagulation, maintain the fluidity of blood within 
the vasculature, and prevent thrombosis mainly through the regulation of thrombin 
generation. Antiphospholipid antibodies (aPL) may interfere with the anticoagulant 
activity of activated PC (APC) to induce acquired activated PC resistance (APCr). 
This effect of aPL on APC is one of the proposed mechanisms for the development 
of thrombosis in patients with APS (Rodeghiero & Tosetto, 1999). Therefore 
phenotypic evaluation of APC resistance has been suggested as an alternative 
screening strategy (Rodeghiero & Tosetto, 1999). However, direct association 
between an aPL -dependent APCr phenotype and thrombotic events is still not 
established (Male et al, 2001;Nojima et al, 2005). There are limited data on APCr in 
patients with APS using exogenous APC (rhAPC) (Zuily et al, 2013;Liestol et al, 
2007b) with endogenous activation of protein C in these patients undefined. 
The aim of this study was to investigate the frequency and nature of APCr using ex 
vivo TG with exogenous APC as well as activation of endogenous PC, in APS 
patients on long term warfarin for VTE.  
3.2 Intra and inter-assay imprecision of thrombin generation with buffer 
control, rhAPC and Protac 
To evaluate the assay imprecision with buffer control, rhAPC and Protac in the 
presence of 5 pmol/L tissue factor (TF) and 4 µM phospholipid (PPP reagent) 
measurement of TG was assessed in pooled normal plasma. To measure intra- assay 
imprecision, TG of the pooled normal plasma was tested 8 times (in triplicate for 
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buffer control, with rhAPC and Protac) in the same run, while inter-assay 
imprecision was assessed for TG using buffer control, rhAPC and Protac on 6 
different days. 
3.2.1 Results 
Figure 3-1 shows an example on the effect of rhAPC and Protac® on thrombin 
generation in pooled normal plasma. The mean intra-assay coefficient of variation 
(CV) for ETP (n=8) using PNP with buffer control, rhAPC and Protac® were: 2.5, 
3.0 and 4.5% respectively; and the inter-assay CV (daily for 6 days) was: 4.0, 4.5 and 
8.3% respectively. 
Figure 3-1 Example of thrombin generation of pooled normal plasma with buffer control,   
               rhAPC and Protac 
 
This figure demonstrates the thrombin generation of pooled normal plasma with buffer control, 
rhAPC (5nM) and Protac® (0.2units/mL). Both rhAPC and Protac comparable inhibition of thrombin 
generation in pooled normal plasma (PNP). 
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3.3 Patients and normal controls  
Having obtained written informed consent, blood samples were obtained from 102 
patients on long-term anticoagulation with warfarin for VTE (a cohort of 51 patients 
with APS; and 51 non-APS patients) and 51 healthy normal controls.  
3.3.1  Inclusion criteria 
 Patients with antiphospholipid syndrome on warfarin for venous 
thromboembolism 
 Patients without antiphospholipid syndrome on warfarin for venous 
thromboembolism 
 Healthy normal controls who were not on any anticoagulants or oestrogen 
containing oral contraceptive pills/hormone replacement therapy. 
3.3.2  Exclusion criteria 
 Patients with FV Leiden/ G20210A prothrombin gene mutation 
 Patients with history of congenital PS and PC deficiency 
 Patients on oestrogen containing oral contraceptive preparations  
 Patients with history of malignancy or myeloproliferative disease  
 Patients and normal controls who were on oestrogen-containing preparations 
or who were pregnant were also excluded. 
Blood samples were collected and processed as described in section 2.2. The 51 
patients with APS fulfilled the revised International consensus criteria for definite 
APS (Miyakis et al, 2006). Assays for aPL were performed as part of routine clinical 
management in the hospital diagnostic laboratory. All patients were on warfarin for 
at least 3 months following a thromboembolic event at the time of study. There are 
no agreed, published definitions of the clinical phenotype of thrombosis in APS 
patients, although those who have experienced recurrent VTE or arterial thrombosis 
are recognised as high risk patients (Kasthuri & Roubey, 2007;Ruiz-Irastorza et al, 
2007). I used the term ‘severe thrombotic phenotype’ for patients who had recurrent 
VTE whilst receiving therapeutic anticoagulation and /or patients with both venous 
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and arterial thrombosis. Sixteen of the 51 APS patients (31%) were classified as 
having a severe thrombotic phenotype; 9/16 patients had recurrent VTE whilst on 
therapeutic anticoagulation and 7/16 patients had both venous and arterial 
thrombosis. Ten of these 16 patients (62.5%) were triple aPL positive. Five of 51 
non-APS patients (10%) also had a severe thrombotic phenotype; all these had 
recurrent VTE whilst on therapeutic anticoagulation. Patients with a severe 
thrombotic phenotype were maintained at a target INR of 3.5 (range 3.0-4.0) whilst 
the target INR in the remainder was 2.5 (range 2.0-3.0). Table 3-1describes 
demographic data and the clinical features of two patients groups and the normal 
controls.   
Table 3-1 clinical features of the three groups of subjects studied 
 APS  Non-APS  Normal Controls 
Age, mean year 49.43±14.8 50±15.1 41±12.1 
Sex, male/female 26/22 24/27 24/27 
Vascular thrombosis  
DVT alone 
PE alone 
DVT+PE 
VTE+ arterial 
Recurrent VTE 
 
17 (33%) 
14 (27%) 
4 (8%) 
7 (14%) 
9 (18%) 
 
25 (49%) 
15 (29%) 
6 (12%) 
0 (0%) 
5 (10%) 
 
n/a 
n/a 
n/a 
n/a 
n/a 
APS=antiphospholipid syndrome; non-APS=Patients without APS; DVT=deep vein thrombosis; 
PE=pulmonary embolism; VTE= venous thromboembolism * 2/51 (4%) patients with APS had SLE 
3.4 Antiphospholipid antibodies and INR 
Of 51 patients with APS, 4% (2/51) also had systemic lupus erythematosus (SLE). 
Ninety-six percent (49/51) had lupus anticoagulant and 59% (30/51) had various 
combinations of aCL and/or aβ2GPI as follows (percentage, median aPL level): IgG 
aCL 19.6%, 69.3 GPLU/mL; IgM aCL 27%, 58.5 MPLU/mL; IgG aβ2GPI 27%, 
51.45U/mL; and IgM aβ2GPI 37%, 28.6U/mL. Sixteen of the 51 APS patients (31%) 
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were triple aPL positive; and 62.5% (10/16) of the triple aPL positive APS patients 
had a severe thrombotic phenotype. INR values (median (range) were 2.4 (1.8-4.2) 
and 2.3 (1.8-4.3) for the APS and non-APS groups respectively.  
3.5 Resistance to rhAPC and activation of endogenous protein C by 
thrombin generation 
TG was performed after mixing samples 1:1 with pooled normal plasma (PNP) to 
correct for warfarin induced coagulation factor deficiency, using the CAT system as 
described in section 2.16, resistance to rhAPC and activation of endogenous protein 
C using Protac®  as described  in section 2.16.1. APCr was expressed as percentage 
inhibition of ETP after normalising the results in test samples against PNP (adapted 
from Liestøl et al) (Liestol et al, 2007b), using the following equation:  
Percentage inhibition of ETP
=
(1 − (ETP sample +  rhAPC or Protac/ ETP sample +  buffer)) x100
(1 − (ETP PNP +  rhAPC or Protac / ETP PNP + buffer))
 
The lower the value of percentage inhibition of ETP, the greater the APCr.   
3.5.1 Results      
An example of TG with buffer control, rhAPC and Protac® in a NC and a patient 
with APS is shown in Figure 3-2. 
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Figure 3-2 An example of TG with buffer control, rhAPC and Protac® in a NC and a patient      
with APS showing APCr 
 
 
 
 
 
 
 
The normal control had >50% inhibition of thrombin generation with rhAPC and Protac and was 
comparable. The patient with APS demonstrated variable inhibition of thrombin generation with 
rhAPC and Protac and resistance to activation of endogenous PC with protac was higher compared to 
rhAPC. 
Greater APCr (lower percent inhibition of ETP) was observed after activation of 
endogenous protein C with Protac® in both APS (median inhibition of ETP [95% 
CI]) (66.0% [59.5-72.6%] and non-APS patients (80.7%) [74.2-87.2%], p<0.0001) 
compared to normal controls (102.2%) [96.2-108.1%] (Figure 3-3A). Non-APS 
patients also showed greater resistance to activation of endogenous PC compared to 
NC (p<0.0001), but resistance was greater in APS patients (p=0.0034).  APS patients 
also showed greater resistance to exogenous rhAPC (median [range]: 90% [18.0-
109.0], p=0.0006) compared to non-APS patients (99% [46.6-130.6]), and normal 
controls (94% [56-132]), mainly due to a sub-group of six patients who were triple 
positive for aPL with marked APCr (16.6-40.8%) (Figure 3-3B). Those six patients 
had marked resistance to activation of endogenous PC (3.7-33.8%) and also had high 
avidity anti-PC antibodies (see below). 
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Figure 3-3 Distribution of APCr in plasma samples from healthy normal controls (NC), APS    
                and non APS patients; A: with Protac, B: with rhAPC 
 
It is possible that patients with APS demonstrated greater resistance to activation of 
endogenous PC as well as rhAPC due to autoantibodies to PC or PS interfering in the 
PC pathway. I therefore investigated the presence of PC or PS antibodies in these 
patients.  
3.6 Anti-protein C antibodies 
Anti-protein C antibodies were studied as described in section 2.19. I did not find 
any non-specific binding to the protein C uncoated plate. Samples were considered 
positive for anti-protein C antibodies if the absorbance was >3SD above the mean 
(0.36 absorbance units) for normal controls (n=51). Intra-assay and inter assay CV 
for anti-protein C antibodies were 1.8% and 2.2% respectively.  
Anti-protein C antibodies were detected more frequently in patients with APS (25/51 
(49%) compared to non-APS patients (4/51 (8%), p<0.0001. Furthermore patients 
with APS had higher anti- protein C antibody levels compared to non-APS patients; 
p<0.0001 
p<0.0002 P=0.0068 
P<0.0002 
p=0.006 
p=0.89 
p=0.011 P=0.002 
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median absorbance [range]: 0.45 [0.37-1.34] for APS and 0.39 [0.37-0.42] for non 
APS respectively (p<0.0001) (Figure 3-4). 
Figure 3-4 Anti-PC antibodies in APS and non-APS patients 
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The dotted line indicates 3SD above the mean (0.36 absorbance units) for normal controls (n=51). 
3.7 Anti-protein S antibodies 
Anti-protein S IgG antibodies were measured as described in section 2.20. Samples 
were considered positive for anti-protein S antibodies if the absorbance was >3SD 
above the mean (0.1 absorbance units) for normal controls (n=51). Positive and 
negative quality control samples were run on each plate. Intra-assay and inter-assay 
CV for anti-protein S antibodies were 2% and 2.5% respectively. Anti-protein S 
antibodies were found in 7/51 (14%) APS patients (median absorbance [range]: 0.30 
[0.19-0.61] and 1/51 (2%) non-APS (absorbance 0.2) patients respectively. Four of 
p<0.0001 
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the seven APS patients with anti-protein S antibodies also had anti-protein C 
antibodies.  
3.8 Determination of the avidity of anti-protein C and anti-protein S 
antibodies 
 The avidity of the IgG anti-protein C and anti-protein S antibodies was assessed by 
introducing chaotropic conditions to the ELISA as described in section 2.21. Avidity 
was determined by calculating the percentage of maximum binding. 
The avidity studies of anti-protein C antibodies in the 25 APS patients displaying 
them identified two clear groups (Figure 3-5): one group showed a rapid decrease in 
percentage of residual protein C binding as the NaCL concentration increased, with 
binding completely abolished at 4M NaCl (low avidity). The other group also 
showed a decrease in the percentage binding as NaCl increased, but a plateau was 
observed at approximately 1M NaCl and residual binding remained above 25% even 
at 6M NaCl (high avidity) (Figure 3-5). 
Ten of the 25 patients had low avidity and 15 had high avidity antibodies. The 
difference in the percentage of maximum binding to protein C in these two groups 
showed a clear difference at 1M NaCl (mean residual binding 39.7% for the high 
avidity samples, compared to 16.5% for those with low avidity (p<0.0001) and this 
difference remained at higher NaCl concentrations. All four patients with non-APS, 
who had anti- protein C antibodies, demonstrated low avidity antibodies.   
Avidity studies of anti-PS antibodies demonstrated only the low avidity antibodies 
(Figure 3-6).Four of the seven APS patients with anti-protein S antibodies also had 
anti-protein C antibodies. 
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Figure 3-5 Avidity of anti-protein C antibodies 
 
Figure 3-6 Avidity of anti-protein S antibodies 
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3.9  Anti-protein C antibodies and activated Protein C resistance   
Patients with high avidity anti-protein C antibodies had significantly greater APCr to 
both rhAPC and activation of endogenous protein C with Protac® than those with 
low avidity anti-protein C antibodies; (median [CI]:  62.8% [35.2-74.9] and 90.8% 
[84.0-103.1], p=0.0018 for rhAPC and 43.3% [14.6-54.4] and 74.1% [66.6-87.3], 
p<0.0001) for Protac® respectively. The presence of high avidity anti-protein C 
antibodies in APS patients was strongly associated with a severe clinical phenotype  
defined as patients who had recurrent VTE whilst receiving therapeutic 
anticoagulation and /or patients with both venous and arterial thrombosis (section 
3.3.2) (Fisher’s exact test p<0.0001). Ninety-four percent (15/16) of the patients with 
a severe thrombotic clinical phenotype had high avidity anti-protein C antibodies and 
62.5% (10/16) of those patients were triple positive for aPL. Nine of 15 (60%) had 
recurrent VTE whist on therapeutic anticoagulation and 6/15 (40%) had experienced 
both venous and arterial thrombosis. 
Four of 51 patients in the non-APS group with anti-protein C antibodies, which were 
low avidity also demonstrated marked resistance to activation of endogenous PC 
with Protac® (range 12.4-41.4%) and had clinically severe thrombotic disease.  
3.10 Anti-protein S antibodies and activated Protein C resistance 
Only 7 patients with APS and one patient with non–APS had anti-PS antibodies. The 
presence of anti-protein S antibodies alone appeared to have no independent effect 
on APCr with rhAPC or Protac® in patients with APS as there was no difference in 
the percentage inhibition of TG with rhAPC or Protac® in patients with anti-PS 
antibodies and without antibodies. 
3.11 Evaluation of the presence of anti-protein C antibodies according to APS 
classification categories 
The presence of anti-protein C antibodies was evaluated according to the APS 
classification category (I, IIa, IIb, IIc according to Miyakis et al, 2006) (Miyakis et 
al, 2006). Definition of APS classification categories are as follows: category I ,more 
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than one laboratory criteria present [any combination], IIa, LA present alone; IIb, 
aCL antibody present alone; IIC, aβ2-GPI alone). Twelve of 15 (80%) patients with 
APS who had high avidity anti-protein C antibodies were classified as APS category 
I and the other three patients (20%) were classified as category IIa. Forty percent 
(4/10) and 60% (6/10) of APS patients who had low avidity anti-protein C were 
classified as category I and IIa respectively. 
3.11.1 PC activity and free PS antigen level 
PC activity and free PS antigen levels were measured for two reasons;  
1. To confirm that the observed differences in APCr with rhAPC and activation 
to endogenous PC with Protac® between patients with APS and non-APS 
was not due to differences in PC activity and free PS antigen level. 
2. To assess the influence of anti-protein C and anti-protein S antibodies on PC 
activity and free PS antigen levels respectively. 
All patients showed a reduction in PC activity and free PS antigen levels consistent 
with warfarin anticoagulation with no significant difference in levels between APS 
and non-APS patients. After 1:1 mixing of patient plasma with PNP for TG, all 
samples had PC and PS levels >60 IU/dL. Anti-protein C and anti-protein S 
antibodies had no apparent effect on PC activity or free PS antigen levels, as patients 
with and without anti- protein C and anti- protein S antibodies had similar levels of 
PC activity and free PS antigen (Table 3-2). 
 
 
 
 
96 
 
Table 3-2 PC activity and free PS antigen level in patients with APS and non-APS 
 Original samples 1:1 mixed with PNP 
 PC activity 
(IU/dL) 
Free PS 
antigen 
(IU/dL) 
PC activity 
(IU/dL) 
Free PS 
antigen 
(IU/dL) 
APS          Mean 
Range 
51.0 
23.6-66.3 
38.3 
26.6-66.1 
83.65 
69.1-107.2 
72.68 
66.1-102.4 
Non -APS Mean  
Range 
52.7 
26.2-60.2 
40.5 
19.4-53.1 
84.5 
71.5-102.2 
73.8 
63.2-95.3 
 
Adult reference 
range 
 
PC  (65–135 IU/dL)                 
 
PS antigen Males >73U/dL 
                   Females>63U/dl 
PC= protein C; PS= protein S; APS= antiphospholipid syndrome 
3.12 Discussion  
This study has demonstrated that APS patients with vascular thrombosis on long-
term warfarin exhibit greater resistance to both exogenous rhAPC as well as to 
activation of endogenous PC by Protac®, using the CAT assay system, compared to 
non-APS patients with VTE and normal controls. Non-APS patients also showed 
greater resistance to activation of endogenous PC compared to healthy controls, but 
resistance was greater in the APS patients. Protac®, is an enzyme  isolated  from 
Agkistrodon contortrix contortrix venom which converts protein C into APC 
(Martinoli & Stocker, 1986). APS patients also had a significantly higher frequency 
and higher levels of anti- protein C antibodies: approximately half (49%) of the 51 
patients with thrombotic APS had anti-protein C antibodies, compared to 8% of the 
non-APS patients, with 60% (15/25) of these antibodies in APS patients (29.4% 
(15/51 overall) with high avidity antibodies. The APS patients with high avidity anti-
protein C antibodies had significantly greater APCr to both rhAPC and activation of 
endogenous PC with Protac® than those with low avidity anti- protein C antibodies. 
The presence of high avidity anti-protein C antibodies was also strongly associated 
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with a severe thrombotic phenotype in APS patients as defined in the methods 
section. Ninety-four percent (15/16) of the patients with a severe thrombotic 
phenotype had high avidity anti-protein C antibodies and 62.5% (10/16) of those 
patients were triple positive for aPL. 
Previous studies have mainly focused on APCr using exogenous APC rather than on 
the activation of endogenous PC. Liestol et al (Liestol et al, 2007b) studied 
resistance to rhAPC using TG with the CAT system in 52 LA positive APS patients 
(29 had isolated VTE, 8 arterial thrombosis, 8 isolated obstetric complications and 7 
had combined events). They found that most patients with LA showed resistance to 
the anticoagulant effect of exogenous APC, although a wide range of inhibitory 
effects were evident, and could partly have been a reflection of the heterogeneous 
nature of LA. Subgroup analysis suggested that a history of thrombotic events was 
associated with stronger APC resistance, although the comparison was made against 
35 individuals on long-term warfarin therapy for non-valvular AF. In other studies 
using smaller patient numbers and different techniques, Devreese et al (Devreese et 
al, 2009) found that 83 % (40/48) non-anticoagulated  LA  positive  subjects showed 
APCr to exogenous APC, however only 1/9 patients with LA on  anticoagulation  
had APCr. Oosting et al (Oosting et al, 1991) found no effect of aPL and β2GPI on 
PC activation at the surface of endothelial cells, although Borrell et al found that aPL 
impaired APC function against FVa on the endothelial cell surface (Borrell et al, 
1992). Previous work from our group (Green et al, 2012) demonstrated APCr in 
11/17 APS patients (60%) when Protac was used to activate endogenous PC using an 
automated chromogenic TG assay. The findings of that study, which did not include 
assessment of clinical phenotype and aPL status of individual patients, established 
that the TGT exhibited good sensitivity to defects in the PC pathway.  
My observation that APS patients frequently exhibit resistance to the activation of 
endogenous PC suggests a possible defect in the mechanism through which PC 
becomes activated. In many patients, a higher degree of APCr was associated with 
the presence of anti-protein C antibodies that may interfere with the mechanism of 
activation of PC or the anticoagulant action of APC. Differences observed between 
the APS and non-APS patients with regard to APCr with rhAPC and Protac® could 
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not be attributed to variation in PC, PS or procoagulant factor levels, since all 
samples were diluted with PNP to normalise levels of these factors.   
Neither anti-protein C antibodies, nor aPL appeared to interfere with PC activity, 
since there was no difference in PC activity in the APS and non-APS groups and the 
warfarin induced PC deficiency was easily corrected by mixing with PNP as 
demonstrated by the chromogenic PC results. This suggests that anti-protein C 
antibodies or aPL do not bind directly to the active site of PC, but could bind to a site 
in close proximity, or induce a conformational change thus inhibiting or delaying PC 
activation. The explanation for the observations that anti-protein C antibodies in 
some patients have no obvious effect in PC chromogenic assays utilising Protac® 
activation, but influence APCr TG tests including this snake venom is unclear, but 
they could be due to the different reaction conditions. Chromogenic PC assay does 
not require phospholipid but effects of the endogenous activation of PC assessed 
through TG required phospholipids. The presence of resistance to activation of 
endogenous PC and /or exogenous PC in some but not all the thrombotic APS 
patients studied may be related to the avidity of the anti-PC antibodies or 
heterogeneity of their aPL phenotype. My findings that patients with high avidity 
anti-protein C antibodies had significantly greater APCr to both rhAPC and 
activation of endogenous PC with Protac® than those with low avidity anti-PC 
antibodies and had a severe thrombotic phenotype, suggests that these antibodies 
may contribute to the pathogenesis of thrombosis in APS, and extends previous 
observations in this area. Cucnik et al (Cucnik et al, 2004) reported that in 18 
patients with APS, with or without SLE, high avidity aβ2-GPI appeared to be 
associated with thrombosis and APS; and Lambriandides et al (Lambrianides et al, 
2011) reported in 32 patients with APS and 29 with SLE that high avidity 
antithrombin antibodies, which prevent inactivation of thrombin, distinguish patients 
with APS from those with SLE who have aPL. The number of APS patients with 
SLE in my study was very small (2/51; 4%). Therefore, I did not analyse them 
separately. Patients with SLE/APS could behave differently to those who with APS 
alone due to number of reasons including presence of other auto antibodies in 
patients with SLE/APS. However, I do not believe my results were influenced by the 
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coexistence of SLE in (2/51) of patients because samples from these two patients did 
not behave differently from those of the other primary APS in the coagulation and 
binding assays examined in this chapter. 
 
It is possible that anti-protein C antibodies represent a different subset from those 
which define APS: aCL, aβ2-GPI or lupus anticoagulant. These antibodies as a whole 
(i.e. both high and low avidity) do not cosegregate with the presence of APS-defining 
aPL. However, high avidity anti-protein C antibodies were present only in patients 
with APS, with 80% (12/15) (versus 40% with low avidity antibodies) classified as 
category I APS risk stratification (i.e. the presence of more than one aPL in any 
combination) (Miyakis et al, 2006). This suggests that high avidity anti-protein C 
antibodies might play a role as an adjunctive risk factor in APS patients with a severe 
thrombotic phenotype. APS patients may have a variety of other autoantibodies with 
different specificities (i.e. to phosphatidyl serine (PS), prothrombin, factor XII, tissue 
factor pathway inhibitor, factor X, etc), and the clinical relevance of these antibodies 
is being unravelled. aCL/aβ2-GPI and anti-PS/prothrombin have been shown to 
induce APCr in a clotting based assay (Nojima et al, 2005). The high avidity anti-
protein C antibodies in our study were specific for human protein C, and not due to 
cross-reactivity with aCL/aβ2-GPI. In our study, there was no association between 
APCr and aCL or aβ2-GPI. The relevance of low avidity anti-protein C antibodies, 
which were also observed in some non-APS patients with a severe thrombotic 
phenotype, remains to be defined.  
Anti-protein C antibodies were not specific to thrombotic APS, as 8% (4/51) of the 
thrombotic non-APS patients also had anti-protein C antibodies, although these were 
low avidity antibodies. However, these patients demonstrated marked resistance to 
activation of endogenous PC and had clinically more severe disease, i.e. recurrent 
VTE whilst on therapeutic anticoagulation (none had both venous and arterial 
thrombosis). The difference in the behaviour of the low avidity anti-protein C 
antibodies in the APS and non-APS patients is unclear. Possible explanations include 
that aPL in APS patients may require higher avidity antibodies to impair activation of 
endogenous PC or alternative explanation is that antibodies other than anti-protein C 
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antibodies and aPL are implicated in the activation of endogenous PC in these 
patients.  
Anti-protein S antibodies were far less frequent than anti-protein C antibodies in this 
study (7/51 APS and 1/51 non-APS patients), and were all low avidity. Anti-PS 
antibodies were not independently associated with increased APCr or with a severe 
thrombotic phenotype. The small number of anti-PS antibodies detected in this study 
preclude definitive conclusion. My results concur with those of Bertolaccini et al 
(Bertolaccini et al, 2003), but in contrast, Nojima et al (Nojima et al, 2002),  
demonstrated that the presence of anti-PS antibodies was strongly associated with 
acquired APCr, although they did not report on avidity of the antibodies.  
In conclusion, thrombotic APS patients showed greater APCr to both exogenous 
rhAPC and activation of endogenous PC. APS patients had a significantly higher 
frequency and higher levels of anti-protein C antibodies: approximately half (49%) 
of the 51 patients with thrombotic APS had anti-PC antibodies. High avidity anti-
protein C antibodies were present in 29.4% (15/51) of these patients and associated 
with greater APCr to both rhAPC and activation of endogenous PC with Protac®. 
This could be attributed to the presence of different antibodies against PC that may 
interfere with the anticoagulant action of APC or with the mechanism of activation. 
The presence of high avidity anti-PC antibodies was also strongly associated with a 
severe thrombotic phenotype in APS patients. Ninety-four percent (15/16) of the 
patients with a severe thrombotic clinical phenotype had high avidity anti-protein C 
antibodies and 62.5% (10/16) of those patients were triple positive for aPL. High 
avidity anti-protein C antibodies, associated with greater APCr, may provide a 
marker for a more severe thrombotic phenotype in APS. 
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 Sensitivity of commonly used thromboplastin reagents to Chapter 4
rivaroxaban  
4.1 Introduction 
Routine monitoring of the anticoagulant effect of NOAC is not required due to the 
predictable anticoagulant effect of these preparations. However, measurement may 
be needed in certain clinical situations. These include: bleeding, before surgery or an 
invasive procedure, identification of subtherapeutic or supratherapeutic levels in 
patients taking other drugs that significantly affect pharmacokinetics, extremes of 
body weight, deteriorating renal function, perioperative management, reversal of 
anticoagulation, suspicion of overdose and assessment of compliance (Baglin et al, 
2012;Baglin et al, 2013) 
In vitro data indicate that there is a linear concentration-response relationship 
between the level of rivaroxaban and prothrombin time (PT) ratio, although there is a 
marked variability in the sensitivity between different PT reagents (Hillarp et al, 
2011;Samama et al, 2010). The Scientific and Standardization Committee (SSC) of 
the International Society on Thrombosis and Haemostasis (ISTH) and British 
Committee for Standards in Haematology (BCSH) (Baglin et al, 2012;Baglin et al, 
2013) recommend that a PT with a suitable thromboplastin can be used to determine 
the relative intensity of anticoagulation achieved with rivaroxaban in an emergency 
or urgent clinical scenario, but should not be used to quantify the plasma drug 
concentration. However, there is a paucity of ex vivo data on the sensitivity of 
different thromboplastin reagents to rivaroxaban. Therefore studies with ex vivo 
samples are required to determine the relative sensitivity of different PT reagents to 
rivaroxaban. This would provide more specific information regarding the choice of 
PT reagent (Baglin et al, 2012;Baglin et al, 2013).  
The main objective of this chapter is to assess the sensitivity of different 
thromboplastin reagents, commonly used in routine hospital laboratories (based on 
UK National External Quality Assessment Service reports), to rivaroxaban 
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concentrations using blood samples from patients receiving therapeutic dose 
rivaroxaban.  
4.2 Patients and blood sampling 
Blood samples were collected from 20 patients [8 males and 12 females, median age 
46 years (range 34-78)] receiving therapeutic dose rivaroxaban. They had switched 
to rivaroxaban therapy due to: warfarin allergy, lack of phenindione availability, 
lifestyle or difficulty in monitoring. Samples were taken at a single time-point, 2-4 
hours after their last dose of rivaroxaban, during routine outpatient appointments.  
All patients had been prescribed 20mg rivaroxaban daily (to be taken with food), for 
the preceding 3-12 weeks, for stroke prevention in non-valvular atrial fibrillation 
(6/20), or for the prevention of venous thromboembolism recurrence (14/20).  No 
patient received other anticoagulants, antiplatelet agents, or drugs known to interact 
with rivaroxaban; all had a creatinine clearance >50mL/min (Cockcroft and Gault) 
(Cockcroft & Gault, 1976) and normal liver function tests.  
Venous blood samples were collected with minimal stasis into 0.105M citrate 
Vacutainers®. Plasma was prepared within 1 hour by double centrifugation at 2000g 
for 15 minutes and stored at -80°C for up to 12 weeks.  
4.3 Rivaroxaban levels 
Rivaroxaban levels were measured using an amidolytic anti-Xa assay (Biophen 
DiXaI; with Biophen rivaroxaban calibrators, covering a range of 0 to 500ng/mL, 
which the manufacturer validated by HPLC  (Rohde, 2008) as described in section 
2.4.  The assay was performed as a single run on a CS-2000i analyser (Sysmex) and 
samples were tested in duplicate. The intra-assay CV was 7% at 100ng/mL and 4% at 
300ng/mL rivaroxaban. 
The median plasma rivaroxaban level in the 20 patients was 246ng/mL (range 41-
457ng/mL).  A detailed pharmacokinetic study showed that 20mg rivaroxaban once 
daily gives peak plasma concentrations of 160-360ng/mL and trough concentrations 
of 4-96ng/mL (Mueck et al, 2008). In 11 of our patients, rivaroxaban levels (200-
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356ng/mL) were within the expected therapeutic peak plasma concentration range, 
but six patients had rivaroxaban levels less than 160ng/mL (41-156ng/mL), and three 
patients had levels (455-457ng/mL) above the expected peak plasma concentration. 
 
4.4 Prothrombin time 
The PT was measured using a CS-5100 analyser (Sysmex) as described in section 2.3 
with six different thromboplastin reagents (ISI & mean normal PT): 
Recombiplastin®2G (ISI 1.0 & 11.1s) and PT-Fibrinogen HS PLUS (ISI 1.2 & 
16.1s) (Instrumentation Laboratory UK Ltd); Innovin® (ISI 1.0 & 11.4s) and 
Thromborel®S (ISI 1.0 & 12.8s) (Siemens Healthcare Diagnostics); Thrombotest
TM  
(ISI 1.0 & 36.6s) (Alere Ltd, Stockport, UK) and Neoplastin®R (ISI 1.0 & 14.6s) 
(Diagnostica Stago, Asnières, France). Neoplastin R, Recombiplastin and Innovin are 
recombinant human tissue factor thromboplastins, Thromborel S is derived from 
human placenta, PT-Fibrinogen HS PLUS and Thrombotest are derived from rabbit 
and bovine brain, respectively. All samples were tested in the same analytical run. 
Results were expressed as prothrombin time ratio (PTR) = PT patient/PT normal. 
Geometric mean normal PT (seconds) for each thromboplastin reagent was 
established using samples from 30 healthy normal subjects (Table 4-1). 
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Table 4-1 Geometric mean normal PT for different thromboplastin reagents 
Normal 
controls 
Innovin Thromborel 
S 
PT Fib 
HS 
Neoplastin 
R 
Thrombotest Recombiplastin   
2G 
1 11.4 12.8 16.2 14.6 36.3 10.4 
2 11.6 12.5 16.3 14.9 38.0 11.2 
3 11.2 12.4 16.3 14.9 36.2 11.3 
4 11.4 12.4 15.4 14.7 36.3 10.3 
5 11.0 12.3 16.8 15.0 36.6 10.8 
6 11.1 12.3 16.5 14.8 36.8 11.7 
7 11.1 13.1 15.0 14.9 36.7 10.6 
8 11.2 14 15.8 14.8 36.6 11.4 
9 11.1 11.8 15.1 14.8 36.7 10.6 
10 11.4 11.2 16.8 14.7 36.7 10.7 
11 11.6 12.1 15.8 14.2 37.7 10.6 
12 11.7 12.3 15.3 14.9 36.8 10.8 
13 11.9 12.2 15.7 14.9 36.0 11.6 
14 11.4 13.1 15.9 14.5 37.0 10.0 
15 11.1 13.2 15.9 14.7 36.6 11.6 
16 11.2 14.0 15.8 14.4 36.1 10.9 
17 12.0 13.6 17.0 14.5 36.1 11.8 
18 11.9 13.5 15.8 14.4 36.2 12.3 
19 11.8 14.0 16.6 14.4 37.1 12.3 
20 11.1 11.0 15.9 14.4 36.2 12.3 
21 12.0 14.0 15.8 14.7 36.3 11.7 
22 11.0 11.2 16.8 14.9 36.6 10.6 
23 11.3 13.3 16.9 14.9 36.8 13.0 
24 11.2 11.2 15.8 13.0 36.7 10.6 
25 11.0 13.9 15.8 14.9 36.0 10.7 
26 11.9 12.8 16.7 14.8 36.7 10.6 
27 10.0 12.16 16.1 14.3 36.5 10.8 
28 13.0 14.0 16.8 15.0 36.7 11.6 
29 10.9 13.2 17.0 14.8 36.8 10.5 
30 12.9 14.0 16.9 14.7 36.0 11.6 
Geometric 
Mean 
PT(S) 
11.4 12.8 16.1 14.6 36.6 11.1 
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4.5 Prothrombin time ratio 
Figure 4-1 The relative sensitivity of thromboplastin reagents in samples from 20 patients  
                  receiving rivaroxaban 
 
PT ratio =Prothrombin Time Ratios  
The different thromboplastin reagents showed marked differences in sensitivity to 
rivaroxaban, as indicated by the PTR (Figure 4-1 and Figure 4-2). Neoplastin R® 
exhibited the widest spread of PTR values amongst the different patients and the 
greatest sensitivity to rivaroxaban, while Innovin® and Thromborel®S exhibited the 
least variability and sensitivity (Figure 4-1 and Figure 4-2). All thromboplastin 
reagents exhibited a significant correlation with rivaroxaban concentration (Figure 
4-2).  
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However, in samples with therapeutic levels of rivaroxaban (as measured by the anti-
Xa assay), the PTR was less than 1.5 for all samples tested with Innovin® and for 
95% of the samples with Thromborel S. 
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Figure 4-2  Spearman correlation of Rivaroxaban levels and the prothrombin time ratio    
                  determined with six different individual thromboplastin reagent 
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4.6 Discussion 
This study has established the sensitivity of six different thromboplastin reagents, 
commonly used in routine UK hospital laboratories for PT testing, in ex vivo samples 
from patients receiving therapeutic dose rivaroxaban. All thromboplastin reagents 
exhibited significant correlation between PTR and rivaroxaban level (rs >0.61, 
p<0.005). Neoplastin®R was the most sensitive reagent to rivaroxaban, while 
Innovin® and Thromborel®S were the least sensitive.  
Previous in vitro studies have suggested a wide range of sensitivity depending on the 
PT reagent. Limited ex vivo data using two PT reagents Triniclot PT Excel S® and 
Innovin® and an anti-Xa assay for rivaroxaban  (Douxfils et al, 2013) suggested that  
the PTR using these two reagents did not correlate well with plasma levels of 
rivaroxaban (measured by liquid chromatography-tandem mass spectrometry, with 
levels ranging between 0-485ng/mL); the timing of blood samples in relation to 
rivaroxaban administration and the number of samples with therapeutic rivaroxaban 
levels were not stated. Two case reports (Patel et al, 2013;van Veen et al, 2013)  
have described patients with therapeutic levels of rivaroxaban, showing normal PTR 
with Innovin® and Thromborel®S. My findings with Innovin® concur with these 
observations, and in addition I have identified reagents that are more sensitive to 
rivaroxaban, indicating potential clinical utility.  
My findings highlight that the choice of thromboplastin, based on the sensitivity of 
individual thromboplastin reagents to rivaroxaban, is critically important for accurate 
qualitative assessment of rivaroxaban levels using a PTR. The ISTH SSC (Baglin et 
al, 2013)  has suggested that the PT could be used as the first line test, while an anti-
Xa assay (rivaroxaban level) should be employed when an accurate anticoagulant 
level is required. They also suggested that all hospital laboratories should have a test 
that is easy to perform, readily available, and able to provide results within one hour 
of receiving a patient sample (Baglin et al, 2013). Such testing should aid decision 
making in the acute management of the patient by indicating whether the patient is 
anticoagulated in the therapeutic, subtherapeutic or supratherapeutic range. Each 
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laboratory should know the sensitivity of its own PT reagent and APTT tests to 
rivaroxaban and advice on interpretation (Kitchen et al, 2014). 
The INR-ISI methodology currently used for vitamin K antagonists is not 
recommended by the BCSH. However, some studies have investigated the suitability 
of employing a rivaroxaban sensitivity index similar to the specific ISI in a PT/INR 
system to normalised and reduce the variability of the results obtained with different 
thromboplastin reagents (Harenberg et al, 2011;Tripodi et al, 2011a). 
Assays that would provide quantitative information about the anticoagulation 
intensity (rivaroxaban level) are usually only available on a non-urgent basis in a 
limited number of clinical laboratories. Furthermore, test results are dependent on 
when the last dose of drug was taken and these therefore require interpretation with 
reference to the dose, anticipated half-life, and other factors that influence 
pharmacokinetics, such as renal function.  
The PT can be prolonged due to a number of reasons including hepatic impairment, 
vitamin K deficiency and sepsis, and these factors may contribute to a prolonged PT 
in patients on rivaroxaban. Therefore, determining a baseline PT may be useful when 
later interpreting PT results during therapy. In my study, all patients had been 
switched from therapeutic dose warfarin to therapeutic dose rivaroxaban at least 
three weeks prior to sampling; a baseline PT was therefore not available. Limitations 
of my study were that the number of patients was relatively low and did not include 
patients with impaired renal function.  
The use of Innovin® or Thromborel®S may give false reassurance as normal results 
are likely to be obtained from patients with therapeutic levels of rivaroxaban. Of note 
in this context, Mani et al demonstrated that two hours after rivaroxaban 
administration (10 mg once daily), the activities of clotting factors (II, V, VII, VIII, 
IX, XI, XII) appeared to be significantly decreased while factor XIII levels were 
unchanged, when performed as a single point assay (Mani et al, 2013). When using 
different dilutions of plasma samples in factor VIII and factor X assays, rivaroxaban 
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effects disappeared at higher plasma dilutions, demonstrating the importance of 
performing assays at multiple dilutions. These results were obtained with either 
Innovin® or the activated partial thromboplastin time (aPTT) reagent SynthASil®, 
which are less sensitive to rivaroxaban (Mani et al, 2013). Reagents which are more 
sensitive to rivaroxaban may exhibit an even greater interference on coagulation 
factor assays. These effects need to be taken into account when laboratories assess 
coagulation factor levels in patients taking rivaroxaban, using PT or APTT based 
assays especially in terms of timing and dose of rivaroxaban intake.  
The median plasma rivaroxaban level in the 20 patients was 246ng/mL (range 41-
457ng/mL). No patient experienced recurrence of thrombosis or clinically significant 
bleeding during treatment.  Based on population pharmacokinetic study (Mueck et al, 
2008), it is expected to have peak plasma concentrations of 160-360ng/mL and 
trough concentrations of 4-96ng/mL (Mueck et al, 2008) with 20mg rivaroxaban  
given once daily to individuals with normal renal functions.  Nearly 50% (9/20) of 
the patients had rivaroxaban levels outside the expected therapeutic range. Six 
patients had rivaroxaban levels less than 160ng/mL (41-156ng/mL), and three 
patients had levels (455-457ng/mL) above the expected peak plasma concentration. 
Although patients were asked to take rivaroxaban 2-4 hours prior to outpatient 
attendance, nearly half had rivaroxaban levels outside the expected peak plasma 
concentration range. A pharmacokinetic study showed that if blood samples were 
taken at two or at four hours after rivaroxaban, plasma levels would vary by about 
12% (Mueck et al, 2011), which means that therapeutic rivaroxaban levels should 
vary by only 60ng/mL. This suggests poor compliance in some of the patients we 
studied. 
The sensitivity of different APTT reagents to rivaroxaban levels has also shown a 
similar pattern of those observed with PT reagents. In an in vitro study (Dale et al, 
2014), using seven different APPT reagents (Actin FSL, Actin FS [Siemens], 
TriniCLOT S, TriniCLOT HS, STA-CK PREST, STA-PTT A [Stago Diagnostica], 
and SynthASil [Instrumentation Laboratory] has shown that all APTT reagents were 
sensitive to rivaroxaban but their sensitives differed. The four most sensitive reagents 
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were Actin FSL, Actin FS, STA-CK PREST and STA-PTT A. These four reagents 
exhibited similar sensitivities with lower concentrations of rivaroxaban, with higher 
concentrations; Actin FSL was the most sensitive reagent. 
In conclusion, there is a wide variation in the sensitivity of thromboplastin reagents 
to rivaroxaban. Of the six commonly used thromboplastin reagents studied, 
Neoplastin®R was the most sensitive while Innovin® and Thromborel®S were the 
least sensitive. These ex vivo findings, based on samples from patients on therapeutic 
dose rivaroxaban, are in keeping with those previously reported from in vitro studies. 
Rivaroxaban levels within the therapeutic range can give a normal PTR with the less 
sensitive reagents, which may be clinically misleading. In the absence of anti-Xa 
assays, the assessment of rivaroxaban anticoagulation should only be performed 
using PT reagents with good sensitivity. 
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  Detection of lupus anticoagulant in the presence of Chapter 5
rivaroxaban and effects of antiphospholipid antibodies 
on rivaroxaban anticoagulant action 
The thrombotic manifestations of APS correlate best with the prolongation of 
phospholipid-dependent clotting assays associated with LA (Galli et al, 2003).  
Patients with APS are at increased risk of recurrent thrombosis. The current mainstay 
of treatment for thrombotic APS is long term anticoagulation with vitamin K 
antagonists (VKA) such as warfarin (Keeling et al, 2012). However, NOAC drugs 
such as rivaroxaban, apixaban, edoxaban and dabigatran are increasingly being used 
in clinical practice for different indications, including the treatment and prevention of 
VTE. 
Approximately 10% of patients with acute VTE have APS (Andreoli et al, 2013), 
and it is therefore likely that patients with APS were included in the phase III clinical 
trials of NOAC versus VKA in patients with VTE. However, aPL status was not 
documented in these trials (Bauersachs et al, 2010;Buller et al, 2012;Schulman et al, 
2009). Due to increasing use of rivaroxaban, it is clinically relevant to define the 
appropriate methodology for ex vivo LA testing, firstly to enable the diagnosis of 
APS in patients treated with rivaroxaban; and secondly, to inform and be considered 
for the update of the national and international guidelines. This could be established 
by in vitro and ex vivo in studies of LA detection in thrombotic APS patients 
receiving therapeutic dose rivaroxaban.  However, such studies are lacking.  
It is theoretically possible that aPL could directly interfere with the anticoagulant 
effects of rivaroxaban, although it is hypothesised that this is unlikely due to its small 
molecular size (436Da) and the high specificity for its target. Rivaroxaban affects 
various parameters of ex vivo thrombin generation (TG) measured by using 
calibrated automated thrombography (CAT) (Arachchillage et al, 2015). TG as a 
global test of haemostasis can be used to assess the anticoagulant effects of 
anticoagulants including rivaroxaban. The effects of aPL on the anticoagulant action 
of rivaroxaban have not been clearly defined.  
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The aim of this chapter was to establish the influence of therapeutic dose rivaroxaban 
on LA detection in vitro and ex vivo, and of aPL on rivaroxaban anticoagulant action 
assessed using TG testing and anti-Xa assays.  
5.1 Patients, sample collection and preparation 
5.1.1 In vitro studies: 
 Polyclonal IgG fraction was purified (section 2.22) from venous samples collected 
into 0.105M citrate Vacutainers®, from 32 patients with thrombotic APS who 
fulfilled the revised International consensus classification criteria for APS (20 
patients with persistent LA and 12 patients without LA, but positive for either aCL or 
aβ2GPI or both) and 20 healthy normal controls (NC), who tested negative for aPL. 
The presence of persistently positive LA in these 20 patients had been confirmed in 
accordance with the ISTH (Pengo et al, 2009) and BCSH (Keeling et al, 2012) 
guidelines on LA detection. Clinical features and APS classification categories of the 
30 APS patients (I, IIa, IIb) (Miyakis et al, 2006) selected for IgG purification are 
shown in Table 5-1. All normal controls were tested for aPL and were completely 
negative.  
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Table 5-1 Clinical features and APS classification categories of the 30 APS patients (I, IIa, IIb,   
                IIc according to Miyakis et al, 2006) selected for IgG purification 
Clinical features and APS category of 30 APS patients  
Age, mean years 41.43± 8.6 
               Sex, male/female                                  18/12 
Vascular thrombosis DVT alone 
                                     PE alone 
                                     DVT+PE 
                                   Arterial              
12 (40%) 
8(27%) 
6 (20%) 
4 (13%) 
     APS category 
1                       19/30 (63%) 
                         IIa                                          5/30 (17%) 
IIb 3/30 (10%) 
                          IIc                                          3/30 (10%) 
(Category I: more than one laboratory criteria present [any combination]; IIa: LA present alone; IIb: 
aCL antibody present alone; IIC: aβ2GPI antibody alone. All normal controls were tested for aPL).  
IgG was quantified by an in-house IgG ELISA (section 2.23). The amount of IgG 
purified per mL of plasma did not differ between APS and NC and ranged from 5-
10mg/mL, consistent with the normal level of circulating IgG in adults.  Rivaroxaban 
was diluted in DMSO (Sigma) and Owren’s veronal buffer (OVB); Siemens 
Healthcare Diagnostics) (section 2.24. Following addition of required volume of 
rivaroxaban preparation to PNP resulted in DMSO concentration of ≤ 1% (1% for 
LA testing and 0.75% for TG).  Both in our experiments and also work from others 
have shown that DMSO at this concentration has no effect on TG and other 
coagulation assays (Perzborn et al, 2014). 
115 
 
Rivaroxaban 50ng/mL, 250ng/mL and 0ng/mL (buffer control) and IgG (500ug/mL) 
preparations in 20mM HEPES buffer (20mM HEPES, 140mM NaCl, 0.02% Sodium 
Azide at pH 7.35) with 1% BSA from 32 APS patients (20 LA positive, 12 LA 
negative) and 20 NC were spiked into pooled normal plasma (PNP) to give the final 
plasma: IgG a and rivaroxaban ratio 80:20  v/v 80%  incubated for 10 minutes at 
37
0
C. I established that DMSO, OVB and PBS had no influence on TG (data not 
shown) before proceeding with the rest of the experiments. Rivaroxaban 
concentrations were selected to represent the expected peak (160-360µg/L) and 
trough (4-96µg/L) rivaroxaban levels with rivaroxaban 20mg daily based on previous 
population pharmacokinetic studies (Mueck et al, 2011).  An IgG concentration of 
500ug/mL was selected based on my preliminary studies and also experience of other 
workers (Pericleous et al, 2013). 
5.1.2 Ex vivo studies 
Blood samples for ex vivo LA studies were collected with minimal stasis from 24 
thrombotic APS  patients, who were on anticoagulation with warfarin for VTE, target 
INR 2.5 (range 2.0-3.0) for at least 3 months, at baseline pre-randomisation to the 
RAPS trial. This is a phase II/III clinical trial of warfarin versus rivaroxaban 
(http://isrctn.org/ISRCTN68222801) aiming to demonstrate, in patients with APS 
and previous VTE that the intensity of anticoagulation achieved with rivaroxaban is 
not inferior to that of warfarin. The safety of rivaroxaban is assessed in terms of rates 
of bleeding and further thrombosis, and compare serious adverse events in patients 
on rivaroxaban with those on warfarin as the secondary outcome measures. These 24 
patients comprised the first consecutive persistently LA positive and LA negative 
patients at the UCLH site randomised to the rivaroxaban arm or to remain on 
warfarin, respectively (12 patients in each group, comprising the first 6 consecutive 
persistently LA positive and 6 LA negative patients) (Figure 5-1).  LA status of all 
patients had been confirmed previously during definition of their APS-defining aPL, 
in accordance with the ISTH and BCSH guidelines on LA detection (Keeling et al, 
2012;Pengo et al, 2009). Of those 12 patients on rivaroxaban, (6 LA positive and 6 
LA negative) were collected 2-4 hours after the morning dose of rivaroxaban to 
represent peak levels and at least 18 (range 18-24) hours following the last dose to 
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represent trough levels. All patient samples were collected after at least 30 days 
(range 30-90 days) of anticoagulation with either warfarin or rivaroxaban. PPP 
samples were stored in aliquots and the samples were thawed for 10 minutes at 37°C 
immediately prior to analysis. 
 
Figure 5-1 : Patients selection for ex vivo LA detection studies 
 
5.1.3 Prothrombin time (PT) 
PT was performed on samples from patients on warfarin, at baseline and after at least 
30 (range 30-90) days on the 12 patients randomised to warfarin, using a single lot 
number of Innovin (Siemens Healthcare Diagnostics), on a CS-5100 analyser 
(Sysmex UK Ltd) employing an instrument-specific ISI value (0.99) (section 2.3). 
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5.1.4 Rivaroxaban anti-Xa levels  
Rivaroxaban anti-Xa levels were measured on the 12 RAPS trial patients on 
rivaroxaban and on in vitro spiked samples, which were also tested for TGT, using 
an amidolytic anti-Xa assay (section 2.4). In vitro spiked and patient samples were 
assayed separately with samples from each group assayed in the same analytical run. 
5.1.5 Lupus anticoagulant 
LA tests on in vitro spiked samples were performed using Textarin® time; dilute 
prothrombin time (dPT); DRVVT; and TVT/ECT (sections 2.10, 2.5, 2.6 and 2.11).  
The following DRVVT tests were performed on both in vitro and ex vivo samples: 
LA1 screening (low phospholipid concentration) and LA2 confirmation (high 
phospholipid concentration) reagents (Siemens Healthcare Diagnostics Products), 
and HemosIL dRVVT screen and confirm (Instrumentation Laboratory), reagents 
consisting of a screen and confirmatory reagents. In addition, an in-house method 
was undertaken in the initial in vitro studies. TVT/ECT were also performed in ex 
vivo studies. DRVVT on plasma samples taken from patient treated with warfarin 
were tested on equal volume (50:50) mixtures of patient plasma and PNP. Normal 
plasma, LA control high and low and a local quality control sample from a patient 
with confirmed LA were tested at the beginning and end of the test run. All samples 
were tested using the same lot numbers of reagents for each LA assay. 
5.1.5.1 LA results interpretation 
DRVVT results were interpreted as the normalised test/confirm ratio to correct for 
differences in instrument and reagent combinations. The 99th centile was used as a 
cut-off for normality; 1.19 (<1.2) and LA 1/LA 2 normalised ratio of >1.19 was 
considered to be positive for LA. 
The TVT ratio (TVTR) was calculated by dividing the clotting time for each test 
sample by the clotting time for PNP obtained with Taipan venom. A similar ratio 
calculation was performed for the confirm step with Ecarin clotting time. These two 
ratios were used to determine the normalised TVT/ECT ratio. Normal reference 
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ranges for TVTR, ECT ratio and TVTR/ECT ratio are 0.96 – 1.30, 0.99 – 1.14 and 
0.9 – 1.2 respectively.  A TVTR/ECT ratio of >1.2 was considered to be positive for 
LA. 
5.1.6  Studies to define the effects of aPL on rivaroxaban anticoagulant 
action  
The effects of aPL on the anticoagulant effects of rivaroxaban were assessed using 
the TG test and anti-Xa assays on PNP spiked with four different concentrations of 
rivaroxaban (0, 25, 50 and 100ng/mL) with two concentrations of IgG (500μg/mL 
and 250μg/mL) from 30 APS and 20 NC. These rivaroxaban concentrations were 
chosen following preliminary investigation with increasing concentrations of 
rivaroxaban spiked into PNP on TG to demonstrate clearly measurable effects on 
each parameter of TG (Figure 5-2). TG was performed using the CAT system 
(section 2.15). 
Figure 5-2 Thrombin generation with increasing concentration of rivaroxaban 
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5.2 Results 
Lupus anticoagulant studies 
Imprecision studies using commercial QC plasmas (mean LA 1: 50.3 & 74.5s, LA 2: 
34.7 & 37.7s, respectively; normalised LA 1/LA 2 ratio: 1.28 & 1.75 respectively) 
showed a coefficient of variation (CV) of approximately 1.0% for LA 1, 0.5% for LA 
2, and 1.0% for the normalised ratio from the samples tested on 8 different days. 
Imprecision studies using commercial QC plasmas (mean TVT: 50.3 & 74.5s, ECT: 
34.7 & 37.7s, respectively; normalised TVTR/ECT ratio: 1.28 & 1.75 respectively) 
showed a CV of approximately 1.0% for TVT, 0.5% for ECT, and 1.0% for the 
normalised ratio from the samples tested on 8 different days. 
5.2.1 In vitro studies: lupus anticoagulant 
Rivaroxaban caused a concentration dependent increase in clotting times with the 
dPT and DRVVT (Figure 5-3), but not with the TVT, ECT (Figure 5-4) or Textarin 
time. 
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Figure 5-3 DRVVT with phospholipid and platelet neutralizing reagents with increasing  
                concentration of rivaroxaban (in house method) 
 
Rivaroxaban caused a concentration dependent increase in clotting times with the DRVVT with both 
phospholipid and platelet neutralizing reagents. 
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Figure 5-4 TVT and ECT with increasing concentration of rivaroxaban (KC4A method) 
TVT and ECT remain unchanged with increasing concentration of rivaroxaban 
Figure 5-5 Textarin time with increasing concentration of rivaroxaban (KC4A method) 
Textarin time remains unchanged with increasing concentration of rivaroxaban 
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The dPT screen ratio became abnormal at 250ng/mL rivaroxaban. However, the dPT 
confirm ratio also increased in parallel, with the screen/confirm ratio (SCR) 
unchanged, and there were no false positives with IgG from LA negative APS 
patients and NC (Table 5-2). IgG spiked into PNP from 19 of the 20 LA positive 
APS patients remained positive for LA by dPT, irrespective of the rivaroxaban 
concentration (SCR mean [CI]: 1.4 [1.3-1.6] and 1.4 [1.3-1.7 for 50ng/mL and 
250ng/mL respectively) (Table 5-2). The remaining patient had negative LA with 
dPT without spiking with rivaroxaban, and this remained unchanged at both 
concentrations of rivaroxaban. 
The in-house DRVVT showed no false LA positive or negative LA results at either 
rivaroxaban level (Table 5-3). The PNP spiked with IgG from NC and rivaroxaban 
50ng/ml or 250ng/mL exhibited similar results to those obtained from samples 
spiked with IgG from LA –ve APS patients. With the commercial DRVVT reagents, 
the SCR became abnormal when PNP spiked with IgG from NC or LA negative APS 
patients and 250ng/mL rivaroxaban, giving false positive results in 18/20 (90%) in 
NC and11/12 (92%) LA negative APS ( Table 5-4). This phenomenon was not 
observed with 50ng/mL rivaroxaban. PNP spiked with LA positive APS IgG 
remained LA positive at both levels of rivaroxaban ( Table 5-4).  
There was no effect of rivaroxaban on Textarin time (Table 5-5) or TVT/ECT ratio 
and LA was detected at both rivaroxaban levels for all APS IgG spiked samples 
(TVT/ECT ratio: 1.4 [1.3-1.5], 1.3 [1.25-1.35] and 1.3 [1.23-1.36] for 0, 50 and 
250ng/mL rivaroxaban respectively (normal TVT/ECT < 1.2). There were no false 
LA positive results with TVT/ECT ( Table 5-6). 
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Table 5-2 dPT ratios with APS LA+ve IgG and negative IgG with rivaroxaban 50ng/mL or 250ng/mL. (Normal Screen/confirm ratio  >1.2) 
dPT ratio APS 
LA+VE 
IgG 
APS LA+VE IgG+ 
Rivaroxaban 
50ng/mL 
APS LA+VE 
IgG+ 
Rivaroxaban 
250ng/mL 
APS LA-VE     
IgG 
APS LA-VE IgG 
+ Rivaroxaban 
50ng/mL 
APS LA-VE 
IgG+ 
Rivaroxaban 
250ng/mL 
Screen ratio 1.3  
(1.2-1.5) 
1.8 
 (1.5-2.27) 
2.7  
(2.3-3.4) 
1.0  
(1.0-1.1) 
1.2 
(1.2-1.3) 
1.8  
(1.8-2.0) 
Confirm ratio 1.0  
(0.9-1.2) 
1.3 
 (1.2-1.6) 
1.9  
(1.6-2.2) 
1.0 
 (0.9-1.0) 
1.2  
(1.1-1.3) 
1.8  
(1.8-1.9) 
Screen/Confirm 
ratio 
1.4 
 (1.2-1.6) 
1.4  
(1.3-1.6) 
1.4 
 (1.3-1.7) 
1.0 
 (1.0-1.1) 
1.0 
 (1.0-1.1) 
1.0  
(0.9-1.1) 
    Data is shown as median ratio with 95% confidence interval.
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Table 5-3 DRVVT ratios (in-house method) with APS LA+ve IgG and negative IgG with rivaroxaban 50ng/mL or 250ng/mL ((Normal Screen/confirm ratio >1.2) 
DRVVT ratio APS LA+VE 
IgG 
APS LA+VE 
IgG+ 
Rivaroxaban 
50ng/mL 
APS LA+VE 
IgG+ 
Rivaroxaban 
250ng/mL 
 APS  
 LA-VE IgG 
APS LA-VE 
IgG + 
Rivaroxaban 
50ng/mL 
APS LA-VE IgG +       
 Rivaroxaban  
250ng/mL 
Screen ratio 1.5 
(1.4-1.6) 
2.5 
(2.1-2.8) 
3.6 
(3.3-3.9) 
1.0 
(1.0-1.1) 
1.5 
(1.4-1.6) 
2.4 
(2.2-2.5) 
Confirm ratio 1.1 
(1.1-1.4) 
1.6 
(1.5-2.2) 
2.7 
(2.4-2.9) 
1.0 
(0.9-1.0) 
1.4 
(1.3-1.5) 
2.3 
(2.1-2.4) 
Screen/Confirm 
ratio 
1.3 
(1.2-1.4) 
1.5 
(1.3-1.7) 
1.4 
(1.2-1.7) 
1.0 
(0.9-1.1) 
1.0 
(1.0-1.1) 
1.0 
(0.9-1.1) 
    Data is shown as median ratio with 95% confidence interval.
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 Table 5-4 1DRVVT ratios (Siemens reagents) with APS LA+ve IgG and negative IgG with rivaroxaban 50ng/mL or 250ng/mL (Normal Screen/confirm ratio >1.2) 
DRVVT 
ratio 
APS LA+VE IgG APS LA+VE 
IgG+ 
Rivaroxaban 
50ng/mL 
APS LA+VE 
IgG+ 
Rivaroxaban 
250ng/mL 
APS LA-
VE IgG 
APS LA-VE IgG 
+ Rivaroxaban 
50ng/mL 
APS LA-VE 
IgG+ 
Rivaroxaban 
250ng/mL 
Screen ratio 1.3 
(1.2-1.4) 
1.8 
(1.7-2.3) 
2.8 
(2.6-3.6) 
1.0 
(0.9-1.1) 
1.7 
(1.6-1.8) 
2.6 
(2.2-2.5) 
Confirm ratio 1.1 
(1.0-1.1) 
1.5 
(1.3-1.6) 
2.1 
(2.0-2.2 
1.0 
(0.9-1.0) 
1.5 
(1.4-1.6) 
2.1 
(2.0-2.2) 
Screen/Confirm 
ratio 
1.3 
(1.2-1.4) 
1.3 
(1.2-1.5) 
1.3 
(1.2-1.8) 
1.0 
(0.9-1.1) 
1.0 
(1.0-1.1) 
1.3 
(1.2-1.4) 
       Data is shown as median ratio with 95% confidence interval.
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5-5 Textarin time, Ecarin clotting time (ECT) and Textarin time/ECT ratios with APS LA+ve IgG and negative IgG with  rivaroxaban   50ng/mL or 250ng/mL 
 APS LA+VE IgG APS LA+VE 
IgG+ Rivaroxaban 
50ng/mL 
APS LA+VE 
 IgG + Rivaroxaban 
250ng/mL 
APS LA-VE  
IgG 
APS LA-VE  
IgG + Rivaroxaban 
50ng/mL 
  APS LA-VE  
IgG + Rivaroxaban 
250ng/mL 
Textarin 
time(seconds) 
35.7(33.0-37.1) 36.9 (36.0-38.1) 36.2 (34.9-37.8) 
 
23.0(22.6-24.1) 
 
23.1 (22-23.8) 23.6 (23.1-24.1) 
ECT (seconds) 25.0 (24.6-25.2) 25.6 (24.2-26.3) 25.4 (24.6-26.7) 23.4 (22.9-24.1) 23.0 (22.1-24.5) 23.9(22.9.2-25.0) 
Textarin 
time/ECT ratio 
1.4 (1.2-1.6) 
 
1.4 (1.2-1.6) 1.3 (1.2-1.6) 
 
0.9 (0.8-0.1.1) 
 
0.9(0.8 -1.1) 1.0(0.9-1.1) 
 
Textarin time/ECT ratio >1.19 confirm LA. There were no false positive or negative LA results at both rivaroxaban levels. Data is shown as median ratio with 95% 
confidence interval.
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 Table 5-6 TVT and ECT ratios with APS LA+ve IgG and negative IgG with rivaroxaban 50ng/mL or 250ng/mL 
 APS 
LA+VE 
IgG 
APS LA+VE IgG+ 
Rivaroxaban 
50ng/mL 
APS LA+VE IgG+ 
Rivaroxaban 
250ng/mL 
APS LA-VE 
IgG 
APS LA-VE IgG + 
Rivaroxaban 
50ng/mL 
 APS LA-VE IgG 
+    Rivaroxaban 
250ng/mL 
TVT ratio 1.4 
(1.3-1.5) 
1.4 
(1.3-1.5) 
1.5 
(1.3-1.5) 
1.0 
(0.9-1.1) 
1.0 
(0.9-1.1) 
1.0 
(0.9-1.1) 
ECT ratio 1.1 
(1.0-1.1) 
1.2 
(1.1-1.2) 
1.2 
(1.1-1.2) 
1.0 
(0.9-1.0) 
1.1 
(1.0-1.1) 
1.1 
(1.0-1.1) 
TVT/ECT 
ratio 
1.3 
(1.2-1.4) 
1.2 
(1.2-1.4) 
1.3 
(1.2-1.4) 
1.0 
(0.9-1.1) 
0.9 
(0.9-1.1) 
0.9 
(0.9-1.1) 
         Normal TVT 0.93-1.30, ECT 1.03-1.14, TVT/ECT ratio >1.19 confirm presence of LA. Data is shown as median ratio with 95% confidence interval 
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5.2.2 Ex vivo studies 
5.2.2.1 International normalised ratio (INR)  
INR values on the 24 patients on warfarin pre-randomisation and in those 12 patients 
who remained on warfarin were; (mean [CI]) 2.4 [2.1-3.2] and 2.3 [1.9-3.1] 
respectively. 
5.2.2.2 Rivaroxaban levels 
The plasma rivaroxaban levels of the 12 patients went onto rivaroxaban treatment, 
when samples taken at 2-4 hours following the last morning dose of rivaroxaban 
(mean [CI]) were 240 [165-270] ng/mL and the levels expected to be at the trough 
plasma rivaroxaban levels when samples were taken at over 18 (18-24) hours after 
the last morning dose of rivaroxaban were (mean [CI]) 55 (36-80) ng/mL. These 
peak and trough levels concur with those previously reported in population 
pharmacokinetic studies (Mueck et al, 2011). 
5.2.2.3 Lupus anticoagulant 
There were no false positive or negative LA results in the 24 RAPS patients when 
they were on warfarin, based on their APS-defining LA status determined prior to 
randomisation into RAPS trial. Six confirmed LA positive patients receiving 
rivaroxaban remained LA positive with TVT/ECT and DRVVT reagents at both peak 
(162-278ng/mL) and trough (30-85ng/mL) levels of rivaroxaban, except one patient 
(178ng/mL) who appeared LA negative with one commercial reagent. There was a 
greater prolongation of the screen DRVVT compared with the DRVVT confirm 
assay with both commercial reagents in patients treated with rivaroxaban at 
therapeutic levels, causing an increased normalised test/confirm ratio. This led to six 
LA negative patients becoming (apparently) LA positive with two DRVVT reagents, 
test/confirm ratio median [CI]: 1.6 [1.3-1.8], 1.6 [1.4-1.9] Figure 5-6A), but not by 
TVT/ECT (1.1 [0.8-1.2]). On samples taken at least 18 (18-24) hours after the last 
dose of rivaroxaban from those six patients who were previously LA negative and 
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randomised to rivaroxaban remained LA negative with both DRVVT reagents 
(Figure 5-6B), and with TVT/ECT. 
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Figure 5-6 Paired results on DRVVT screen, confirm and screen/confirm ratios in 6 patients   
                 negative whilst on warfarin and at least 6 weeks on rivaroxaban with therapeutic  
                levels (A), with trough levels (B). 
 
Normal screen/confirm ratio is <1.2. Mean rivaroxaban levels of these 6 patients that were expected to 
be within the therapeutic and trough levels were 240 [CI: 165-270ng/mL] and 55 [CI: 36-80ng/mL] 
respectively. War= Warfarin; Riva = Rivaroxaban  
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5.2.3 Effects of aPL on rivaroxaban anticoagulant action 
5.2.3.1 Thrombin generation 
Spiking PNP with IgG 500ug/mL from patients with LA positive APS caused a 
prolonged lag time and time to peak with LA positive IgG compared to LA negative 
IgG and NC IgG) (Figure 5-7): mean lag time [CI]:  5.2 [4.1-6.5], p= 0.02 LA 
positive IgG compared to LA negative 3.2 [2.7-3.6], and NC 3.1 [2.7-3.5] and mean 
time to peak:  8.1 [7.1-9.5], p=0.01 compared to LA negative 6.4 [6.2-6.6] and NC 
6.4 [6.1-6.6]. There were no differences in peak thrombin and ETP in PNP spiked 
with LA positive IgG compared to PNP spiked with  LA negative or NC IgG. The 
differences in the lag time and time to peak between three groups remained when 
PNP/IgG mixtures were also spiked with increasing concentrations of rivaroxaban 
(25, 50 and 100ng/mL). However, there was no difference in peak thrombin (Table 
5-7) and ETP (Table 5-8) between the three groups. There was no difference in the 
lag time or time to peak in the three groups at 250ug/mL IgG demonstrating that the 
LA effect is dose dependent. 
5.2.3.2 Rivaroxaban anti-Xa assay 
When PNP containing rivroxaban was spiked with 250μg/mL and 500μg/mL from 
20 LA positive, 12 LA negative and 20 NC with rivaroxaban 0, 25, 50 and 
100ng/mL, caused no change in the rivaroxaban concentration by anti-Xa assay. 
Mean [CI] rivaroxaban anti-Xa levels for 0, 25, 50 and 100ng/mL PNP respectively, 
spiked with IgG from the three groups were: 0, 20 [19-24], 46 [44-48] and 95 [94-98] 
ng/mL in LA positive APS; 0, 22 [21-24], 45 [44-47] and 97 [96-98] ng/mL in LA 
negative APS; and 0, 23 [21-24], 46 [44-47] and 97 [96-98] ng/mL in NC. 
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Figure 5-7  Example of thrombin generation in pooled normal plasma spiked with IgG  
                     500μg/mL, NC and LA negative APS (A), with IgG 500μg/mL, NC and LA positive  
                    APS (B) with increasing concentration of rivaroxaban 
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Table 5-7 Peak thrombin  
Peak thrombin 
(nM) 
LA positive LA negative NC p value 
0ng/mL 
rivaroxaban 
301  
[258-335] 
290 
[236-340] 
287  
[248-338] 
P=0.09 
25ng/mL 
rivaroxaban 
123  
[99-150] 
118 
[102-140] 
 
113 
[98-136] 
P=0.81 
50ng/mL 
rivaroxaban 
88 
76-101 
 
78 
[65-98] 
83 
[68=104] 
P=0.72 
100ng/mL 
rivaroxaban 
65 
[51-78] 
63 
[54-70] 
65 
[51-78] 
P=0.62 
 
Table 5-8  Endogenous thrombin potential (ETP) 
ETP(nM.minutes) LA positive LA negative NC p value 
     
0ng/mL 
rivaroxaban 
1738  
[1528-2188] 
1690 
[1470-2210] 
1680 
[1441-2342] 
p=0.08 
25ng/mL 
rivaroxaban 
1529 
[1360-1890] 
1490 
[1382-1790] 
1472 
[1376-1801] 
P=0.52 
50ng/mL 
rivaroxaban 
1326 
[1094-1565] 
1290 
[1090-1560] 
1284.5 
[1145-1540] 
P=0.63 
100ng/mL 
rivaroxaban 
1120 
[890-1320] 
1145 
[980-1360] 
1090 
[976-1356] 
P=0.71 
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5.3 Discussion 
This study has provided new insights into interactions between rivaroxaban and aPL. 
First, studies in vitro (using IgG preparations from thrombotic APS patients) and ex 
vivo (using plasma from thrombotic APS patients treated with therapeutic dose 
rivaroxaban), at peak and trough concentrations of rivaroxaban, established that false 
positive DRVVT may occur with rivaroxaban mainly at therapeutic plasma levels 
(165-270 ng/mL). However, the TVT/ECT ratio and Textarin time were not affected, 
irrespective of the rivaroxaban level, enabling accurate detection of LA. In vitro 
studies showed no false negative LA results with any of the tests used. In vitro 
studies also established, as hypothesised, that aPL do not influence rivaroxaban 
anticoagulant action as assessed using TG testing and anti-Xa assays. The findings in 
these studies should be considered for the development of future national and 
international guidelines on LA detection in patients treated with rivaroxaban.  
My studies on LA detection in the presence of rivaroxaban represents a systematic 
and detailed approach to LA detection, both in vitro and ex vivo, using well 
characterised patients with thrombotic APS and defined LA status, and treated with 
rivaroxaban at both peak and trough levels of rivaroxaban. Limited previous studies 
provided no in vitro or ex vivo data using thrombotic APS patients, a group that can 
provide clinically relevant information on LA detection. An in vitro study (van Os et 
al, 2011), using rivaroxaban spiked into plasma from 13 patients with systemic lupus 
erythematosus. Six of these patients deemed to have positive LA, demonstrated that 
the LA ratio was not influenced by rivaroxaban when tested with TVT/ECT but 
activated partial thromboplastin time (aPTT) was slightly increased and a 
commercial DRVVT reagent was strongly influenced. In the seven remaining 
patients, stated to be LA negative, three became positive for LA with an aPTT, but 
not with TVT/ECT (the DRVVT was not assessed in the presence of rivaroxaban).  
Another study (Merriman et al, 2011) reported that 19 patients randomised to the 
EINSTEIN trial receiving rivaroxaban 20mg daily with no documented LA or APS, 
demonstrated positive LA with a DRVVT screening test, when samples were taken 
between 1-19.5 hours following the previous dose of rivaroxaban. However, a 
DRVVT confirm assay was not performed in this study, limiting the clinical 
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applicability of the findings. Martinuzzo et al, studied 26 patients,four on therapeutic 
dose, and the remainder on prophylactic dose, with no previously documented LA or 
history of APS for LA. Based on DRVVT screen and confirm tests with one 
commercial reagent, these authors reported that 75% of patient samples were 
apparently LA positive by DRVVT, but none had a prolonged silica clotting time 
(Martinuzzo et al, 2014). 
The TVT/ECT ratio and Textarin time were not affected irrespective of rivaroxaban 
level, enabling appropriate detection of LA. False positive DRVVT may occur with 
rivaroxaban mainly at therapeutic plasma levels (165-270ng/mL). There was a 
greater prolongation of the DRVVT screen compared with the DRVVT confirm test 
with both commercial reagents, in patients treated with rivaroxaban at therapeutic 
levels, causing an increased normalised test/confirm ratio. This led to six LA 
negative patients becoming (apparently) LA positive with two DRVVT reagents, but 
not by TVT/ECT. In vitro studies of LA detection using a dPT or DRVVT with in-
house reagents did not produce false positive results as there was a parallel increase 
in the LA screen and LA confirm DRVVT producing normal SCR. This is most 
likely due to the phospholipid content of the reagents (low phospholipid content in 
the in-house confirm reagents compared to high phospholipid content in commercial 
DRVVT confirm reagents). However, at trough rivaroxaban levels (30-85ng/mL), 
when samples were taken at least 18 (18-24) hours after the last dose of rivaroxaban, 
those six patients who were previously LA negative, (with LA status confirmed 
negative whilst on warfarin) remained LA negative with two commercial DRVVT 
reagents. These data support the use of the TVT/ECT to detect LA, even at peak 
plasma rivaroxaban levels and suggest that the DRVVT may be acceptable at trough 
rivaroxaban levels.  
Patients with thrombotic APS are inherently different from other patients with VTE 
by virtue of their aPL, particularly LA and anti-prothrombin antibodies  (Sciascia et 
al, 2014), which are known to interfere with a number of haemostatic mechanisms, 
and which could therefore modulate the actions of anticoagulants (Arachchillage et 
al, 2014a). It follows that information on the influence of aPL on rivaroxaban is 
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clinically relevant in thrombotic APS patients. Our in vitro studies demonstrated that 
LA led to prolonged lag times and time to peak in a TG system. These observations 
are in accordance with others (Liestol et al, 2007b;Regnault et al, 2003). 
In vitro studies also showed that aPL did not affect rivaroxaban anticoagulant action 
at peak or trough levels, based on TG testing and anti-Xa levels. This was 
hypothesised as rivaroxaban is a small molecule with high affinity for a specific 
target. At the time of writing this chapter, as far as I was aware, there were no 
reported observations on the influence of aPL on rivaroxaban anticoagulant effects. 
Of note in this context, anecdotal clinical reports suggest thromboembolism 
recurrence following switching from warfarin to dabigatran (one patient who 
developed thrombotic endocarditis with symptomatic cerebral emboli) and 
rivaroxaban (two patients, one who experienced ischemic arterial strokes and right 
transverse-sigmoid sinus thrombosis, and the second, porto-mesenteric venous 
thrombosis) (Schaefer et al, 2014).  There is another case report involving  three APS 
patients who experienced recurrent thrombosis while receiving rivaroxaban or 
dabigatran (Win & Rodgers, 2014) Appropriately designed and powered clinical 
trials such as RAPS are required in patients with thrombotic APS to establish the 
potential use of each NOAC in these patients.  
In conclusion, false positive DRVVT may occur in rivaroxaban treated patients 
mainly at therapeutic levels. The TVT/ECT ratio and Textarin time are not affected 
irrespective of the rivaroxaban levels, enabling accurate detection of LA in patients 
receiving rivaroxaban. In thrombotic APS patients treated with rivaroxaban, the 
TVT/ECT appears reliable even at therapeutic plasma levels of rivaroxaban. The 
DRVVT may be acceptable at trough rivaroxaban plasma levels, in samples taken at 
least 18 hours following the previous dose of rivaroxaban. The findings in this in 
vitro and ex vivo studies will guide detection of LA. This will enable diagnosis of 
APS in patients treated with rivaroxaban as well as monitoring of LA in APS 
patients, and also inform national and international guidelines. Finally, in vitro 
studies indicate that aPL do not influence anticoagulant activity of rivaroxaban as 
measured by TGT and rivaroxaban anti-Xa levels. 
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   Thrombin generation and in vivo coagulation activation Chapter 6
markers in patients without APS, treated with 
therapeutic dose rivaroxaban or warfarin for venous 
thromboembolism 
6.1 Introduction 
Clinical outcome measures in patients receiving warfarin or rivaroxaban have been 
assessed in a number of different multicentre prospective clinical trials involving 
thousands of patients, including those with VTE [EINSTEIN-DVT (Bauersachs et al, 
2010) and EINSTEIN-PE (Buller et al, 2012) ] (196;196;196). Rivaroxaban has been 
shown to be non-inferior to warfarin with regard to relevant clinical efficacy and 
safety outcome measures. However, the ex-vivo effects of warfarin versus therapeutic 
dose rivaroxaban on TG and in vivo markers of coagulation activation remain 
undefined. 
Thrombin is a pivotal component of the haemostatic mechanism. It has been shown 
that increased ex-vivo TG as measured by ETP is a key marker of thrombogenic 
potential and of predictive value for the development of recurrent VTE (Eichinger et 
al, 2008;Besser et al, 2008). In patients with acute thrombosis, in-vivo markers of 
coagulation activation such as prothrombin fragment 1.2 (F1.2), thrombin-
antithrombin complex (TAT), and D-dimer are frequently elevated, and 
anticoagulation reduces the levels of these markers (Conway et al, 1987). One 
molecule of F1.2 is released with the generation of each thrombin molecule (Teitel et 
al, 1982). F1.2 level reflects thrombin activity more directly and may be a better 
clinical marker of the intensity of anticoagulation. All anticoagulant agents directly 
or indirectly inhibit TG (Adams, 2009;Eerenberg et al, 2011). F1.2, as the activation 
peptide originating from the factor Xa-mediated activation of prothrombin, has been 
reported to be a sensitive marker of anticoagulation (Tripodi et al, 1998;Millenson et 
al, 1992), and evidence supports the use of F1.2 and D-dimer in identifying patients 
at increased risk of VTE recurrence who need continued anticoagulation, or a 
different intensity anticoagulant regime (Palareti et al, 2006;Poli et al, 2008;Poli et 
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al, 2010). In-vitro experiments, where rivaroxaban has been spiked into normal 
plasma, as well as ex-vivo data from patients receiving prophylactic rivaroxaban, 
have shown that rivaroxaban affects various parameters of the TG assay using the 
CAT system. A greater inhibitory effect was observed on the initiation phase (lag 
time) and the peak TG compared to that on the area under the curve i.e. ETP 
(Samama et al, 2013;Samama et al, 2010) compared to fondaparinux in vitro; and 
patients on prophylactic dose rivaroxaban 10 mg daily undergoing elective total 
hip/knee replacement showed a greater decrease of TG, F1.2 and TAT (but not D-
dimer) than those on dalteparin (Green et al, 2010) . 
Aim of this chapter was to compare ex-vivo TG (using the CAT system) and in vivo 
markers of coagulation activation (F1.2, TAT complexes and D-dimer) in patients on 
long term anticoagulation with warfarin or rivaroxaban following VTE without APS 
6.2 Patients and Methods 
6.2.1 Patients 
The study included 45 patients on warfarin with a target INR of 2.5 (range 2.0-3.0) 
and 40 patients on therapeutic dose rivaroxaban (20mg) daily for the prevention of 
recurrent VTE following a first episode of DVT or PE. Patients on rivaroxaban had 
previously switched from therapeutic dose warfarin to rivaroxaban because of: 
allergy to warfarin, lack of availability of phenindione, lifestyle and difficulty in 
monitoring warfarin due to needle-phobia. Rivaroxaban had been administered for at 
least 3 weeks (3-12 weeks) and taken with food, which increases the absorption of 
the drug  (SPC Xarelto film-coated tablets, 2014). None of these patients were taking 
other anticoagulants, antiplatelet agents, or any other drugs known to interact with 
rivaroxaban. None of the patients had an episode of acute VTE within the last 3 
months or acute or chronic infections/inflammation.  Duration of anticoagulation in 
patients groups varies from 4 to 6 months. Patient demographic details are shown in 
Table 6-1. All patients in both anticoagulant treatment groups had a creatinine 
clearance over 50mL/min (Cockcroft & Gault, 1976) and normal liver function tests.   
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Table 6-1 Baseline characteristics of the two patients groups 
 Warfarin (n=45) Rivaroxaban (n=40) 
Age in years: median (range) 47 (28-70) 46 (34-68) 
Male/Female 28/17 26/14 
Intensity of anticoagulation Target INR 2.5  
(range 2.0-3.0) 
Rivaroxaban 20mg 
daily 
Type of thrombosis  
          DVT                                    
          PE                                  
          DVT+ PE 
 
25/45 (55.5%) 
12/45 (26.7%) 
8/45 (17.8%) 
 
23/40 (57.5%) 
11/40 (27.5%) 
6/40 (15%) 
Creatinine clearance (mL/min)  
Median (range) 
75 (63-92) 76 (62-95) 
 
All patients were tested for aPL and were negative. As patients were already on 
warfarin, lupus anticoagulant (LA) tests were performed using the Taipan/Ecarin 
time ratio (which shows little impact of warfarin) and/or DRVVT using  equal 
volume mixtures  with normal plasma, to correct for warfarin-induced coagulation 
factor deficiency), in accordance with recommendations  by the ISTH and BCSH 
guidelines on LA detection (Keeling et al, 2012;Pengo et al, 2009). All patients were 
tested for aPL at least 6 weeks after  initiation of anticoagulation.TG was also 
assessed in 51 normal controls (median age 40 [range 23-70]).  
6.2.2 Blood sampling 
Venous blood samples were collected following informed consent at a single time-
point using a 21 gauge butterfly needle, with minimal venous stasis, within 2-4 hours 
of the last dose of rivaroxaban, when they attended a routine clinic appointment. 
Blood was drawn into 5mL citrate Vacutainer® (BD, Oxford, UK) containing 0.5mL 
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of 0.105M buffered  sodium citrate which gave a ratio of 1 part anticoagulant to 9 
parts blood. Platelet poor plasma (PPP) was prepared within 1 hour of collection by 
double centrifugation (2000g for 15 minutes) at ambient temperature and 0.75mL 
aliquots were transferred to 2.0mL cryo-tubes (Sarstedt Ltd, Beaumont Leys, 
Leicester, UK) and stored at -80°C for up to 12 weeks. Immediately prior to analysis 
the samples were thawed at 37°C.   
6.3 Coagulation assays 
6.3.1 Prothrombin time (PT) and International normalised ratio 
PT was performed only on samples from patients taking warfarin, using a single lot 
number of Innovin (Siemens Healthcare Diagnostics), on a CS-5100 analyser 
(Sysmex UK Ltd) and employing an instrument-specific ISI value (0.99) (section 
2.3). 
The median INR of the patients on warfarin was 2.29 (range 1.70-3.24). Seventy-one 
percent (32/45) of patients on warfarin had an INR within the target therapeutic 
range. Eight patients had INR values below 1.9 (17.7%) and five patients had INR 
>3.0 (11.1%). 
6.3.2 Rivaroxaban levels 
Rivaroxaban levels were measured using an amidolytic anti-Xa assay (Biophen 
DiXaI; Hyphen BioMed) (section 2.4) on a Sysmex CS-2000i analyser (Sysmex UK 
Ltd). Samples were tested in duplicate. All patient samples were processed on a 
single occasion. 
The median plasma rivaroxaban level in the 40 patients was 284ng/mL (range 56-
457ng/mL). In 26 of these patients (65%), rivaroxaban levels were within the 
expected range for therapeutic peak plasma concentrations (162-356ng/mL), as 
previously determined in a population pharmacokinetics study of once daily dose of 
rivaroxaban (Mueck et al, 2008). Nine patients (22.5%) had rivaroxaban levels less 
than 160ng/mL (56-157ng/mL), which were considered to be subtherapeutic, and in 
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five patients (12.5%) rivaroxaban levels were above the expected peak plasma 
concentration (412-457ng/mL) (Mueck et al, 2008).  
6.3.3 Ex vivo thrombin generation  
TG was measured using the CAT system (Thrombinoscope BV) in conjunction with 
PPP reagent (Stago) which gave reaction concentrations of 5 pmol/L tissue factor 
(TF) and 4µmol/L phospholipid (section 2.15). These experimental conditions were 
selected based on our previous experience (Lawrie et al, 2012) and that of others 
(Gatt et al, 2008). Since the samples tested were from patients on anticoagulation, 
the use of a low concentration tissue factor reagent (i.e. 1 pmol/L or less) was not 
appropriate as there would have been minimal or no thrombin generation. It has been 
demonstrated that addition of corn trypsin inhibitor (CTI)  after plasma preparation 
had no significant influence on thrombin generation triggered with 0.5 pM TF or 
higher, as demonstrated by unaltered ETP and lag time values between analyses with 
and without CTI (Spronk et al, 2009). Addition of CTI before blood collection 
reduced thrombin generation triggered with 0.5 pM TF: both the ETP and peak 
height were significantly reduced compared to no CTI addition. In contrast, thrombin 
generation remained unaltered at a 1 pM TF trigger or above. As 5pM TF was used 
in this study, blood collection into CTI was not necessary. 
 All TG reactions for both samples and calibrators were tested in triplicate. The 
following parameters of the TG curve were recorded: lag-time; time to peak TG, 
peak thrombin and ETP. Normal ranges for TG were established using 51 normal 
controls (NC) none of whom were on any oestrogen preparations.  The intra- and 
inter-assay imprecision, using normal plasma were 2.5% and 4% respectively.  
6.4 Results 
Figure 6-1 provides an example of the effect of warfarin and rivaroxaban on TG 
compared to a NC. TG was significantly lower in patients receiving rivaroxaban or 
warfarin (Figure 6-2) compared to NC (p<0.0001 for ETP and peak thrombin). Both 
groups had significantly prolonged lag time (p<0.0001) as well as time to peak 
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(p<0.003) compared to NC. Patients treated with rivaroxaban had significantly 
prolonged lag time and time to peak TG along with significantly lower peak 
thrombin compared with those treated with warfarin (p<0.0001 for all three 
parameters). However, ETP was significantly lower in warfarin-treated patients 
compared with those receiving rivaroxaban (p<0.0001). The significance levels 
remained unchanged even after excluding the results of eight patients in the warfarin-
treated group who had subtherapeutic INR values (<1.9).  
Rivaroxaban levels were correlated with lag time and time to peak thrombin and 
inversely correlated with ETP and peak thrombin (rs=0.61, p<0.0001, rs=0.72, 
p<0.0001, rs = -0.51, p = 0.001 and rs = -0.39, p = 0.013 respectively) [Figure 6-3]. 
However, the correlation between INR and TG was poor in warfarin treated patients, 
even after removing results of samples with subtherapeutic INR values.  
Figure 6-1 An example of the effect of warfarin and rivaroxaban on TG compared to a normal  
                control 
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Figure 6-2 Thrombin generation parameters 
Thrombin generation parameters are shown in the two study groups (warfarin n=45; rivaroxaban 
n=40). Normal ranges (NR) and the median for the each parameter based on results in the 
(unanticoagulated) normal controls is shown in brackets and the dotted lines respectively. 
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Figure 6-3 Spearman rank correlation between rivaroxabn level and thrombin generation  
                 parameters 
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6.5 In-vivo coagulation activation markers:  
D-dimer was measured by an immunoturbidometric technique (Innovance D Dimer; 
Siemens Healthcare Diagnostics) on a CS-5100 analyser (Sysmex UK Ltd) (section 
2.12). F1.2 and TAT complexes were measured by enzyme-linked immunosorbent 
assay (Enzygnost® F1.2 and Enzygnost® TAT respectively; Siemens Healthcare 
Diagnostics) (sections 2.13 and 2.14).  
Table 6-2 Comparison of in vivo coagulation activation markers in warfarin and rivaroxaban  
               treated patients. 
 Warfarin Rivaroxaban Normal cut-off  
D-dimer  
(μg/L FEU) 
190 
(<190-510) 
190 
(<190-300) 
<550 
 
F1.2 
(pmol/L) 
54.3 
(19.9-233.3) 
58.3 
(18.2-121.2) 
< 229 
 
TAT 
(μg/L) 
2.7 
(1.9-4.9) 
2.5* 
(1.6- 3.5) 
<4.2 
F 1.2 = prothrombin fragments 1. 2; TAT = thrombin-antithrombin complex (TAT); All values are 
given in median and ranges. The majority of the patients in both groups had undetectable D-dimer 
levels (<190μg/L FEU); * p< 0.001  
In vivo coagulation activation markers were within their normal reference ranges in 
all the patients treated with rivaroxaban and 37/45 warfarin-treated patients with INR 
2.0-3.2 (Table 6-2). Six of eight warfarin-treated patients with subtherapeutic INR 
values (i.e. <2.0; range 1.7-1.85) (13.3% (6/45) of the total) exhibited slightly raised 
TAT (n=6) and few of those also had raised F1.2 levels (Table 6-3). In vivo 
coagulation activation markers were maintained within their normal reference ranges 
in all the rivaroxaban-treated patients, including nine patients with subtherapeutic 
rivaroxaban levels (as defined above).  
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Patients treated with rivaroxaban had significantly lower TAT levels compared with 
those on warfarin (p=0.006) (Figure 6-4) and the difference remained significant 
even after removing the six patients with subtherapeutic INR levels (p=0.03).  
Table 6-3 In vivo coagulation activation markers, ETP and peak thrombin of the warfarin- 
               treated patients who had subtherapeutic INR values 
INR F1.2 
(pmol/L) 
TAT 
(μg/L) 
ETP 
(nM.minutes) 
Peak thrombin  
(nM) 
1.70 260.3 5.1 1453 233.9 
1.78 263.7 5.0 951 141.1 
1.78 127.7 5.1 924 143.3 
1.82 433.3 4.7 1282 134.2 
1.83 147.8 5.0 984.4 135.7 
1.85 413.8 4.3 1281 156.3 
1.88 223.0 3.2 898 163.7 
1.90 85.9 2.5 656 152.8 
Normal cut-
off/ range 
229 4.2 1826-2354 283-359 
INR = international normalised ratio; F 1.2 = prothrombin fragments 1. 2; TAT = thrombin-
antithrombin complex (TAT); ETP=endogenous thrombin potential; INR normal range: 0.91-1.11; 
ETP normal range 1826-2354nM.min); peak thrombin normal range (283-359nM); values in bold 
indicate those above the normal reference range 
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Figure 6-4 Comparison of TAT level between warfarin and rivaroxaban 
 
 
 
 
 
 
 
 
6.6 Bleeding and thrombotic episodes 
None of the patients experienced clinically significant bleeding prior to, during, or 
immediately after the study. One patient, who had the highest ETP (1287nM.min) in 
the rivaroxaban-treated group developed arterial thrombosis in the left leg 
immediately after the study. However, this patient’s ETP was well below the normal 
reference range (1826-2354nM.min). Activation markers of in-vivo coagulation in 
this patient were well within the normal range.  
6.7 Discussion 
The results of this study provide insight into the effects of therapeutic dose warfarin 
and rivaroxaban on TG and markers of coagulation activation in patients with VTE. 
Both rivaroxaban and warfarin significantly reduced TG, with regard to all 
parameters measured, compared to (unanticoagulated) NC. The effect of rivaroxaban 
on TG was more marked compared with warfarin for all parameters except ETP, 
where warfarin-treated patients had significantly lower values. In-vivo coagulation 
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activation markers were within the normal reference ranges in all rivaroxaban-treated 
patients and 37/45 warfarin-treated patients with INR 2.0-3.2. Six of eight (13.1% of 
the total) warfarin-treated patients with subtherapeutic INR values exhibited slightly 
raised F1.2 and/or TAT. In-vivo coagulation activation markers were maintained 
within the normal reference ranges in all the rivaroxaban-treated patients, including 
9/40 (22.5%) with subtherapeutic rivaroxaban levels. None of the patients 
experienced clinically significant bleeding during the study period; however one 
rivaroxaban-treated patient, who had the highest ETP in this group, but below the 
range of NC, developed arterial thrombosis. This study was not designed to have 
statistical power for clinical outcome i.e. recurrence of thrombosis or bleeding. 
The significantly reduced peak thrombin and relatively less inhibited ETP with 
rivaroxaban are probably explained by protraction of the thrombin generation 
process with rivaroxaban compared to warfarin. The ETP is considered to depend on 
the propagation and termination phases of the TG process and has been reported to 
show decreased sensitivity to direct Xa inhibitors during in-vitro studies (Samama et 
al, 2012;Samama et al, 2010). This is assumed to be due to inhibition of the positive 
feedback action of FXa on factor VII, which results in  prolongation of the lag time 
and a slow start of prothrombinase complex formation and hence, a longer time to 
peak TG (Bloemen et al, 2013;Jesty et al, 1996). The TG test, as a global measure of 
anticoagulation, can assess the anticoagulant effects of both rivaroxaban and 
warfarin, and effects on the ETP should be assessed in combination with the other 
TG parameters. ETP has been shown be a predictive marker for recurrent thrombosis 
(Eichinger et al, 2008;Besser et al, 2008) and in my study, the only patient who 
developed arterial thrombosis had the highest ETP in the group treated with 
rivaroxaban. However, the study was not designed to assess ETP as a marker for 
prediction of thrombotic risk in patients treated with rivaroxaban. 
My findings of significantly inhibited peak thrombin with rivaroxaban concur with 
those by Samama’s group, whose in-vitro studies compared both rivaroxaban and 
edoxaban with fondaparinux, and demonstrated that rivaroxaban and edoxaban were 
more effective in reducing peak thrombin (Samama et al, 2012;Samama et al, 2010). 
In that study, using molar concentrations to compare the effect of anticoagulants, 
149 
 
rivaroxaban and edoxaban induced more inhibition than fondaparinux of all the TG 
parameters, with the exception of ETP. Recently, Hermann et al (Herrmann et al, 
2014) demonstrated that prophylactic dose rivaroxaban (10mg daily)  significantly 
reduced the ETP and peak thrombin and prolonged the lag time in samples tested at 
two hours compared to 24 hours post dose. A strong relationship has also been 
demonstrated between the concentration of a given anticoagulant and the amount of 
thrombin generated (Bostrom et al, 2004). In my study all six patients on warfarin 
with subtherapeutic INR values had slightly raised F1.2 and/or TAT levels, and an 
ETP above 900nM.min (Figure 6-3C and Table 6-3). The ETP results in warfarin-
treated patients agreed with other reported observations that patients on warfarin with 
an INR between 2.0-3.0, where an ETP range of approximately 500-700nM.min  was 
found (Hemker & Beguin, 2000). This range is equivalent to 30%-50% of the pre-
warfarin result (Brodin et al, 2009) or that in normal controls (Gerotziafas et al, 
2009). In patients treated with rivaroxaban, the median ETP was 903nM.min (range 
224-1287) in patients treated with rivaroxaban, and was significantly higher than in 
patients on warfarin.  
I observed normal in vivo coagulation activation markers in both the warfarin and 
rivaroxaban treated patients, with the exception of a few patients in the warfarin 
group with subtherapeutic INR values who showed slightly raised TAT and F1.2 
levels. However, the D-dimer level was below the normal cut-off in both groups, 
irrespective of anticoagulation intensity suggesting that gross fibrin deposition was 
not occurring. In a study to investigate the effects of low-dose rivaroxaban (10mg 
daily) on coagulation factor activities based on the administration time, Mani et al 
(Mani et al, 2013) showed that there was no significant difference in the D-dimer 
level at different time intervals after rivaroxaban administration. Corresponding 
effects of rivaroxaban on F1.2 and TAT levels are unknown.  
As TAT complexes and F1.2 have much shorter half-lives (15 minutes (Pelzer et al, 
1988) and 90 minutes respectively (Greenberg et al, 1994) compared to D-dimer (8 
hours) (Hager & Platt, 1995), there may be differences in the levels of TAT 
complexes and F1.2 based on the rivaroxaban administration time. The purpose of 
once daily anticoagulation is to have a sustained reduction in thrombotic risk for 24 
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hours until the next dose of anticoagulation is administered. Although the plasma 
rivaroxaban level reaches a peak within 2-3 hours of ingestion, the anticoagulant 
effect is expected to last for 24 hours as it is given once daily. Even at trough levels 
of rivaroxaban, TG should be inhibited below that of the normal controls. This effect 
is reflected in the results of my study, which demonstrated that even at 
subtherapeutic levels of rivaroxaban, there was good inhibition of TG and markers of 
coagulation activation remained within normal limits. 
This study was designed to investigate and provide information on ex vivo TG and 
markers of in vivo coagulation activation in a routine hospital anticoagulation clinic 
population. Patients were asked to attend clinics to provide blood samples 2-4 hours 
following their last morning dose of rivaroxaban; 65% had plasma rivaroxaban levels 
within the expected range for their therapeutic dose. Of the patients on warfarin, 70% 
had an INR within their target therapeutic range (2.0-3.0). However, even if the 
analysis was performed excluding patients who had INR values or plasma 
rivaroxaban levels lower than expected range following 2-4 hours of the last dose, 
the results showed no difference. 
Based on TG tests from patients with congenital factor deficiencies, TG values below 
approximately 20% of normal (which corresponds to an ETP <350nM.min) is 
associated with a definite risk of bleeding (Al et al, 2002). Six of 45 (13.3%) patients 
in the warfarin group and 3 out 40 (7.5%) rivaroxaban patients had an ETP below 
350nM.min. None of these patients experienced clinically relevant bleeding 
manifestations, suggesting that a lower ETP alone was not indicative of bleeding 
phenotype in the patients studied. It is possible that anticoagulated patients with a 
thrombotic phenotype may have a lower risk of bleeding in the presence of a similar 
amount of generated thrombin compared to those with inherited bleeding disorders. 
At the time of writing this chapter, no studies investigating relationship of  D-dimer, 
F1.2 level and TAT complex in patients with VTE who develop clinically significant 
bleeding or thrombosis whilst on treatment dose rivaroxban had been published. In a 
study on patients given prophylactic rivaroxaban (Borris et al, 2008), there was a 
significantly lower level of urinary F1.2 in patients who developed bleeding 
compared to patients who developed VTE, following total hip replacement (THR). 
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However, urinary F1.2 levels were increased for several days after THR due to 
activation of coagulation factors and increased TG as a result of surgical trauma. As 
a result, the level of urinary F1.2 associated with bleeding or VTE following THR 
cannot be applied to VTE patients on long term anticoagulation with rivaroxaban.  
6.7.1 Limitations of this study 
Limitations of this study were that the number of subjects studied was relatively 
small and the study design was cross-sectional rather than a prospective cross over 
trial. A further limitation is that samples were taken only at a single time point from 
each patient, and were not designed to correlate ex-vivo TG parameters and markers 
of in-vivo thrombin activation with clinical outcome. Despite these limitations, the 
findings should inform haematologists and physicians regarding the overall 
coagulation response with rivaroxaban compared to warfarin and provide evidence 
that even at trough levels of rivaroxaban, there is no in vivo evidence of increased 
TG. 
6.8 Conclusion 
 In conclusion, both rivaroxaban and warfarin achieve effective anticoagulation, as 
assessed by inhibition of TG and in-vivo coagulation activation markers. The effect 
of rivaroxaban on TG was more marked compared with warfarin for all parameters 
except ETP, where warfarin-treated patients had significantly lower values. The TG 
test, as a global measure of anticoagulation, can assess the anticoagulant effects of 
both rivaroxaban and warfarin, and effects on the ETP should be assessed in 
combination with the other TG parameters. In-vivo coagulation activation markers 
were within the normal reference ranges in all rivaroxaban-treated patients (including 
those with subtherapeutic levels) and in 37/45 warfarin-treated patients who had an 
INR ≥2.0, with a minority of warfarin-treated patients with subtherapeutic INR 
values exhibiting slightly raised F1.2 and/or TAT. 
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 In vivo markers of coagulation activation in patients Chapter 7
with antiphospholipid syndrome treated with 
rivaroxaban or warfarin following venous 
thromboembolism 
Rivaroxaban is licensed for the treatment and prevention of VTE. However, use of 
this anticoagulant in patients with APS is not yet recommended apart from in the 
clinical trial setting. Rivaroxaban is currently being evaluated in a phase II/III 
randomised clinical trial (RAPS) for prevention of recurrent VTE in patients with 
APS following a first episode of DVT or PE, or recurrence of VTE after stopping 
therapeutic anticoagulation (http://isrctn.org/ISRCTN68222801).  
In the previous chapter, following the study of TG and activation markers of in vivo 
coagulation in patients without antiphospholipid syndrome, treated with rivaroxaban 
or warfarin, I found that effective anticoagulation was achieved with both 
anticoagulants, as assessed by inhibition of TG and in vivo coagulation activation 
markers. Studies of the effects of rivaroxaban on TG in patients with APS are limited 
to in vitro studies and activation markers of in vivo coagulation have not been 
reported.  
The aim of this chapter was to compare in vivo markers of coagulation activation 
(F1.2, TAT complexes and D-dimer) in APS patients on long term anticoagulation 
with warfarin or rivaroxaban (at least for 6 weeks following  the switch to 
rivaroxaban from warfarin) for VTE.  
7.1 Patients and blood sample collection 
A total of 48 patients with VTE, on long term anticoagulation with warfarin, target 
INR 2.5 (2.0-3.0), who, fulfilled the revised international consensus criteria for 
definite APS (Miyakis et al, 2006) were studied. These patients were from the RAPS 
trial, and consented for the translational research at the UCLH. Out of a total of 48 
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patients, 25 patients remained on warfarin, whilst 23 patients switched to 
rivaroxaban. 
All patients in both anticoagulant treatment groups had a creatinine clearance over 
50mL/min (Cockcroft & Gault, 1976)  creatinine clearance < 50mL/min, rivaroxaban 
dose was altered  to 15mg daily instead of 20mg daily. All patients had alanine 
transaminase level less than the twice upper limit of normal. Citrated blood samples 
were collected from patients receiving rivaroxaban 2-4 hours following the last 
morning dose (day 42 days following the randomisation). All samples were 
processed, stored and thawed as described in section 2.2. For each patient, day 0 and 
42 samples were tested at the same time in order to avoid inter-assay variation 
7.2 Results 
7.2.1 Warfarin group 
INR was assessed using Innovin as described in section 2.3. There was no significant 
difference in the INR values in the 25 patients at day 0 and day 42 following 
randomisation to remain on warfarin (Figure 7-1). 
Day 0 Day 42
0.0
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1.0
1.5
2.0
2.5
3.0
3.5
4.0
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Figure 7-1 INR values in the 25 patients on day 0 and day 42  
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F1.2, TAT and D-dimer 
F1.2, TAT and D-dimer were performed in all patients (day 0 and day 42) as 
described in section 2.13, 2.14 and 2.12 respectively.  
On day 0, 4% (1/25), 4% (1/25) and 16% (4/25) had raised F1.2, TAT and D dimer 
levels above the normal cut- off levels respectively (Table 7-1). On day 42, TAT and 
D-dimer were above the normal cut-off values in one (4%) and two (8%) patients 
respectively (Table 7-2) while none of the patients had raised F1.2 level. However, 
none of the patients had more than one activation marker above the normal cut-off 
levels and patients who had elevated activation markers at day 0 were not the same 
patients who had elevated markers at day 42. There were no significant differences in 
F1.2, TAT and D dimer levels on samples taken on day 0 and day 42 in the 25 
patients who remained on warfarin anticoagulation  
Table 7-1 Patients with raised activation markers treated with warfarin on day 0 
Patient INR F1.2 
(pmol/L) 
TAT (μg/L) D dimer 
(μg/L FEU) 
A 1.3 240.7 3.9 560 
B 1.5 44.2 3.1 560 
C 1.1 67.2 3.1 650 
D 1.5 89.3 3.7 900 
E 1.9 59.2 6.2 450 
Normal range     0.91-1.1      < 229           <4.2         <550 
INR = international normalised ratio; F 1.2 = prothrombin fragments 1. 2; TAT = thrombin-
antithrombin complex (TAT); values in bold indicate those above the normal reference range 
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Table 7-2 Patients with raised activation markers treated with warfarin on day 42 
Patient   INR F1.2 (pmol/L) TAT (μg/L) D dimer 
(μg/L 
FEU) 
F 1.68 67.2 3.1 650 
G 1.79 60.4 2.7 590 
H 1.9 65.8 4.7 430 
Normal 
range 
0.91-1.1 < 229 <4.2  <550 
INR = international normalised ratio; F 1.2 = prothrombin fragments 1. 2; TAT = thrombin-
antithrombin complex (TAT); values in bold indicate those above the normal reference range. 
Figure 7-2  F1.2 TAT and D-dimer level on day 0 and day 42 in warfarin group 
The dotted lines indicate the normal cut off levels 
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INR showed a linear correlation with F1.2 at both time points; day 0: rs= -0.41, 95% 
CI -0.69 to -0.02, p=0.04 (Figure 7-3) and day 42: rs= -0.61, 95% CI -0.81to - 0.27, p 
= 0.0014 (Figure 7-4).  The correlation between INR and F1.2 remained even after 
removing the two outliers at day 0 and day 42.  
Figure 7-3 Correlation between INR and F1.2 level day 0 
 
Figure 7-4 Correlation between INR and F1.2 level day 42 
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7.2.2 Rivaroxaban group 
Of the 23 patients randomised to rivaroxaban anticoagulation, the median INR (95% 
CI) was 2.8 (2.2-3.1) while still on warfarin at day 0 and the median rivaroxaban 
level (CI) was 183ng/mL (121-247) at day 42. 
F1.2, TAT and D-dimer 
All patients had normal F1.2, TAT and D-dimer on day 0 on warfarin and day 42 on 
rivaroxaban.  However, there was a significantly lower level of F1.2 (p<0.0001) at 
day 0 while on warfarin compared to day 42 on rivaroxaban (Figure 7-5). There were 
no differences in TAT complex or D-dimer between day 0 and day 42. 
Figure 7-5 F1.2, TAT and D-dimer level on day 0 and day 42 in patients randomised to 
rivaroxaban 
The dotted lines indicate the normal cut off levels 
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There was no correlation between rivaroxaban level and F1.2 (rs -0.28, 95%CI -0.82 
to 0.15, p= 0.19) (Figure 7-6) (which was seen with INR in warfarin treated group) 
or with TAT and D-dimer. 
 Figure 7-6 There was no correlation between rivaroxaban level and F1.2 
 
7.2.3 Comparison of warfarin and Rivaroxaban arms on day 42  
There were no differences in F1.2, TAT or D-dimer levels at base line (day 0) 
between the two patients groups when they were on warfarin.  
On day 42, the warfarin treated group had significantly lower levels of F1.2; (median 
[95% CI]) 48.1 pmol/L [34.2-67.2%] compared to rivaroxaban 90.1pmol/L [71.6-
139.1] (Figure 7-7). However, all patients had F1.2 levels within the normal range 
irrespective of the anticoagulant. There were no differences in the TAT and D-dimer 
levels between the two groups. One patient in the warfarin treated group had slightly 
raised TAT level, and three patients in the warfarin treated group and two patients in 
the rivaroxaban treated group had D-dimer level above the normal cut-off. 
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Figure 7-7  Comparison of TAT, F1.2 and D-dimer levels between patients treated with 
warfarin vs rivaroxaban on day 42  
 
The dotted lines indicate the normal cut off levels 
7.3 Discussion 
Patients with APS have an increased risk of recurrent thrombosis without 
anticoagulation and therefore, it is critical to deliver effective long term 
anticoagulation to prevent recurrence of thrombosis. I assessed and compared the 
effects of warfarin with a target INR of 2.5 (2.0-3.0) (n=25) and rivaroxaban 20mg 
daily (n=23) on in vivo markers of TG and D-dimer in APS patients with VTE. 
Although significantly lower levels of F1.2 were observed in the warfarin treated 
group compared to the rivaroxaban treated group at day 42, F1.2 levels in both 
groups were normal and hence not clinically significant. Furthermore, there were no 
differences in the TAT and D-dimer levels between the two groups and also only a 
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minority of patients (less than 5 in total in both groups) had activation markers above 
the normal reference at any one point of assessment, suggesting that both warfarin 
and rivaroxaban achieve effective long term anticoagulation in APS patients with 
previous VTE.  
Patients with thrombotic APS inherently differ from others with thrombosis due to 
the presence of aPL which have various effects on the coagulation system mainly 
through phospholipid binding proteins. Furthermore, the  INR may not be accurate in 
certain patients with APS because LA  and other aPL may affect prothrombin time 
and frequently  cause underestimation of the anticoagulant effect of  warfarin 
(Rapaport & Le, 1995).  In a study investigating, coagulation activation markers in 
patients with thrombotic APS treated with warfarin anticoagulation, it was noticed 
that 17%, 14% and 17% of the patients had increased levels of TAT, F1.2 and D- 
dimer respectively (Arkel et al, 2002). However, INR values were not stated for 
these patients at the time the samples were taken for the assessment of activation 
markers.  
There is a limited amount of data concerning treatment failure when rivaroxaban or 
dabigatran have been used in thrombotic APS. One report described three 
consecutive APS patients who had had no recurrence of VTE whilst on warfarin,  but 
developed thrombosis when they were switched to rivaroxaban or dabigatran 
(Schaefer et al, 2014). The three cases were as follows: A woman with primary APS 
who developed thrombotic endocarditis with symptomatic cerebral emboli after 
transition to dabigatran. A second woman with primary APS experienced ischemic 
arterial strokes and right transverse-sigmoid sinus thrombosis after conversion to 
rivaroxaban. A man with secondary APS suffered porto-mesenteric venous 
thrombosis after switching to rivaroxaban. A second report also descried three 
patients with APS and  a history of multiple thrombotic complications, who  
experienced recurrent thrombosis while receiving rivaroxaban or dabigatran (Win & 
Rodgers, 2014). However, the rivaroxaban and dabigatran levels were not reported in 
these case reports and compliance is uncertain. Conversely, another case report 
described the successful treatment of a patient with APS who had relapsing 
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superficial thrombophlebitits of the legs with rivaroxaban (Bachmeyer & Elalamy, 
2014). Therefore, until results of prospective randomised trials are available, these 
drugs should be used with caution for the prevention and treatment of VTE in APS 
patients.  
At the time of writing this chapter, there were no other published studies comparing 
the in vivo activation markers in patients treated with warfarin compared to 
rivaroxaban. A similar comparison was made in patients without APS, with VTE, in 
my previous chapter where I found that both anticoagulants achieved effective 
anticoagulation in terms of in vivo markers. However, VTE patients without APS 
showed no differences in F1.2 levels between those treated with rivaroxaban or 
warfarin. In contrast, in APS patients, those treated with warfarin had significantly 
lower levels of F1.2 compared to rivaroxaban treated patients. In addition, non-APS 
patients treated with rivaroxaban had significantly lower TAT complex compared to 
warfarin which was not seen in VTE patients with APS. The differences seen in the 
two groups, was not clinically relevant as nearly all the patients had normal 
activation markers.  
In conclusion, both rivaroxaban and warfarin achieve effective anticoagulation, as 
assessed by inhibition of in-vivo coagulation activation markers. The effect of 
warfarin was more marked compared with rivaroxaban for F1.2 where warfarin-
treated patients had significantly lower values. However, almost all patients had F1.2 
levels within the normal ranges irrespective of the type of anticoagulant. In-vivo 
coagulation activation markers were within the normal reference ranges in all 
rivaroxaban-treated patients (including those with subtherapeutic anti-Xa levels) and 
in warfarin-treated patients who had an INR <2.0, with a minority of patients in both 
groups exhibiting slightly raised activation markers. 
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  General discussion and future directions Chapter 8
I have demonstrated that APS patients with vascular thrombosis on long-term 
warfarin exhibit greater resistance to both exogenous rhAPC as well as to activation 
of endogenous protein C compared to non-APS patients with VTE and normal 
controls using thrombin generation system. Non-APS patients also showed greater 
resistance to activation of endogenous protein C compared to normal controls, but 
resistance was greater in the APS patients. APS patients also had a higher frequency 
(approximately 50%) and higher levels of anti-protein C antibodies; 60% (15/25) of 
these were high avidity antibodies. The APS patients with high avidity anti-protein C 
antibodies had significantly greater APCr to both rhAPC and activation of 
endogenous protein C. The presence of high avidity anti-protein C antibodies was 
also strongly associated with a severe thrombotic phenotype in APS patients as 
defined as patients who developed recurrent VTE whilst receiving therapeutic 
anticoagulation or those with arterial as well as venous thrombosis. Ninety-four 
percent (15/16) of the patients with a severe thrombotic phenotype had high avidity 
anti-protein C antibodies and 62.5% (10/16) of those patients were triple positive for 
aPL. 
My observations that APS patients frequently exhibit resistance to the activation of 
endogenous protein C suggests a possible defect in the mechanism through which 
protein C becomes activated. High avidity anti-protein C antibodies, present in some 
APS patients, may interfere with the mechanism of activation of protein C or the 
anticoagulant action of APC. Differences observed between the APS and non-APS 
patients with regard to APCr could not be attributed to variation in protein C, protein 
S or procoagulant factor levels, since all samples were diluted with PNP to normalise 
levels of these factors.  
Although, I have demonstrated that patients with thrombotic APS with high avidity 
anti-protein C antibodies have the greater resistance to APCr and activation to 
endogenous protein C, whether anti-protein C antibodies are the underlying aetiology 
of the impairment of activation of protein C pathway is not proven. In APS, 
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antibodies directed against β2GPI and particularly, domain I of the protein, possess 
LA activity and are associated with thromboembolic events and are thus candidates 
in the pathogenesis. It not clear whether anti-protein C antibodies are an adjunctive 
risk factor in patients with APS or anti-protein C antibodies alone are responsible for 
APCr and hence the thrombotic risk. There is a possibility that anti-protein C 
antibodies have cross reactivity with aβ2-GPI antibodies as shown in some other 
studies and promote APCr via β2-GPI (Nojima et al, 2005). However, patients with 
APS can have a variety of other autoantibodies with different specificities, including 
anti-protein C, as demonstrated in my study (as well as other antibodies to 
prothrombin, factor XII, TFPI, factor X), and the clinical relevance of these 
antibodies is being unravelled. High avidity anti-protein C antibodies may be an 
adjunctive risk factor in patients with APS, and therefore associated with a severe 
thrombotic phenotype. Whether these antibodies cross-react with aβ2GPI antibodies 
is not known. In my study, there was no relationship between APCr and aβ2GPI. The 
only way to prove that high avidity anti-protein C antibodies promote activated 
protein C resistance is by demonstrating this effect in pooled normal plasma spiked 
with affinity purified anti-protein C antibodies. This is an important area of further 
investigation which is planned in the UCL Haemostasis Research Unit.  
In my study, a small proportion of severe thrombotic phenotype patients without 
APS also had anti-protein C antibodies, which were low avidity antibodies in 
contrast, high avidity antibodies seen in APS patients with a severe thrombotic 
phenotype. The relevance of those low avidity anti-protein C antibodies in the non-
APS patients remains to be defined. 
The prevalence and clinical significance of APCr in association with anti-protein C 
antibodies have not been reported in patients with obstetric APS and those with 
asymptomatic aPL. However, APCr has been described in obstetric APS (Bergrem et 
al, 2011;Gardiner et al, 2006;Rotmensch et al, 1997). It is therefore plausible that 
APCr associated with anti-PC antibodies may also provide a marker for a severe 
obstetric phenotype, which may be defined as the presence of both early and late 
pregnancy morbidity, with these categories as defined in the Sydney clinical criteria 
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for APS (Miyakis et al, 2006) or pregnancy morbidity whilst receiving anticoagulant 
therapy (Gardiner et al, 2013), as well as for future thrombotic risk in women with 
obstetric APS.  
Thrombomodulin (TM) is a protein cofactor expressed on endothelial cell surfaces 
and acts as cofactor/receptor for thrombin, accelerating the activation of protein C by 
thrombin ~ 2000-fold (Sadler, 1997). In addition to its role in protein C activation, 
TM also transforms the functional specificity of bound thrombin from procoagulant 
to anticoagulant.  I have not investigated the thrombin/TM activation of protein C in 
thrombotic patients with APS in my studies, which is a key area of interest for 
further research.   
I found a wide variation of the sensitivity of thromboplastin reagents to rivaroxaban. 
Of the six commonly used thromboplastin reagents studied, Neoplastin®R was the 
most sensitive while Innovin® and Thromborel®S were the least sensitive. My 
findings from ex vivo studies of patients on therapeutic dose rivaroxaban, were in 
keeping with those previously reported from in vitro studies. Rivaroxaban levels 
within the therapeutic range can give a normal prothrombin time ratio with the less 
sensitive reagents, which may be clinically misleading. In the absence of anti-Xa 
assays, the assessment of rivaroxaban anticoagulation should only be performed 
using PT reagents with good sensitivity. Such testing should aid decision making in 
the acute management of the patient by indicating whether the patient is 
anticoagulated in the therapeutic, subtherapeutic or supratherapeutic range. Because 
of the wide variation in the sensitivity thromboplastin reagents to rivaroxaban,  each 
laboratory should know the sensitivity of its own PT reagent as  recommended in the 
BCSH guidelines (Kitchen et al, 2014). 
Due to the increasing use of rivaroxaban, it is clinically relevant to define the 
appropriate methodology for ex vivo LA testing, to enable the diagnosis of APS in 
patients treated with rivaroxaban. I established this by in vitro and ex vivo studies of 
LA detection in thrombotic APS patients receiving therapeutic dose rivaroxaban. I 
found that false positive DRVVT occurred in rivaroxaban treated patients mainly at 
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therapeutic levels. The TVT/ECT ratio and Textarin time were not affected, 
irrespective of the rivaroxaban level, enabling LA detection in patients receiving 
rivaroxaban. In thrombotic APS patients treated with rivaroxaban, the TVT/ECT 
appears reliable even at therapeutic plasma levels of rivaroxaban. However, 
TVT/ECT is known to be less sensitive than DRVVT for detection of LA. DRVVT 
may be acceptable at trough rivaroxaban plasma levels, in samples taken at least 18 
hours following the previous dose of rivaroxaban. In this situation, rivaroxaban 
levels should always be measured to ensure that trough levels really are present, if 
not results should be interpreted with caution.  The findings in this in vitro and ex 
vivo studies guide detection of LA and enable diagnosis of APS in patients treated 
with rivaroxaban as well as monitoring of LA in APS patients, and also inform 
national and international guidelines.  
It is theoretically possible that aPL could directly interfere with the anticoagulant 
effects of rivaroxaban, although it is hypothesised that this is unlikely due to its small 
molecular size and the high specificity for its target. I have shown that thrombotic 
patients without APS treated with rivaroxaban, the anticoagulant can affect various 
parameters of ex vivo TG measured using the CAT system. Similar studies in APS 
patients treated with rivaroxaban have not been published at the time of writing this 
thesis. I demonstrated in my in vitro studies that aPL do not influence anticoagulant 
activity of rivaroxaban as measured by TGT and anti-Xa assays. 
I have demonstrated that both rivaroxaban and warfarin can achieve effective 
anticoagulation in thrombotic patients without APS, as assessed by inhibition of TG 
and in vivo coagulation activation markers. The effect of rivaroxaban on TG was 
more marked compared with warfarin for all parameters except ETP (as shown in 
previous in vitro studies), where warfarin-treated patients had significantly lower 
values. The TG test, as a global measure of anticoagulation, can assess the 
anticoagulant effects of both rivaroxaban and warfarin, and effects on the ETP 
should be assessed in combination with the other TG parameters. In vivo coagulation 
activation markers were within the normal reference ranges in all rivaroxaban-treated 
patients (including those with subtherapeutic levels) and in 37/45 warfarin-treated 
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patients who had an INR ≥2.0, with a minority of warfarin-treated patients with 
subtherapeutic INR values exhibiting slightly raised F1.2 and/or TAT. 
In studies on thrombotic APS patients, in vivo markers of coagulation activation gave 
similar results to those of patients without APS, although some patients treated with 
warfarin who had subtherapeutic INR also had raised D-dimer. However, there was a 
significantly lower level of F1.2 levels in patients treated with warfarin compared to 
rivaroxaban in APS patients which was not observed in the non-APS patients, but the 
difference was not clinically relevant and F1.2 levels remained normal in all 
rivaroxaban treated patients.  
In summary, I have fulfilled the aims of my thesis and believe that I have made 
several important contributions to the medical literature. I have established that 
thrombotic patients have greater resistance to both activated protein C and activation 
of endogenous protein C. Nearly half of the patients that  I studied had anti-protein C 
antibodies and those who had high avidity anti-protein C antibodies had significantly 
greater APCr to both rhAPC and activation of endogenous protein C. The presence 
of high avidity anti-protein C antibodies was also strongly associated with a severe 
thrombotic phenotype in APS patients and could be used as a marker in future once it 
is validated in a larger cohort of patients. Establishing the sensitivity of commonly 
used thromboplastin reagents to rivaroxaban is a major clinical relevance as it aids 
decision making in the acute management of the patient by indicating whether the 
patient is anticoagulated in the therapeutic, subtherapeutic or supratherapeutic range 
when measurement of rivaroxaban level is not readily available. Methods of 
detecting LA in APS patients treated with rivaroxaban are important both nationally 
and internationally. Finally, I have demonstrated in vitro studies, that aPL do not 
influence the anticoagulant activity of rivaroxaban as measured by TG and 
rivaroxaban anti-Xa levels. 
Future directions 
High avidity anti-PC antibodies may be an adjunctive risk factor in patients with 
APS, and thus associated with a severe thrombotic phenotype. The findings in my 
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study are therefore potentially of major clinical relevance as they could provide a 
basis for early recognition of patients who may benefit from escalated therapeutic 
interventions, including immunomodulation. The prevalence or clinical significance 
of APCr in association with anti-PC has not been reported in patients with obstetric 
APS and those with asymptomatic aPL. It is relevant to establish the prevalence and 
clinical significance of APCr in association with anti-protein C antibodies with 
obstetric APS and those with asymptomatic aPL.  
The high avidity anti-protein C antibodies  detected in APS patients with a severe 
thrombotic phenotype may represent an underlying aetiology of thrombotic APS and 
this need to confirmed by  in vitro studies by demonstrating APCr in PNP spiked 
with affinity purified anti-PC antibodies. 
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